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Abstract 
Hepatocellular carcinoma accounts for 85% of primary liver cancer that are usually 
characterised by defective or ineffective apoptosis which is considered to be the 
main cause of cancer progression. In this study, Cytochrome-C which is a pro-
apoptotic protein is combined with hybrid (iron oxide-gold) nanoparticles and 
triggers mitochondrial downstream apoptosis pathway in the tumour cells. The 
nanoparticle complex enables delivery of this difficult protein through the cell 
membrane. In this research, five different anticancer drugs (doxorubicin, 
oxaliplatin, paclitaxel, vincristine and vinblastine) were used against liver cancer 
and U937 cell lines to assess their IC50 values alone and to check their toxicity 
after their co-administration with cytochrome C hybrid formulation. These 
combinations resulted in an increase in the cytotoxicity of the used 
chemotherapeutic drugs and remarkable decrease in the amount needed to kill 
hepatic cancer cells. For that reason, Iron-gold hybrid nanoparticles offer a 
promising tool for cytochrome-c delivery into tumour cells and enhance the specific 
targeting of therapeutic particles to their site of action. 
The preliminary results reflected the increasing killing abilities of chemotherapeutic 
therapies when co-administered with cytochrome C hybrid formulation by targeting 
the natural killing mechanism inside the cells and activating its pathways. 
Subsequent to these results, further work was done in formulation of one platform 
therapeutic device with Polymeric amphiphiles hydrophilic poly(allylamine) polymer 
(PAA)  grafting with 5-(4-chlorophenyl)-1,3,4-oxadiazole-2-thiol(oxadiazole, Ox). 
Paclitaxel (PTX) was selected as a hydrophobic drug model to check its water 
solubility behaviour after loading into PAA-HNP-C platform. These new devices 
showed a significant increase in drug uptake level and increase in PTX cytotoxicity 
against liver cancer cell lines. The data from this work showed a significant 
increase in the apoptosis activities of combining treatment anticancer agents 
(doxorubicin, paclitaxel, oxaliplatin, vinblastine and vincristine) and the hybrid 
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formulation of the cytochrome-C within the liver cell lines, which leads to cellular 
death. Therefore, this combined method may give promise step for the future of 
liver cancer treatment regimes. In addition to, formulating the HNP-CYT-C and 
PTX into as active single platform for increasing the PTX cytotoxicity. More 
laboratory investigation is needed to check the activity of this formulation as a 
preparing step to further in vivo studies.  
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1.1. Cancer  
 
Cancer is defined as a malignant neoplasm disease which is produced by 
abnormal and uncontrolled cell growth and is considered as the second cause of 
death after heart disease worldwide. The nature of this disease is categorised as 
the most dangerous type of cell proliferation, with heterogeneous abnormal growth 
of cells that may localize within an affected organ (or invading to other body parts 
with process called metastasis) (World Health Organization, 2014). However, not 
all types of tumours are defined as cancerous; benign tumours also exist which 
are not capable of transferring into other parts of the body. Malignant tumours, 
develop and when they undergo metastasis they begin to other regions of the 
body. Mortality caused by malignant evolution of cancer increases every year due 
to several factors (Figure 1.1.) such as chemo-resistance, improper delivery of the 
drug at the required dose inside the specific cells, gene alteration of the tumour 
cells and other factors that affect the normal cell cycle (de Miguel et al. 2016). 
 The lungs, liver, brain, and bones are the usual metastasis locations arising from 
original tumour cells (National Cancer Institute, 2008). The tumour initiates once 
cells grow in an uncontrollable manner, dividing and developing into a bulge or 
cancer. In this study, the retardation of liver cancer progression was investigated 
by developing new delivery technique of bio-therapeutic molecules. The majority of 
liver cancers are either hepatocellular carcinoma, or hepatoma, accounting for 
85% of all cases. These occur in the liver cells (hepatocytes) particularly in 
patients suffering from liver cirrhosis. The other types represented in a lower 
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percentage include (Cholangiocarcinoma, Angiosarcoma and Hepatoblastoma) 
(Khan, SA. et al. 2012). 
 
Figure 1.1. Critical elements of cancer development (Hanahan and Weinberg, 
2000).  
 
1.1.1. Liver cancer  
 
The liver (the second biggest organ of the body) is one of the most important 
organs in the body, it controls 500 processes or more inside the human body, for 
instance fat digestion, eliminating toxins and poisons, controlling blood pressure 
by monitoring the blood clotting factors and various types of hormones. Therefore, 
liver cancer is the most dangerous malignant type of growth which results in the 
disturbance or stoppage of many of the normal functions of this vital organ. In the 
UK, 2014, there were 5,550 new cases of liver cancer discovered. Affecting about 
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3,652 (66%) of men and 1,898 (34%) of women with nearly 70% of cases include 
65 years of age or older people. During recent years, the prevalence of the liver 
cancer in the UK has grown abruptly with increase the cases of alcohol abuse and 
obesity (Figure 1.2.).  Liver cancer is the fifth main continually diagnosed cancer 
and the third biggest cause of cancer related death in the world after the lung and 
stomach cancer (Lozano, R ,2012). 
Figure 1.2. Average Number of New Cases of liver cancer Per Year, UK Liver 
Cancer (2014).  
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1.1.2. Causes of liver cancer 
 
There are several sources of the liver cancer including: Viral infection, Hepatitis C 
virus (HCV) and Hepatitis B virus (HBV) (Figure 1.3.) which are responsible for 
80% of all types of liver cancer especially hepatocellular carcinoma (HCC) (Jeong 
et al. 2012; Ralphs et al. 2013; Kew and MC,2013; Sharma et al. 2016). 
 
The main reason of developing the hepatocellular carcinoma with hepatitis C or B 
virus infection is the countless abnormal cells fibrosis that lead to cirrhosis effect 
inside the liver and caused by the virus infection with yearly occurrence of 1.7% in 
HCV-diseased patients (Fattovich, 2004). About 5-10% of HBV patients are 
registered as chronic stage and around 30% of these cases are developed to HCC 
(Jeong et al. 2012). Moreover, viruses may affect the liver cells resulting in a 
significant genetic alteration in the normal growth pathways of liver cells by 
targeting viral duplication or persistence and/or inhibiting the normal signaling 
mechanism of apoptosis. (Fattovich, 2004). The second source of liver cancer is 
cirrhosis, which is mainly related with alcohol abuse. This accounts for 37% of all 
the cases of liver cancer related death. Irresponsible consumption of alcohol links 
with development of liver cancer affecting two points, the oxidative stress levels 
within cells and the process of alcohol metabolism inside the liver may produce 
chemicals groups which cause chronic inflammation and fibrosis. Besides, the 
damaging effect of excessive alcohol intake  on the liver, the intestine may also be 
infected due to the bacteria toxins inside the intestine permeating into the scarring 
and fibrosis (Di Tommaso et al. 2013). Food contamination with Aspergillus flavus 
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and Aspergillus parasiticus (Alfatoxin) can also be considered as a harmful and 
toxic cause of hepatocellular carcinoma. The most common food types with this 
kind of contamination include: peanuts, cereals and other types of vegetables. 
These categories of toxic fungi contamination are presented in large proportion in 
Africa, China and South-East Asia, in the prevalence of three times more 
dangerous than HBV infection (Razumilava et al. 2013; DeBaun et al. 1998). More 
causes are concerned with obesity and the development of steatohepatitis, 
diabetes., smoking and cholangiocarcinoma (5-10%) of the human with primary 
sclerosing cholangitits (Chuang et al. 2009) as the additional causes of HCC.  
 
 
Figure 1.3. The main causes of liver cancer. (Modern Cancer Hospital 
Guangzhou, 2012) 
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1.1.3. Types of liver cancer 
 
There are many types of liver cancer that classified according to the affecting liver 
parts and the most common one is the Hepatocellular carcinoma (HCC) that 
originates primarily on the liver cells. In addition to other malignant types of liver 
cancer as illustrated in Table 1-1. 
Table 1-1.Types of liver cancer. 
Types Origin Percentage 
Hepatoma 
,Hepatocellular 
carcinoma(HCC) 
liver cell 75% of liver cancer cases, 
(Razumilava et al. 2013) 
 
(Cholangiocarcinoma 
(Cystadenocarcinoma) 
bile duct cancer  Approximately 6% of liver 
cancer cases.( Di Tommaso et 
al. 2013) 
Hepatoblastoma   the right lobe of the 
live , blood vessel and 
immune system  
1% of children and 79% of liver 
tumour lower than age 15, 
(Chuang et al. 2009) 
Angiosarcoma Blood vessel cancer  1% of adult primary liver cancer 
Fibrosarcoma mesenchymal 
connective tissue  
 < 10% (Bruix and J; 
Sherman,2011) 
Rhabdomyosarcoma liver muscle cancer  65% of cases in children 10 to 
18-year-old age group. (Bruix 
and J; Sherman,2011) 
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The cancer can originate from another part in the body and then spread to the liver 
through metastasis, the most common point of origin for this is in the 
gastrointestinal tract or due to ovarian renal or prostate cancer (Emre, S et al. 
2004; Khan et al. 2012). 
The cancer cells are diagnosed either by routine screening or observed symptoms 
depending on the origin and the size of the cancer. Liver cancer may appear as a 
locally affected region or as a diffuse abnormal growth, which cannot be easily 
distinguished from the neighboring liver cirrhosis. The lesion may effects the biliary 
system that can develop to vascular obstruction and accompanied with improper 
surgical liver amputation or chemoresistance therapy which leads to liver failure 
and death (Seeff, 2004; Bosch, et al. 2004).The proper diagnosis of hepatic 
cancer is very difficult since the diagnosed symptoms do not present themselves 
until the final stages of cancer progression. They involve mainly: nausea, unclear 
loss of weight, vomiting, jaundice yellowing color of the skin and eye and others 
depending on the type and the stage of liver cancers primary or secondary origin 
(Lake , 1993). 
Systemic or local chemotherapy have been used as one of hepatocellular 
carcinoma therapeutic pathways, but this method is faced with slightly and 
temporary responding effects as reported previously with various treated cases. 
Doxorubicin is reported with negligible positive results in 20-30% HCC treated 
patients that effect on the survival rate. There is also  specific limitation with single 
treatment types such as with radiofrequency ablation (RFA) treatment(Liu et al. 
2014) In an effort to provide alternative pathways to improve the action of 
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chemotherapy, most of the new studies are focused on discovering of the new bio-
therapeutic technique to overcome these therapeutic resistances. (Mathurin P et 
al.  2003; Sharma et al. 2016). 
 
1.1.4. Types of Hepatocellular carcinoma treatment 
 
Surgical resection is considered as a main choice for non-cirrhotic liver cancer, 
while the chance with the cirrhotic type it is less useful because of the possibility of 
liver failure after resection (Bruix et al. 2011). Liver transplantation is other applied 
therapeutic method with less than 30-40% of patients responding to this option 
accompanied with late diagnosed problem of liver. Radiofrequency ablation (RFA) 
may be suggested as an alternative way of surgery in the treatment of liver cancer 
and favored in early stages of cancer, preferably when the tumour smaller than 
5cm (2 inches) in diameter. This treatment option may be applied with larger 
cancer cell size (more than 5cm) but it may be repeated with additional 
substances such as acetic acid or ethanol. Directed heat /radiation into the liver by 
the process called percutaneous ablation is also considered as another way of 
HCC treatment using needle through different ways (percutaneous needle applied 
through abdomen) but with precaution in applying of heat or radiation that may 
spread to the normal neighbor cells or blood vessels near liver (Wang et al. 2013). 
Systemic use of antineoplastic drugs is not very effective in HCC treatment, in 
spite of using local trans-arterial chemoembolization of specific drugs such as 
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doxorubicin or oxaliplatin. Many problems are faced with this procedure such as  
blockages of the liver artery by gelatin or small drug particles. A new drug called 
sorafenib is considered as a main hope in the treatment of HCC that targets the 
abnormal liver cancerous cells and excessive blood vessel proliferation (de Lope 
et al. 2012). A main aim in the treatment of cancer cells is to initiate the apoptosis 
in the abnormal cells. However, many cancer types are possess a highly 
resistance response to the action of anticancer drugs, so novel therapeutic ways 
to overcome this resistance and to initiate programed cell death is the aim of the 
most recent studies in this field. Combination therapies of cancer treatment are 
represented as an ideal way in which cancer cell regression occurs by targeting 
apoptosis signalling pathways and leaving normal cells without any additional 
harmful effects (Ray S and Almasan, 2003). 
 
1.1.4.1. Chemotherapy Treatment 
 
Chemotherapy uses chemical substances to destroy cells that are rapidly 
separating in the body by targeting cell cycle and interfere with cell division 
process, particularly at the level of DNA to initiate apoptosis. They are classified 
according to the mechanism of action, anthracycline group such as Doxorubicin 
affect the synthesis of the DNA and inhibiting topoisomerases prevent the 
replication of the DNA, Platinum group such as oxaliplatin directly interfere with 
DNA synthesize and transcription leading to the initiation of apoptosis and death of 
tumour cells, Taxan mitotic inhibitor group for example Paclitaxel and Vinca 
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alkaloid group Vincristine and Vinblastine inhibit microtubule formation that prevent 
DNA synthesis and promotes cell death(Waterman-Storer CM, et al. 1997). 
Chemotherapy studies have shown the cytotoxic effects of antineoplastic drugs 
such as Doxorubicin, oxaliplatin, paclitaxel and vincristine that works in different 
targeting pathways to treat many types of the tumour cells, but the biggest 
difficulties in applying these therapies are the indistinguishable drug targeting that 
produced harmful effect on the normal body tissues and unbalanced relation 
between the sensitivity of these drugs and the resistance response of the tumour 
cells to chemotherapy effect(Nakamura et al.,2000). For that reason, studies on 
drug metabolism, drug transport and clearance rate are considered as vital ways 
to determine the pharmacokinetic and pharmacodynamics properties of the drug 
inside the body. Many of the anticancer drugs show a sharp dose-response curve 
and low therapeutic index with high systemic toxicity that can be life threatening. 
Therefore, the use of combination technique by treating with more than one type of 
anticancer drugs can be the way in opening new clinical approach and interaction 
of the multiple drugs pharmacokinetic that achieved remarkable modification in 
host toxicity and drugs therapeutic response. The interaction between different 
pharmacokinetic properties of the individual chemotherapeutic drugs may lead to 
multiple toxicity effect causing the chemoresistance (Kivisto et al. 1995).  
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1.1.4.1.1. DNA damage drugs 
 
Anthracycline antibiotic such as Doxorubicin has been generally used as 
anticancer drug to cure several types of the tumour cells (Singal, P. K., and 
Iliskovic, N,1998; Buzdar et al.,1985) recent researches have been concentrated 
on doxorubicin induced apoptosis pathway (Nakamura et al.,2000; Wang et 
al.,1998).The p53 factor is considered as a major protein to start programed cell 
death by tumour suppressing effect and protecting cells against carcinogenic 
activation (Agarwal et al.,1998; Ko, et al.,1996). The principle pathway of 
apoptosis is by targeting p53  protein, for most anticancer drugs including 
doxorubicin ( Lowe et al.,1994; Lotem et al.,1996). Any alteration or mutation in 
p53 results in major resistance to the effect of doxorubicin (Magnelli et al., 1995). 
The mechanism by which doxorubicin acts is either binding to the DNA and 
interrupting the topoisomerase-ll-mediated DNA repair or via the formation of free 
radicals that affect the integrity of DNA, protein and cell membrane.(Gewirtz 
DA,1999) The way by which doxorubicin forms free oxygen radical is by oxidizing 
doxorubicin to semiquinone (unstable metabolite), that is converted back to 
doxorubicin after releasing oxygen radical. These free radical can be consider as 
one of many stimuli in initiating apoptosis by means of lipid peroxidation, DNA 
destruction and oxidative stress (Doroshow JH, 1986) The over activity of 
antioxidant enzymes  are attenuated doxorubicin ability to procedure free radicals 
and inhibited apoptosis (Gouaze et al.,2001; Suresh et al.,2003). On the other 
hand, doxorubicin is directed to the nucleus and causes its lethal effect on the 
topoisomerase-II, leading to DNA damage and death of the cells (TeweyKMetal, 
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1984). Another DNA damage drug used in this study is oxaliplatin, which is 
classified as a member of the platinum-cytotoxic group and is responsible for 
damaging the DNA through the formation of intra and inter-strand cross linking in 
the structure of the DNA and also between the building protein units of the DNA. 
The most common cytotoxic site of oxaliplatin is focused on the binding ability with 
nitrogen atom of guanine to form the mono and di adducts affecting the genomic 
levels of DNA and also nucleosomes (Faivre S, et al. 2003). The significant 
cytotoxic effects of oxaliplatin are mainly observed with lethal biadduct effect on 
the DNA synthesis which inhibits the proper processes of DNA replication and 
transcription, leading to activate the apoptosis pathways subsequent to arrest of 
the cell cycle (Di Francesco A, et al. 2002). Colon cancer cells treated with 
oxaliplatin have been reported in the activation of caspase-3 and releasing of pro-
apoptotic proteins (cytochrome C) as a normal step in apoptosis pathway 
activation (Arango D, et al. 2004). More recent studies are performed with the 
development of platinum (IV) prodrugs derivatives of oxaliplatin and studied their 
apoptotic effects in vitro and in vivo. The cytotoxicity test are performed with colon 
carcinoma cell line under two different conditions of incubation (normoxic and 
hypoxic), the modification in the axial ligand are recorded to improve the cytotoxic 
effects of oxaliplatin by interfering with plasmid DNA and inducing apoptosis 
(Simone Göschl, et al. 2017). 
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1.1.4.1.2. Anti-microtubule targeting drugs  
 
The targeting of microtubule and disturbing the normal spindle function during the 
cell cycle have recognised as a new directing site of cytotoxic drugs in treating 
different types of cancer (Figure 1.4.), by disturbing the normal dynamic  of 
microtubule assembly and affecting the normal cell cycle mitosis and consequently 
leading to cell death (Eiman Mukhtar, et al. 2014). The microtubule are played a 
major biological role in the cell cycle processes by polymerisation (Waterman-
Storer CM, et al. 1997),the main two activated mechanisms are participated in 
polymerization of microtubule concerned with  reversible nucleation and elongation 
processes and the addition of α and β dimers at microtubule ends(Jordan Ma and 
Wilson L. ,2004). Mitosis phase aids in the proper separation of chromosome into 
two identical sets. The successful separating processes are required with 
presence of proper dynamic microtubule (Mitchison TJ.1988; Rusan NM. et al. 
2001). The critical point in the dynamic of microtubule is timely dependent with 
proper attachments of chromosomes at kinetochores with spindle after the 
breakdown of nuclear envelope and is called pro-metaphase, during this phase 
proper aligned of chromosome are placed preparing to anaphase and telophase 
stages (Jordan MA and Wilson L. 2004), pro-metaphase is characterized with 
microtubule originate from each poles of spindle to reach 5-10 µm, and shorten 
again to re-grow successfully till to close  chromosome kinetochores (Hayden JH, 
et al. 1990). It is important that each chromosome is attached to microtubule 
bipolar spindle; unsuccessful attachment processes are enough to halt cell cycle 
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transition to next anaphase steps and to initiate signaling pathway of apoptosis 
(Yvon AM, et al. 1999; Jordan MA. 2002; Gabrielli  et al. 2012). 
 In conclusion, the proper assembly and disassembly of microtubule is considered 
the critical points for proper cell division and growth which adapted to different 
growth environment to progress with suitable shapes (Mitchison TJ. 1988). For 
that reason, great success are reported with anti-microtubule cytotoxic drug as 
effective chemotherapeutic agents against different types of cancer and for further 
developments  in the therapeutic regime to halt tumour progression (Giannakakou 
P. et al. 2000). 
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Figure 1.4.Defective cell cycle as targets for anti-cancer therapies. 
 
Paclitaxel is member of taxan anti-microtubule drugs that has essential effect in 
cancer treatment by targeting the β-tubulin subunit of microtubule, binding the 
tubulin alongside to the microtubule and increase the polymerization processes. 
Consequently, remarkable conformational changes are observed with M-loop part 
of β-tubulin and stable interaction between proto-filament in lateral level. In other 
hand, small amount of paclitaxel are reported to stabilize the microtubule dynamic 
without affecting the rate of polymerization (Nogales E. et al. 1995; Yvon AM. et al. 
1999). Jordan group researchers illustrate that mitosis processes are blocked at 8 
nM dose treatment of paclitaxel in hella cultured cells, while no growth in the 
polymer mass was recorded at 10 nM dose of paclitaxel till the dose was 
increased to 80 nM (Jordan MA. et al. 2002). The cytotoxic effect of paclitaxel are 
noted with suppression of the proper microtubule –spindle separation steps and 
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stops the cancer cells to move from metaphase to  the next anaphase cell cycle 
that prevent cell progression and kill the cells by apoptosis (Jordan MA. et al. 
2002; Yvon AM. et al. 1999; Kelling J. et al. 2003). Additional microtubule targeting 
drugs are vinca alkaloids (vinblastine and vincristine) which tested to destroy 
mitotic spindle at dose (10-100 nM) in cultured HeLa cells and showed irregular 
depolymerizing processes, therefore halting the cancer cells with blocked mitosis 
and abnormal chromosome condensation. For example, vinblastine is powerfully 
blocked mitosis in HeLa cells and indicated IC50 at (0.8 nM) , apoptosis markers 
were also tested as cell suicide pathway (Jordan MA and Wilson L. 
2004),illustrating the apoptotic effect of vinblastine is concentrated with blocking of 
normal dynamic of microtubule rather than the depolymerisation effects in 
microtubule (Jordan MA. et al. 2002).  The main mechanism of action of 
vinblastine is binding to the tubulin dimers at the β-subunit with specific targeting 
region called Vinca-binding domain (Bai RL. et al.1990). This type of binding is 
rapid and reversible and produces remarkable changes in the self-association of 
the tubulin. This specific domain is considered as vital targeting site of the other 
various novels chemotherapeutic (Jordan MA. 2002; Lobert S and Correia JJ. 
2000). In vitro studies have shown that vinblastine binds to other targeting sites at 
the end of microtubule and suppresses the building frame of the tubulin (Jordan 
MA. 2002; Singer WD. et al.1989). The binding of one or more of vinblastine 
molecules is enough to reduce tread milling and produce dynamic instability by 
50% without remarkable changes in microtubule depolymerisation. This 
mechanism is responsible to affect the normal assembly of the mitotic spindle at 
the kinetochores of each chromosome and to block the cell cycle to move from the 
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metaphase into   anaphase and the cells are exposed to apoptosis signaling 
pathways and die (Jordan MA. 2002; Singer WD. et al.1989).  
 
1.1.5. Mitochondria and liver cell  
 
The greatest number of mitochondria which acts as the main power home of 
energy for all metabolic process inside the body are founded in the liver cells 
(1000-2000 of mitochondria per cell)  and to get  the maximum levels of their 
energy that served the requirements of the numerous functions of the liver. 
Recently, most of the cancer researchers are focused on the role of chemotherapy 
on the mitochondria by affecting different parts or chemical reactions of the cells. 
Mitochondria are represented the goal of many drugs either by direct way through 
affecting its function or indirectly by affecting other cellular parts. Any disturbance 
in the activating sequences of apoptosis offered the way to abnormal tumour 
progress, so the identification of mitochondrial signaling pathways improved the 
precise mechanism of apoptosis (Korsmeyer S.J. et al.,1995). There are many 
targeting sites for anticancer drugs inside the mitochondria relating to the electron 
transport chain, ATPase enzyme, outer membrane permeability, (ROS) reactive 
oxygen species, DNA and synthesis process of other protein, pro-apoptotic and 
anti-apoptotic signal and other parts in the mitochondria (Finsterer, J., and Segall, 
L.,2010). Cancer is commonly treated using several methods including 
chemotherapy, radiation therapy and surgery depending on the stage, location and 
the type of cancer. Within the past two decades, there has been an exponential 
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rise in studies exploring the use nanotechnology as therapeutic agents or carriers 
in cancer therapy (Lind M.J. ,2008). Cells that are exposed to cytotoxic effects of 
anticancer drugs are organized with apoptotic changes, including cell contraction 
,chromatin collection and fragmentation of the DNA within cells, the main linking 
between the anticancer drugs and apoptosis has been shown by the compatibility 
in the genetic bases among them ,targeting the same stimulator proteins (Bcl-2 
family, caspase cascade, death receptor and p53 encode gene) and other death 
proteins participating in the up and downstream of apoptosis (Debatin, 1999; 
Kaufmann et al.  2000; Makin et al. 2000). The apoptotic changes have been 
detected in the function of mitochondria starting with increase mitochondrial 
membrane permeability, releasing of apoptotic proteins such as cytochrome c, 
formation of reactive oxygen species (ROS), decreasing the stabilization effect of 
anti-apoptotic Bcl-2 on the outer mitochondrial membrane to initiate apoptosis that 
are considered as the main mechanism of action of most anticancer drugs 
(Costantini et al. 2000).                                                           .                                   
Cytochrome C plays a main role in cellular respiration and in apoptosis pathway 
after being released into cytosol by the action of Bcl-2 family group Bax and 
activating series of caspase cascade. However, in some types of the cancer, 
cytochrome c release are stopped even in the presence of DNA division 
abnormalities by disturbing the normal activation of Bcl-2 family on the outer 
mitochondrial membrane, so the tumour cell with abnormal divided and 
proliferation rates are presented with genetic alteration of apoptotic signaling 
pathways(Dubrez-Daloz L et al. 2008). For that reason, it is very important to 
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target the anticancer drug directly towards cancerous cells and activated apoptosis 
mechanism. New delivery techniques with nanoparticles are offering new hope in 
cytochrome c delivery technique to specific sites in the cancer cells (Pilkington GJ 
et al., 2008).                                                                                                                
1.1.6. Chemotherapy resistance                                                                              
 
Chemotherapy is the main therapeutic technique that is used in the treatment of 
many types of primary or metastatic cancers. In spite of the various methods of 
chemotherapeutic applications, Positive results (but not statistically significant) are 
recorded with most types of treated cancer. Resistance to chemotherapy can be 
contributed to several reasons related to either host factors for example partial 
absorption rate or quick drug metabolism and excretion, leading to unsufficient 
drug levels in cancer cells and reducing their therapeutic effect. Moreover, 
chemotherapy or genetic or epigenetic modifications factors in the tumour and 
non-tumour cells that disturb the normal metabolism pathway of the drug in the 
non-tumour cell. Unfamiliar structures of the blood vessels in the tumour cells are 
diagnosed with remarkable alteration levels of the drugs uptake into tumour cell 
and interaction levels of cancer cells with other interstitial normal cells in the body 
(Pluen A et al. 2001; Green SK et al. 1999)  Each type of cancerous cells has its 
own reaction towards chemotherapy depending on the type and origin of cancer 
tissues and on the oncogene pattern variation resulting in mutation phenotype that 
leads to different response gene of chemo resistance. Apart of these resistance as 
shown below in( Figure 1.5.) concerning with loss of the specific receptors on the 
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cell surface, alteration in the pharmacokinetic and pharmacodynamics properties 
of anticancer drug (low drug uptake or high efflux level) due to mutation effect of 
cancer cells are also involved. These changes in drug properties resulting in the 
alteration of the normal signalling pathway to initiate programmed cell 
death(apoptosis) that is considered the main goal of most the  chemotherapy, 
besides to abnormal modification in the regular cell cycle checkpoints that affects  
the  normal targeting sites of chemotherapies(Borst P et al.,2000; Ambudkar SV et 
al.,1999).                                                                                                                  
           
 
 
 
 
 
 
 
 
Figure1.  5 Mechanisms of chemo resistance.                                                                  
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cancer cells to chemotherapeutic drugs (Michael M. et al. 2009) .                           . 
The P-glycoprotein efflux pump has a broad drugs resistance effect that is 
responsible for resistance against different types of drugs, such as anthracyclines, 
vinca alkaloids and taxanes, so limiting their use (Noack et al. 2014)                       
                                                                              
1.2. Apoptosis 
1.2.1. Introduction 
 
Apoptosis, or programmed cell death, is defined as one of the most important 
physiological processes inside the body. Apoptosis is responsible for the 
regulation, immune response, tissue development and homeostasis. This type of 
cell death is controlled by triggering several signaling molecules, protein-protein 
interaction, binding receptor and gene encoded in their pathways to stimulate 
specific signaling proteins and to produce the required energy for cell work. In 
contrast to apoptosis there is another process called necrosis which is defined as 
an uncontrolled cell death resulting from injury. Apoptosis requires energy to 
complete its process; the same stimuli for the apoptosis in the presence of energy 
may induce necrosis in the absence of it (Saikumar et al., 1999) 
Apoptosis refers to the death of cells ensuing from a regular sequence of 
genetically programmed steps and removed the odd or aged cell that produces 
during abnormal cell growth with keeping the balance between cell production and 
cell death. Any disturbance in these steps leads to variety of diseases including 
cancer. (Kasibhatla and Tseng, 2003). Apoptosis has been considered a key role 
23 
 
in human disease and repeatedly reviewed in many research papers. (Thompson, 
1995). 
 
1.2.2. Morphological changes during apoptosis 
During apoptosis, the cell follows a number of genetic controlled steps to initiate 
programmed cell death. As shown in (Figure 1.6.), in this process, the cell first will 
be diagnosed with a drop in size as its cellular components collapse, followed by 
bubble balls called blebs indicated on the outer membrane of the cell before 
dividing into smaller portions called (apoptotic bodies). Since these pieces are 
either enveloped in membranes they will not affect the neighbor cells or engulfed 
by phagocytic cells and break the apoptotic bodies with no inflammatory effect. 
The main reason in discarding and replacing the abnormal cells is to get proper 
function of the cell and to avoid any undesirable abnormal growth of cells that 
considered as main cause of cancer (Sasi et al., 2009; Marino et al., 2014). 
 
  
    
 
Figure 1.6..Morphological changes during apoptosis.  
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1.2.3 Role of apoptosis inside the body 
 
Apoptosis processes are controlled by many physiological conditions, such as the 
formation of new tissue in the embryonic stage, physiological transformations of 
the endometrium, and the deterioration of lactating breast and changes of the 
epithelium in the gut. In addition to, monitoring many pathological processes such 
as uncontrolled cell growth (tumour), death of the effective cells in Alzheimer’s 
disease and Parkinson’s disease (degenerative diseases), unnatural cell 
production after exposure to radiation, low oxygen level (hypoxia) or moderate 
thermal injury of the cell and in the myocardial infarction affecting the heart cells 
(Morhan H, 2010 , Merkle CJ, 2009) 
1.2.4. Pathways of apoptosis 
There are many stimuli for initiating programmed cell death which is divided into 
two main signaling pathways: 1) extrinsic pathway and 2) intrinsic pathway. 
1.2.4.1. Extrinsic pathway 
 
The extrinsic pathway is initiated by triggering specific ligands of the cell death 
receptor: TNF/FAS (CD95) family followed by stimulating of adaptor proteins 
(FADD, TRADD and RAIDD) to produce death-inducing signal complex (DISC). 
Morphological changes in the mitochondria and specific proteolytic enzymes called 
caspases (family of cysteine proteases) are detected with activating death 
complex (Jourdain et al., 2009). 
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1.2.4.2. Intrinsic pathway 
 
The mitochondria play a major role in the intrinsic apoptosis pathway which is 
known also as mitochondrial apoptotic pathway. These pathways are followed 
genetically controlled stimuli inside the mitochondria. Many apoptosis signals are 
started  once the nuclear receptors are joined with one or more of the following 
stimuli (Figure 1.7.) such as Corticosteroids, external sources of heat or radiation, 
low oxygen level, viral infection and DNA cleavage or any other factors that affect 
the permeability of the mitochondrial cell membrane or elevating intracellular Ca2+ 
concentration all these  previous factors are considered as a key step in starting 
apoptotic pathways (Chiarugi A and Moskowitz MA, 2002).The first step in the 
apoptotic process is the release of the pro apoptotic proteins located in the 
intermembrane space by altering the permeability  features of mitochondrial outer 
membrane controlled by the BCL-2 family that is responsible to  release special 
proteins such as (cytochrome-c, Smac/DIABLO) to the cytosol and  activate 
caspase-9, which is played main role in  activating effector caspases-3, -6 and -7 
and their special cellular substrate release to the cytosol for initiating the 
morphological changes of apoptosis (Zou H et al.,1999; Kuida K et al.,1998).The 
p53 tumour suppressor protein is considered as another way to initiate the intrinsic 
and extrinsic apoptotic pathways by activation of many pro-apoptotic gene that 
have p53 binding sites, pro-apoptotic BCL-2 can also be activated by p53 
transcriptional and transcription-independent initiation of Bax.(Vousden KH and Lu 
X 2002). 
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Figure 1.7. Mechanism of apoptosis (from Kumar Robbins Pathology 7th edition 
2005). 
 
1.2.5. Inter Mitochondrial Membrane Space Proteins (IMMS) Proteins 
 
The energy metabolism in the mitochondria, plays a major role in apoptosis by 
releasing of many types of proteins that are located in inter mitochondrial 
membrane space. Upon increase in the outer mitochondrial membrane 
permeability controlling by Bcl-2 family, a group of proteins are released, and 
these initiate to apoptosis in a caspase-dependent or -independent way. 
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 Cytochrome c is the first mitochondrial protein to be released and directly 
stimulates caspase cascade by contributing to the apoptosome formation on 
condition that apoptotic protease-activating factor-1 (Apaf-1) is 
expressed.(Figure 1.8.) (Cory and Adams, 2002) 
 The Endonuclease G and apoptosis-inducing factor (AIF) proteins are 
mediated in degradation of nuclear DNA, chromatin condensation and 
cleavage of DNA into fragments and initiate apoptosis.(Susin et al.,1999).  
 Smac/DIABLO (second mitochondria-derived activator of caspase/direct IAP-
binding protein with low PI) are released, which initiate cell death by indirect 
activation of caspases and abolishing the activity of inhibitor of apoptosis 
proteins (IAPs) a family of caspase inhibitor. (Shi, Y. 2002) 
 HtrA2/OMI (high-temperature requirement protein A2), stimulate caspase 
activation and initiate caspase-independent cytotoxicity and released in 
response to thermal and oxidative stress affecting cells. (Suzuki, Y. et al. 2001)  
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Figure 1.8. Function of Cytochrome –C in apoptosis. 
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cytochrome c to the cytoplasm and stimulate the pro-apoptotic caspase cascade 
series starting apoptosis (Adams and Cory, 1998; Kroemer et al. 2007). 
 
2. Anti-apoptotic members including the four Bcl-2 homology (BH) domain proteins 
(e.g. Bcl-2, Bcl-xL, Bcl-W and Mcl-1) that inhibit mitochondrial permeability, or 
inhibit the mitochondrial release of cyt c. (Youle and Strasser, 2008). 
Bax represents a good example in illustration the mechanism by which the Bcl-2 
family form voltage ion channel in mitochondrial membrane. In normal condition, 
Bax is located in the cytosol with a negligible amount attached to mitochondria 
(Hsu et al. 1997). After specific apoptotic stimuli, BH3-only proteins involving Bid 
and Bim can cause many changes in the structure of Bax first including its 
hydrophobic C-terminal part that was hidden within the hydrophobic part to 
become uncovered and transport Bax to the mitochondrial outer membrane, then 
the second conformational changes that permit its helices number 5 and 6 to insert 
in the Mitochondrial outer membrane resulting in Bax oligomerisation inside the 
mitochondrial membrane and changing the permeability to release the cytochrome 
c and Smac/DIABLO into cell cytosol (Antonsson et al.  2000; Eskeet et al. 2000 
Ramon Roset. et al.2007);. 
 
Cytochrome c is encoded by the nuclear DNA and it is found as apo-cytochrome c 
in the cytoplasm ribosomes that can insert into the outer membrane of the 
mitochondria by a special procedure. After it’s activated with a specific enzyme 
called cytochrome c heme lyase, heme is merged and the protein released into the 
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intermembrane space of the mitochondria under the controlling of Bcl-2 family 
proteins (Gonzales et al., 1990; Stuart et al., 1990) 
 
The cytochrome c is a small protein that is found in the inner mitochondrial 
membrane as a main part of electron transport chain and have two main action in 
cell energy metabolism and apoptosis, after being released into the cytoplasm and 
binding to apoptotic protease activating factor-1 (Apaf-1) which considered as a 
key molecule of apoptosis and activating procaspase-9 causing series of 
complicated steps to start programmed cell death (Green and D. R., 2005; D. 
Nijhawan et al. 1997). 
 
1.2.7. Mitochondrial outer membrane 
 
The modification of the mitochondrial outer membrane is a key point in apoptosis, 
in normal state the limited size for molecule to pass through mitochondrial 
membrane is less than (5 KDa) resulting from the presence of specific channel in 
mitochondrial membrane known as VDAC (voltage-dependent anion channel) 
(Colombini, 1979; Dolder et al.  1999)  
VDAC channels are only permitted to 2–3 nm molecule size to pass and 
preventing the larger ones especially Cytochrome c apoptotic factors to pass into 
cytosol which is considered as a first step in starting apoptosis and activating 
caspase enzymes. For that reason, the cell requests urgent alteration in the 
mitochondrial permeability and forming larger pores (up to 100 nm in diameter) by 
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stimulating Bcl2 family that act together to alter mitochondrial membrane 
permeability and initiate apoptosis. (Schafer et al.  2009; Bleicken et al. 2010) The 
capability of Bcl-2 family to initiate pores in the mitochondrial membrane starts 
when Bcl-xL, Bax and Bak works together on voltage-dependent anion channel 
(VDAC) in the outer membrane of mitochondria  and forming large pores that are 
suitable  to release cytochrome c into the cytosol and start apoptosis process. 
(Saito M et al., 2000)  
 
Many groups of Bcl-2 family (Bcl-xL, Bax and Bak) (Schlesinger et al. 1997) have 
been examined in artificial types of membranes and showed greater abilities to 
form ion channel in the surface membrane (Minn et al. 1997;. Schendel et al. 
1999). The Bcl-2 family proteins are also discovered in the nuclear envelope and 
in other parts of body cells .The ability of these proteins in forming pore through 
ion selectivity feature inside the artificial membrane has been recognised in many 
researches but still the physiological significance of these ability is not clear 
(Antonsson et al. 1997)  
 
By activation of BAX through apoptotic stimuli, BAX translocate to the outer 
mitochondrial membrane and helps in the releasing of pro-apoptotic proteins from 
the intermembranes space of mitochondria (Figure 1.9.). There are two methods 
for releasing the intra mitochondrial membrane constituent, the first one by binding 
of the BAX, a member of BCL-2 family, to the mitochondrial membrane and the 
second by stimulating the mitochondrial permeability transition (PT),happening 
mostly due to the release of Ca2+ ions from endoplasmic reticulum (ER) , elevated 
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Ca2+ levels inside the mitochondria and swelling of the matrix of mitochondrial 
membrane and burst to release of inter-membrane space content to the cytoplasm 
which is mainly controlled by localizing of Bcl-2-family proteins at the (ER).( 
Scorrano L et al. 2002; Hsu  et al. 1997; Gross et al. 1998) 
 
Figure 1.9. The mechanisms responsible for mitochondrial outer membrane 
permeability (Bras M. et al. 2004). 
 
Tsujimoto’s group are discovered the interactions between BAX and 14-3-3 
proteins (molecules found in the eukaryotic cell that have the capacity to bind to 
specific site of functional specialization signaling proteins such as phosphatase 
and transmembrane receptor) in the cytoplasm of living cells and BAX dissociate 
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from this interaction by two principle ways including: caspase -dependent and 
caspase- independent mechanisms (Tsujimoto, 2003). 
 
There are two types of modules by which the BH3-only domain activate the outer 
membrane permeability, the direct binding of BH3-only domain to Bax or Bak 
domain and move them in the direction of outer membrane.(Cartron et al.  2004; 
Marani et al. 2002) .The other module is called indirect activation, in which BH3-
only proteins need to attach and inhibit anti-apoptotic members including Bcl-xL or 
Bcl-2. By inhibiting the activity of these groups this will open the way for Bax and 
Bak to be free from the anti-apoptotic group’s inhibitory effect and move to the 
outer membrane allowing their release towards the cell cytosol (Adams and Cory, 
2007). 
 
1.2.8. P53 and cancer 
PUMA (p53 up regulated modulator of apoptosis) also called as Bcl-2-binding 
component 3 (BBC3) have been shown to interact with anti-apoptotic Bcl-2 family 
members such as Bcl-2, Bcl-xL, Bcl-W and Mcl-1, inhibiting their binding with the 
pro-apoptotic proteins, Bax and Bak, that is lead to translocation of Bax and 
increasing of mitochondrial membrane permeability which consider the first step in 
releasing of IMMS proteins cytochrome c, SMAC, and apoptosis-inducing factor 
(AIF) starting in caspase activation and apoptosis.(Nakano K and Vousden KH , 
2004). Additionally, numerous types of cancers hold p53 mutation (Vogelstein B 
and Kinzler KW 2004), that is responsible to block PUMA activity, in spite of the 
presence of DNA damage stimulated by radiotherapy or chemotherapeutic use. 
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(Yu J and Zhang L, 2005) Some types of cancers that show over activity of anti-
apoptotic proteins of Bcl-2 family suppress the apoptosis induced action of PUMA. 
(Adams JM and Cory S, 2007) 
 
Although PUMA function is banded in many types of the cancer cells, it does not 
mean that alteration in the genetic sequence of PUMA is a main area of cancer 
research (Hoque MO et al. 2003; Kim MR et al. 2007; Yoo NJ et al. 2007). 
Anticancer drugs that stimulate apoptosis in cancer cells can also cause the same 
effects in the normal cells, so the inhibition of apoptosis stimulated by PUMA 
mutation can be considered as a new target to decrease the adverse effects of 
chemotherapy in cancer treatment and a new way to detect many types of cancer 
because many tumour cells show p53 mutation effect.(Yu J and Zhang L, 2008) 
All the cancer researchers are focused in developing the suitable therapeutic ways 
to stimulate apoptotic pathways in the chemotherapeutic treatments, so the tumour 
suppressor p53 has been considered as a main controller of apoptosis pathway.  
There are many stimuli that  are caused the  translocation of p53 towards 
mitochondria including damage of the DNA, UV irradiation, low oxygen level and 
others which lead to increase permeability properties of the outer membrane which 
can in direct or indirect way stimulate Bax (BCL-2 associated X protein) and Bak 
(Bcl-2-antagonist/killer) which stimulate the outer membrane of the mitochondria to 
release different types of apoptotic proteins such as cytochrome c, 
Smac/DIABLO  to initiate apoptosis. (Erster and Moll, 2005; Schuler and Green, 
2005) 
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1.2.9. Evasion from apoptosis 
 
There are many factors that affect the normal pathways of apoptosis leading to 
cancer progression which includes: The imbalance between pro-apoptotic and 
anti-apoptotic proteins, disturbance in the caspase function, reduced normal 
signaling of the death receptor and other abnormal resistance to the function of 
many apoptotic proteins such as (SMAC/DIABLO), cytochrome C, BCL-2 family 
proteins and other activators of apoptosis. The over expression of Bcl-2 family has 
been formerly described to keep cells away from necrosis and defending the 
cancer cell against apoptosis, showing the importance of the membrane stability 
for the function of this protein. 
 
Many energies are used in cancer researches  to make cancer cells more 
sensitive to the action of chemotherapeutic drugs or other formulation compounds 
These have been focused on the several signaling steps to decrease the 
expression of Bcl-2 family proteins or stabilize their action as the pro-apoptotic 
groups are concerned to exert many morphological changes of the apoptosis such 
as blebbing and destruction of the cell membrane, in contrast to anti-apoptotic 
proteins  action that keeps the integrity of the cell structure (Vaux D.L 1993).Any 
type of cells that follows uncontrolled growth mechanism  and abnormal increase 
in the mass of tumour is considered as main cause of cancer and reveled the 
improper balance between anti-apoptotic proteins and pro-apoptotic protein inside 
apoptotic cells. 
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The first step in treatment regime is to understand cancer mechanism in evading 
apoptosis and to discover new approach that helps in blocking tumour growth 
(Gyrd-Hansen M and Meier P., 2010). In most cases, chemotherapy resistance is 
caused by the same mutation mechanisms that suppress apoptosis and reduce 
chemotherapeutic response against cancer cell even after DNA mutation. 
(Korsmeyer SJ et al. 1995) All these series of disturbances are responsible in 
abnormal genetic alteration and converts normal cells to malignant type of cell 
growth (Hanahan D and Weinberg RA, 2000). In addition to the previous local 
disturbance, the metastasis stage of cancer can also be distributed to other parts 
of the body via blood stream, lymphatic system and other ways that place a new 
challenge in cancer therapy ( Racila et al. 1998). 
 
1.3. Intracellular delivery technique using nanoparticles 
 
Intracellular-acting proteins have been applied as an alternative way to 
extracellular–acting molecule, but there are multiple restriction factors in their 
efficiency and presence of many challenges in the cell membrane restricted 
permeability. Cancer resulted from the absence or faulty function in proteins 
concerning in cellular programmed death. Recent techniques have been 
performed by affecting abnormal cancer cell signaling using intracellular apoptotic 
proteins as tumour inhibitors. 
Intracellular healing proteins (pro-apoptotic proteins -cytochrome c) have faced a 
lot of difficulties to be applied for therapeutic purposes because the nature of their 
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physical and chemical instabilities inside the human body such as proteolysis, 
denaturation and aggregation which restricted their therapeutic effects inside living 
body. For that reason, many efforts have been focused to use a new 
nanotechnology as active therapeutic delivering vehicle  (Tabata Yand Ikada Y, 
1998; Manning M et al.  2010)  
Nanoparticles have been known to control the release of the binding proteins and 
drugs depending on the surface degradation manner of the nanoparticle. The 
accumulation of the nanoparticles at higher concentration in the cancer tissues 
than normal drugs enhances the bioavailability of the conjugated NP drugs and 
reduces the systemic toxicity. Nano-system properties have been used to deliver 
drugs to the most challenging sites in the body, for example the brain tissue and 
the presence of the blood brain barrier (Sahoo and Labhasetwar, 2003; Rawat et 
al. 2006). Other properties of the nanoparticle are noted with large surface area to 
the mass ratio enabling NP to be activated as functional platform with several 
groups and offered as easily directed particles to specific sites in the cells. Adding 
to the smaller size of the NP (1 to 100 nanometers) that helped in favorable 
aggregation at tumour sites (as the tumour do not have lymphatic drainage 
system)(Nie et al.  2007). 
1.3.1. Nanoparticles behavior in vivo 
 
In biological environment the behavior of nanoparticles is largely affected with their 
type of interaction with bio-molecules such as peptides, lipids and nucleic acids. 
The nanoparticles properties of the large surface to mass ratio serves as an 
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effective adsorption platform for different bio-environment molecules, this type of 
binding forms a specific complex which is known as nanoparticles corona. Proteins 
are defined as polypeptide with net surface charged according to the pH of 
surrounding environment. The binding protein to the surfaces of nanoparticles is 
done by different types of forces such as H-bond, Van der Waals interactions and 
others. This type of binding is not only related to the characteristic features of 
nanoparticles but also on the association and dissociation features of binding 
protein. As a result two types of protein corona can be formed either (hard corona) 
with long term binding abilities to the nanoparticles or (soft corona) with easily 
exchange protein rates (Cedervall et al. 2007; Karajanagi et al. 2004) 
Cellular proteins are represented as complex biological system and the complex of 
NPs with these bio-molecules can formed in several systems in vivo. For example 
the inhaled NPs must first pass the mucosal layer and then to lung epithelial cells 
to entered finally to the blood stream.by the same way the NPs which entered the 
cellular levels by monocyte phagocytosis, and then taken into endosome with 
different types of protein that each type of them represent unique environment to 
changing NP complex processes according to adsorption and desorption of 
environmental proteins. Nanoparticles that have introduced inside the body have 
to be measured according to different shaped acquired by protein binding in 
surrounding medium (Cedervall et al. 2007). The amount of protein binding is ruled 
by the concentration of surrounding protein, as approved by Monopoli and his 
researchers by applying different protein concentration ranging from 3% to 80%, 
while other methods are approved that the silica and polystyrene types of 
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nanoparticles are affected with plasma concentration on their range of protein 
binding (Monopoli et al.2011). The travelling of nanoparticles through various rich 
protein environments may form pre-coated layer of specific protein that behave as 
pre-coating sheet for further protein binding with new biological fluid incubation 
(Gasser et al. 2010; Lundqvist et al. 2011) 
When nanoparticles are hosted inside human plasma, they conjugated with 
different serum protein such as albumin, fibrinogen, apolipoprotein etc. A recent 
research of Hellstrand groups approved the binding of protein corona of high 
density lipoprotein on polystyrene types of nanoparticles (Hellstrand et al. 2009) 
The protein adsorption pattern on the surfaces of foreign inorganic particles 
follows dynamic control way by concerning with albumin and fibrinogen as the first 
two binding protein to the nanoparticles surfaces and consequently replaced with 
other highly affinity proteins as approved by Vroman theory in sequential protein 
binding with walled carbon nanotubes. In contrast to ultra-small super 
paramagnetic iron oxide (SPION) binding to plasma protein did not follow the 
Vorman theory when introduced to new types of plasma proteins. So, this theory 
cannot be granted to all types of universal nanoparticles (Vroman ,1962). 
The other factor that effect the protein adsorption to the nanoparticle, it is the 
protein properties itself and these types of binding may affect the type of the bio 
particles effect inside the biological medium. Some researchers are observed 
special adsorption pattern on the surfaces of nanoparticles as shown with human 
serum albumin were adsorbed on the surfaces of iron –platinum NP as a 
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monolayer pattern, while Rezwan and co-workers noticed the adsorption of bovine 
serum albumin (BSA) as a monolayer by applying 36% of its negative charge on 
the aluminium oxide NP. Additionally, the further bovine serum albumin was 
introduced as dimers pattern on the NP surfaces with additional amount of BSA 
founded in the surrounding medium (Rezwan et al. 2004). 
1.3.2. Mechanism of nanoparticles cellular uptake  
The penetration of the nanoparticles across the membrane barrier is largely 
dependent on the particles size. The acceptable particle size to enter cells is 
below 100nm, while the particle size with less than 40nm and 35nm is suitable one 
to enter cell nucleus and blood- brain barrier, respectively. The cellular uptake 
follows different uptake mechanisms such as (phagocytosis, endocytosis and 
macropinocytosis) as shown in (Figure 1.10.).The fate of uptake NPs is varied 
between the formation of lysosome particles accumulation and/or intracellular 
vacuoles in the cellular cytoplasm, this point is very critical to researchers for 
evaluation of bio-nanoparticles activity after dissolve with acidic lysosome and 
exerts the cytotoxicity effect of targeting particles (Dos Santos et al.2011; 
Albanese et al. 2011) 
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Figure 1.10. Interactions of nanoparticles with the cellular interface (Shruti et al. 
2013). 
The cellular uptake of nanoparticles is tracked by two types of pattern either 
specific one with specialized NPs ingestion by phagocytosis cells (macrophage 
and neutrophils)  which forms  special structure of folding plasma membrane 
around NPs called phagosome or non-specific uptake methods may also happen 
via extracellular fluid aggregation of NP. These methods are hosted with 
macropinocytosis by forming plasma membrane vesicle to engulf NPs. 
Additionally; endocytosis of NPs is also reflected by different plasma membrane 
receptors known as caveolins and clathrin-coated vesicles (Ruge et al. 2011; 
Wang et al. 2009). 
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1.3.3. Nanoparticle technologies for cancer therapy 
 
Nanotechnologies are used as one of the most activated search tools in clinical 
therapy during the last two decades. The liposomes and polymeric nanoparticles 
have been approved as additional advance delivery technique for many 
therapeutic drugs. 
 
In recent years, scientist are concentrated their efforts to find a vital solution 
against chemoresistance, which is responsible for unsuccessful treatment of the 
most cases of cancer. Nanoparticles are presented as the alternative ways to 
overwhelm most of these difficulties and to develop cancer treatment in the future 
(Davis ME et al. 2008). 
 
The cancer cells have different physiological properties compared to normal cells 
including high percentage of proliferated endothelial cells, extremely spreading of 
cancer vessels leading to create free spaces between endothelium lines, these 
free pores enable macromolecular particles to penetrate through cancer vessels 
and highly interstitial pressure of tumour cells that helped in external conduction of 
fluid from tumour interstitial. Therefore, this can be considered as one of the 
transport route for anticancer drugs controlled by physiological, physicochemical 
features of interstitial (pressure, structure and composition) and physicochemical 
properties of the used therapeutic molecules (charge, hydrophobicity and other 
features) (Maeda H. 2001). The permeable abilities of nanoparticles through 
abnormal endothelial proliferation spaces of cancer cells are offered a chance to 
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increase the selectivity of nano- binding therapeutic drugs toward tumour cells and 
to avoid undesirable toxic effects of anti-cancer drugs in healthy cells (Brigger et 
al., 2002). 
There are several reasons for using nanotechnology as drug delivery system. One 
of them is that, most of therapeutic drugs are available as oral or injection dose but 
this form is not optimal formulation for nucleic acid or protein formulation. For 
these therapeutic molecules more innovative design should be used to keep 
protein and nucleic acid efficacy and protect its structure from undesirable 
degradation (Slowing II, et al. 2007). 
 
The best method to increase the potency and decrease the toxicity of 
chemotherapy is to direct the active therapeutic parts to its goal and keep it there 
with sufficient concentration and enough time to get the required therapeutic 
effect. The restricted factor that affects drug deliver to various parts of the body is 
drug particle size. Nanotechnology has the ability to increase drug bioavailability, 
control the time of drug molecules release, and support drug targeting .Many 
applications were performed for nanotechnology in drug and gene delivery. 
.Additional uses of Nano scale as drug carriers served as active vehicle to 
decrease drug toxicity and increase drug distribution (Cai and Chen, 2007).   
Advantages of nano-formulated drug technique include the direct delivery capacity 
of drug into cells and the ability to target cancer cells inside healthy tissue 
(Drummond et al.,1999). 
The leaky nature of the tumor microvascular is offered natural architectures 
strategy for passive or diffusion of nanoparticles into tumor cells. The range of 
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these pores are between 100-1000nm in diameter, while the healthy cells 
microvascular pores are less than 10nm.Therefore,the formulated nanodrug 
design into tumor cells within healthy cells should be greater than 10nm but at the 
same time less than tumor pores diameter range to confirm the proper delivery of 
directed drug inside tumor cells(Moselhy et al.,2000). 
The penetrations of drug barriers with negligible loss of their activity in the blood 
are offered a maximum benefit of anticancer drugs that can largely controlled by 
the size of the injected NP. They should be large enough to avoid their rapid 
escape into blood capillaries, but at the same time they should be small enough to 
penetrate the reticulo-endothelial system, for instance the liver and spleen. The 
suitable size for the NP to avoid these two problems are ranged between (30-100 
nm) to penetrate tumour tissues (Yuan F et al. 1995). Additionally, the 
pharmacological and pharmaceutical properties of drugs can be controlled with 
new nano-technique of drug delivery systems (pharmacokinetic and bio 
distribution) to exhaust the possibilities of drug toxicity and to increase therapeutic 
effects against specific part of infected cells (Walsh MD et al. 2012; Chu KS et al. 
2013). 
1.3.4. Nanoparticle application  
 
The theory of nanoparticle was first discovered by Richard Feynman in 1959, by 
expressing the ability to create smaller machine of atoms by using larger machine 
(Feynman, 1959). 
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Nanotechnology is Greek word that referred to one billionth or dwarf. This 
technology is the fastest developing technologies in the recent years for chemical, 
biological, engineering and medical applications. Furthermore, it is considered as 
a promising tool for developing a novel platform in cancer therapy. The particular 
smaller size of nanoparticles which is usually less than (100nm) is enhanced their 
interaction with many biological system and targeted the cell surfaces and/or the 
cellular contents. This technology is used in developing smart methods for 
targeting therapeutic particles towards cancer cells, in addition to many medical 
purposes in diagnosis, detection and treatment (Cai and Chen, 2007).    
Gregoria et al. are the first group that prepared liposomes as a device for drug 
delivery (Gregoria et al., 1974). The variety features of nanoparticles concerning 
with their size, shape and chemical features of prepared nanoparticles opens new 
avenues in medical and technical applications.  
The variety types of nanoparticles are used for different application such as 
quantum dot in biological labelling and detection relating to their fluorescence size 
dependent features (Chan and Nie, 1998; Lee et al. 2012). Magnetic nanoparticles 
are used in drug delivery and as magnetic device in hyperthermia treatment 
(Joubert, 1997; Koppolu et al. 2012).Polymeric nanoparticles have been examined 
in drug delivery towards specific goals by encapsulation of therapeutic agents and 
the enhanced permeability and retention(EPR) ability of cancerous cells in 
delivering processes(Farokhzad and Langer 2006; Moses et al. 2003). 
Photothermal therapy is concerned with carbon-based type of NPs which is also 
applied in drug delivery (Bekyarova et al. 2005; Bianco et al. 2005). 
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1.3.5. Metallic nanoparticles 
 
Metallic NPs have been used extensively in many biomedical applications (Conde 
et al. 2012; Lin et al. 2014). These types of NPs have presented unusual physical 
and chemical properties due to their smaller size and controller ability in their 
synthesis and composition processes (Kogan et al.2007; Kawamura et al. 2013). 
The most appropriate methods in fabricated metal NPs are bottom-up and top-
down methods. The top-down method is dependent on the creation of the bulk 
piece of ingredient, which is followed by gradual removed object to form nano 
scale particles (Feynman, 1959). The bottom-up method have been considered as 
more controlling way in producing one atom  nanostructure particles at a time 
(Pattekari et al. 2011). 
The nickel and cobalt type of metal are characterised by magnetic properties but 
they have highly toxic effect that restricted their biological application (Denkhaus 
and Salnikow, 2002). Iron oxide and gold NPs have been applied in many 
biological and clinical fields with specific surface decoration to increase their 
stability inside biological system (Auffan et al. 2009).     
 
1.3.5.1. Iron oxide nanoparticles 
 
Metallic nanoparticles have been involved in much reported research concerning 
with drug delivery, hyperthermia treatment and imaging technique due to their 
multiple advantages in utilising the EPR effect in their passive delivery to 
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cancerous cells or using external guide(bio-recognising particles) which served as 
active targeting way in NPs delivery (Comoucka et al. 2010; Arruebo et al. 2007). 
The magnetic separation features of iron oxide NPs are served as vital role in their 
preparation which offered the cheapest and easiest way in NPs synthesis. 
Moreover, these magnetic properties facilitate the biological interaction between 
the NPs and cells. In addition to the large surface to volume ratio, surface 
decorating and controlled pH surfaces at physiological environment. However, one 
exceptional problem are experienced with magnetic types of NPs which leads to 
undesirable aggregation of these magnetic NPs inside the biological system as a 
feature of inherent magnetic property that affect the stability and the particles size 
inside the biological environment (Chan, 2007). In addition to degradation nature 
of iron oxide that produces harmful free ions when entered the biological 
environment and negatively affects the cells integrity and cell contents (Stroh et al. 
2004; Hoskins et al.2012a; Hoskins et al. 2012c). To overcome the degradation 
problem most of the researches are concerned with fabrication of magnetic NPs 
and coated their surfaces with more biocompatible material that give additional 
properties in the NPs synthesis processes. Some of these coated materials are 
polyethyleneimine (PEI) (Wang et al. 2009), poly acrylic acid (PAA) (Mak and 
Chen, 2005) or Dextran (Ciobanu et al. 2012). Additional features of coated 
processes are offered more biocompatible NPs, more biological stability and 
proper voiding from reticuloendothelial uptake problem by managing their size.   
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1.3.5.2. Gold Nanoparticles 
 
Gold nanoparticles are one of the most popular types of metallic nanoparticles that 
are used in various branches of science for their biocompatible applications, non-
toxic and simple preparation methods. Recently, remarkable increase in the 
biological applications of gold nanoparticles either alone or in formulation with 
other types of nanoparticles are noticed in drug delivery, photo thermal or  as 
diagnosis tools in different medical application ( Mikami et al. 2013).  
The types of gold nanoparticles are classified according to their shape, size and 
other chemical and physical properties which recorded as nanosphere, nanocages 
or nanorods with different physical and chemical properties for each unique type 
(Kawamura et al. 2013) 
Generally, the gold nanoparticles diameters between (2 nm to 100nm) are 
controlled by the wet chemical method in their synthesis. This method is 
concerned with reduction of chloroauric acid (HAuCl4) as a principle step in gold 
nanoparticles synthesis (Cai et al. 2008). Gold nanoparticles with 2nm in diameter 
are demonstrated as active vehicles in many biological applications and imaging 
processes (Qian et al. 2008; Jain et al. 2012). 
Recently, gold nanoparticles are used as an active platform for the delivery of 
therapeutic and imaging vehicles that experienced with low pharmacokinetics 
behaviour inside biological environments (Zhang et al. 2011; Pylaev et al.2011). 
These types of metal nanoparticles have the abilities to deliver biological 
compound that have unstable physical and chemical properties when introduced 
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into biological environments such as proteins and enhance their intracellular level 
penetration levels such as si RNA (Lee et al.2011; Lu et al.2010). The large 
surface to mass ratio of gold nanoparticles are offered the chance to optimise the 
gold surface binding ability with different ligands and functional targeting particles 
for specific disease types and sites (Torchilin et al. 2001;Jiang et al. 2008). 
The main mechanism of gold nanoparticles to penetrate cellular membrane is 
named receptor mediated endocytosis (RME) (Shukla et al. 2005). The 
penetration abilities of gold nanoparticles are greatly dependent on the particles 
size which is ranged from (1nm) for interaction with nucleus and binding with DNA 
to other size scales between (20-50nm) that show perfect cell membrane 
penetration with no cytotoxic effect (Gao et al. 2011). The surfaces of gold 
nanoparticles can be functionalised with other particles such as protein, carboxylic 
and disulfides (Aubin-Tam,2013;Delong et al.2010) by either electrostatic or 
covalent interaction especially  those with thiol groups(Lee et al. 2010). 
 
1.3.5.3..Gold-Iron oxide hybrid nanoparticles 
 
Iron oxide nanoparticles have multiple properties that are employed in many areas 
of biological researches such as high surface area to volume ratio, surface charge 
and their magnetic features to ensure easy aggregation inside the target cells. In 
some cases adverse aggregation may affect the stability of this type and cluster 
formation which leads to unwanted effects in therapeutic application. For that 
reason, special treatment has been applied to the surface of magnetic 
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nanoparticles by coating the surface with gold, silica or other polymeric 
substances (Arruebo et al. 2007; Bulte et al. 2007; McCarthy and Weissleder, 
2008).  
The most practical type of magnetic nanoparticles is iron oxide surrounded by 
biocompatible surface material which offers equilibrium state in biological 
environment and applying highly affinity ligands to the iron surface which serves 
as good binding features to therapeutic particles such as drugs, proteins and 
others. Additionally, protect the physiological space from the harmful effects of free 
iron oxide radical which could damage the cells in vivo (Tartaj et al. 2003; Gupta 
and Gupta, 2005). 
Hybrid nanoparticles are defined as a collection of more than one type of effective 
particles to be employed in scientific application by combining the multiple physical 
and chemical properties of complex nanoparticles constituents. Iron oxide –gold 
nanoparticles use the physicochemical features of the gold and magnetic property 
of iron oxide (Hoskins et al. 2012a; Hoskins et al. 2012c). 
This combination gives additional features of a rigid structure of iron and protecting 
the biological system from harmful iron oxide free radical generation (Goon et al, 
2009; Smolensky et al. 2011; Zhang et al. 2010). 
 
1.3.6. Importance of gold Nanoparticles application 
 
Recently, cancer researchers are focused on nanotechnology as vital technique in 
targeting and destroying cancer cells. There are a lot of attractive properties such 
as large surface to mass ratio, small size, unique physical and chemical 
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properties, and existence of surface plasmon resonance (SPR) with great 
biocompatibility and ease of surface binding to different functional groups. Gold 
nanoparticles have been operated in medical field during the history of research 
progress for several aspects counting with uncomplicated synthesis technique, 
cheap, inert, highly sized range 2-500 nm using different reaction parameter, the 
existence of surface negative charge enhance the binding with thiol and amine 
group. These features provide additional ability to target specific site within the 
body, reduce the required dose of chemotherapy, improving its efficacy and 
reducing therapeutic toxicity. Gold nanoparticles have the chance to deliver loaded 
particles through smallest arterioles, endothelial fenestration and cell membrane 
by enhanced permeability and retention ability (EPR) enabling the cumulative 
prosperities of nanoparticles into target cells but the main challenges that face 
circulating nanoparticles are the entrapment of gold nanoparticles in the system of 
phagocytosis (Danhier, F. et al.  2010).  
 
However, these features may possibly use as a feature point in liver cancer 
treatment by penetrating cancer cells and releasing loaded particles. The special 
surface modification of gold nanoparticles with polyethylene glycol (PEG) 
increased the presence of gold nanoparticles in the circulation and escape from 
phagocytic system (Huang, X. et al.  2007). 
 
The possibility to utilise protein delivery in the treatment of cancer has a major 
challenge by keeping efficient intracellular delivery of therapeutic proteins without 
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significantly damaging its biological function. In order to achieve these aims, a 
novel method of nanotechnology to deliver drugs and proteins in cancer therapy is 
required. The release of cytochrome-c attached to nanoparticles through the 
targeting cell is responsible to activate the intrinsic apoptotic pathway (Kim, S. K.et 
al. 2012). The metal structure type of NP is a thin layer of metal material such as: 
gold, platinum, silver and palladium encapsulating a central material for example a 
silica nanoparticle. These metal layers can be activated by using irradiation or 
magnetic field to be used as thermal release drug delivery system the method of 
conjugation with drug involves: electrostatic magnetism, nanobead connection or 
lipophilic interaction (Gareth A. Hughes., 2005) Chrysotherapy, the application of 
the gold in therapy has been recognized since olden times in Egypt, India, China 
and other culture. They have used these techniques to cure a lot of diseases such 
as skin diseases, measles and syphilis. (Huaizhi and Yuantao 2001; Richards et 
al.2002; Gielen and Tiekink 2005). 
 
The important points that restricted the proteins delivery within a living system are 
present with permeability of the proteins through the membrane of the cells and 
the second challenge is the breakdown of the proteins by enzymes in the body. 
Actually, the gold nanoparticles (Au NPs) gives the property of Au- thiol binding 
feature to the surfaces of protein via dative covalent bond and facilitate the proper 
protein delivery to the targeting affecting cells to exert their therapeutic goal 
(Malekigorji et al.  2014).The new covalent and non-covalent approaches have 
been used for binding proteins or drugs onto the surfaces of gold nanoparticles. 
Each type of binding has its own properties; covalent bond gives stable delivery 
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way, but needs intracellular pro drug handling while the non-covalent type of 
binding permit the release of active type of drugs directly (Morgan MT et al. 2006). 
As shown in (Figure 1.11.) the mainly vital points to apply drug delivery system is 
depended on proper coated  processes of active drug by nanoparticle, targeted 
specific area with successful manner and productive release of active drug there. 
West et al. have applied a 120nm diameter nanoshell surrounded by gold using it 
in cancer therapy research. These types of nanoshells allow the nanoparticle 
loaded drug to successfully bind to the targeted cancer cell either by connecting 
with antibodies or peptides to the surface of the nanoshell. By using irradiation in 
the direction of specific area of the tumour, the gold part is heated with passing the 
shell and cause death to the tumour specific cell. (Loo C et al., 2004) 
 
 
Figure 1.11. Nanoparticle drug delivery to cancer (Hu et al. 2009). 
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The biological application of nanoparticles have special restricted points including 
the surface properties of the nanoparticles that prefer to be polar in nature to 
prevent aggregation of particles inside the body by giving aqueous solubility 
feature and binding of nanoparticles to biological units such as peptides that can 
represent as address labels to move the nanoparticles towards certain sites inside 
the body. (Akerman ME. et al. 2002). The properties of the nanoparticle 
concerning large surface to mass ratio, particles size and magnetic ability are 
extremely changed from there bulk original substances and have different 
methodology application in clinical research (Kim, 2007; Heath and Davis, 2008). 
Industrial progress and functional modification in the synthesis of the nanoparticles 
gives a new line in the modification of molecular properties such as particles 
targeting, drug loading and the ability to cure diseases by using new imaging 
technique. New devices of multifunctional ability have been used to  overcome 
specific barrier and to drop into specific diseased tissues with appropriate dosage 
of therapeutic agent ,these types of advance regulatory devices are offered 
additional time and money saving in chemotherapeutic course treatment (Baptista, 
2009; Minelli et al. 2010; Ma et al. 2011; Conde et al. 2012). 
Several problems are related to chemotherapy clinical application concerning with 
the absence of specificity of anticancer drugs and rapid bio-distribution inside the 
body affecting both cancer and normal cells. Additionally, tumour cells may not be 
able to receive required therapeutic dose of these drugs that are responsible to 
produce most of the cancer resistance  types and metastasis (Panyam J and  
Labhasetwar V.,2004; Suh H,et al. 1998).For that reason, alternative modification 
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in the drug delivery system are required by applying heat therapy “hyperthermia” 
and photodynamic may facilitate cancer regression through necrotic pathway 
activation with precaution of releasing cellular contents to the extracellular spaces 
and affects neighbour healthy cells during necrosis (McCarthy JR, et al. 2008; 
Park JH, et al. 2010).Opposing to necrosis ,programmed cell death is the aim of 
the most recent cancer research to be activated inside tumour cells and break 
down cells constituent without affecting normal cells by normal clearance through 
lymphocyte and macrophages, cytochrome c is considered as a key point in 
activating apoptosis in cancer cells with proper encapsulation of pro-apoptotic 
protein inside nanoparticles gives a new regime in cancer treatment with high 
therapeutic efficacy and low side effects (Slowing II, et al. 2007). 
Active protein targeting research give great hope for treating tumour cells, but 
great difficulties have been faced with this process ,such as low protein stability 
through blood circulation and low permeability through cell membrane (Michaelis, 
K., et al.  2006). Despite, the successful of some proteins in penetrating cell 
membrane may come to be captured and degraded inside endosomes inhibiting 
their binding to specific cellular parts (Dutta, D., et al.  2007). Membrane 
permeable sequences (MPS) can direct protein therapy to specific cell sites by 
using unique surface modification properties of nanoparticles controlling their size, 
structure and general shape which are totally controlled by the type of loading 
drugs or therapeutic protein. The NPs have high solubility rate in vitro and in vivo, 
enhancing the effective targeting of cytochrome C pro-apoptotic protein without 
aggregation problem that normally occurs into protein binding in vivo and this is 
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achieved by proper functionalised processes of nanoparticles with external ligands 
to get successful targeting process and to keep the physical and chemical 
properties of binding protein or drugs inside body. In addition to, proper Activation 
of the signalling pathways of apoptosis in the cancer cells retarding their growth. 
Therefore, nanotechnology reflected the future hopes in developing the drugs 
delivery system with high efficacy and lower prices (Baptista et al., 2008; Lammers 
et al., 2011). 
1.4. Aims 
The aim of the project is to determine whether nanoparticles can act as vehicles 
for cytochrome c transfection into cells. This will be achieved via the following 
objectives:  
-Synthesis and characterisation of nanoparticles,  
-Conjugation of cytochrome c onto nanoparticle surface. 
-Intracellular concentration quantification of cytochrome c after cellular exposure  
This research is based on the synthesis and characterisation of hybrid iron oxide-
gold nanoparticles; The ICP-OES, UV/Visible spectroscopy and photon correlation 
spectroscopy are used to describe the physical and chemical properties of the 
nanoparticles to confirm the proper coating steps in each adding process. 
Additional, techniques AFM and TEM will be used to determine the size and the 
shape of the particles. Here, the cytochrome C protein loading is achieved via Au-
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thiol bond between the positively charged protein and negatively charged gold of 
HNPs.  
Graphpad prism was used throughout the thesis to detect IC50 and t-test to 
compare between two independent groups by Microsoft Excel software package.  
Biological investigations were used in chapter 3 (MTT assay, trypan blue) for the 
cell viability assays and more to evaluate the apoptosis markers (caspase 3, 
western blot, TUNNEL assay, fluorescent microscope and AFM ). These 
techniques were used in evaluation of the five different chemotherapeutic drugs 
(doxorubicin, oxaliplatin, paclitaxel, vincristine and vinblastine) cytotoxicity against 
(HepG2, Huh-7D, SK-hep-1 and U937) cell lines at specific concentrations to 
assess their IC50 values, and then novel combination of HNP-Cytochrome C was 
co-administered with previous cancer drugs in 10% growth inhibition concentration 
(0.012 mgmL-1) of CYT-C in nano-formulation against liver cancer cell lines. This 
combination will test with several cell viability assays and imaging studies to 
evaluate the potency of each anti-cancer drug. Furthermore, the levels of 
apoptosis were also evaluated in treated cancer cells after triggering with CYT-C 
protein to enhance the mitochondrial apoptotic pathways. 
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2.1. Introduction 
 
Hybrid iron oxide-gold nanoparticles have been the focus of recent cancer 
research dealing with biomedical, drug targeting and gene therapy.(Hoskins et 
al.2012a; Seied Sajadi et al. 2014;Starha et al. 2015). By combining the magnetic 
property of the iron oxide core and large surface to volume ratio with gold and 
PEG surface fabrication in (HNP), this platform results in biocompatible 
nanoparticles to be used in cancer treatment (Hoskins et al.2012b). Additionally, 
the gold surface fabrication of the (HNP) facilitates the binding of the active 
thiolated (-SH) molecules to the gold according to Au-S chemistry (Robinson et 
al.2010). 
The chemo physical stability of the gold surface of the HNP results in more 
biocompatible and simply functionalised group to therapeutic proteins and drugs. 
These properties give rise to more accurate targeting delivery of the therapeutic 
particles in the cancer research. In the recent years, some research has focused 
on polymer as the intermediate layer between iron oxide core and gold shell in 
HNP which work as protective cover to the gold migration toward the core and to 
get highly saturated and stabilized particles (Goon et al.2009). 
There are a number of protocols described for hybrid iron oxide-gold NPs 
synthesis such as iterative reduction and precipitation methods (Cho et al.2005; 
Lyon et al.2004), all strategies are concerned with the importance of sequential 
creation of magnetic iron core and gold shell as a bottom –up processing, which 
was followed with the iron oxide-gold HNP synthesis to produce mono-disperse 
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particles (Goon et al.2009). This method can create hybrid NPs with the shell size 
range of 0.5-2.0 nm and core size between 5-15 nm. Thermally activated method 
can be used as alternative way to process mixed solution of iron oxide and gold 
NPs precursors. This technique increases the thermal induced method in 
producing metal NPs combination (Schadt et al.2006). 
The electrostatic binding between the polymer coated magnetic NPs and the gold 
seed (followed by the subsequent reduction of the gold on this coated surface) can 
result in the whole covering of NPs with gold (Goon et al. 2009; Zhang et al. 2011). 
By using gold seeding technique we can get the highly controlled gold shell 
thickness with 10 nm range. The direct relation between the gold shell thickness 
and the SPR make this process very important to get highly SPR properties with 
thinner shell (Goon et al. 2009; Zhang et al. 2011). 
Barnett and co-workers synthesised magnetic gold NPs with 70 nm core and PEI 
as an intermediate polymer. The produced particles were coated with PEG 
polymer through dative covalent bonding between polymer thiol groups (-SH) and 
Au shell of the particles (Barnett et al. 2013). HNPs were synthesised following the 
Goon and co-workers method by several steps starting with  wet chemical 
precipitation method in iron oxide NP synthesis followed by the iron core coating 
with polyethylenimine (MW 750,000) as an intermediate layer between the 
magnetic core and the gold shell (Goon et al. 2009). Reduction of the HAuCl4 is 
used in the gold seeds production with (2 nm) nano-size that is binding 
electrostatically to the polymer surrounding the iron core. While the iterative 
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reduction of the HAuCl4 producing the complete covering of the particles with gold. 
Finally, to enhance the bioavailability of the particles, they covered with PEG 
polymer to increase the particles circulation time and hiding the particles from the 
engulfing immune cells. The HNP synthesise steps were characterised by several 
techniques to recognize the size, charge and shape of the particles including 
(photon correlation spectroscopy, UV/Visible spectroscopy, ICP-OES, TEM and 
AFM for morphological characteristic of NPs. 
Hybrid iron oxide-gold nanoparticles with magnetic core and biocompatible gold 
shell are offered a good functional platform for precise therapeutic delivery system 
into targeting cells resulting in remarkable decrease of therapeutic side effects. 
Hybrid NPs have presented in previous researches as effective delivery vehicles 
of 6-thioguanin in pancreatic cancer treatment, as shown highly drug uptake to the 
cells binding to NPs comparing to free drug (Barnett et al., 2013).  
The promising steps in cancer treatment have been applied with application of 
nanotechnology in biological field, one of these steps is the targeting of therapeutic 
protein towards cancerous cell by binding with HNPs to enhance the potency of 
co-administer chemotherapeutic drugs in treatment course. Cytochrome C which 
is served as pro-apoptotic signalling protein in intrinsic pathway of apoptosis was 
conjugated with HNPs in liver cancer treatment accompanying with DNA damage 
drug (doxorubicin). This formulation was recorded a significant decrease in 
doxorubicin IC50 co-administered with signalling protein (CYT c) comparing to IC50 
noted with free drug (Malekigorji et al. 2014). 
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Pro-apoptotic protein (cytochrome c) with 12KD molecular weight is categorized as 
a model bio-therapeutic protein for molecular cancer therapeutic evolution. It 
consists from 104 amino acid peptide covalently binding with heme C (Figure 2.1.) 
group at Cys 14 and Cys 17. Also,  it is one of the most important proteins in 
shuttling the electrons from complex III to complex IV in oxidative phosphorylation 
process after its release from intra- mitochondrial membrane space, in addition to 
form of apoptosome complex by binding of (Apaf-1, pro-caspase9 and dATP) that 
is responsible to activate the caspase cascade series to initiate apoptosis (Hill et 
al.  2004; Saelens et al.  2004). 
                   
 
Figure 2.1. Structure of heme C (Mavridou et al. 2013). 
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Nanoparticle characterisation is an important factor in the design and fabrication of 
new nano-sized formulations. Below the major techniques which will be used in 
this work have been outlined. 
2.1.1. Photon correlation spectroscopy (PCS) 
 
Photon correlation spectroscopy (PCS) or also known as dynamic light scattering 
(DLS) is vital instrument for detecting the size and charge of nanomaterials 
(Berne, 2000). The main principle of PCS working is depended on the light 
scattering direction by the suspension particles which follow the Brownian motion 
principle and resulted from the random motion of the small particles in the 
suspension and the collisions with fast particles movement in different direction. 
PCS is used to measure the particle size of different materials such as 
carbohydrate, protein and nanoparticles. Moreover, polydispersity index (PDI) is 
the term applied in the PCS software and reflected the types of particles 
population within the solution. The measured solution with one type of particles 
size is measured as zero value of PDI in contrast with different population size of 
particles which shows PDI values range between (0-1). This values is represented 
the degree of solution stability and the rate of aggregation and hydrodynamic 
diameter changes over time. This analysis is used to measure the nanoparticle 
size of our formulation during each steps of hybrid formulation (Berne, 2000).  
 
 
64 
 
 
2.1.2. Zeta potential 
 
The measurement of the zeta potential is considered as one of characteristic 
features of nanoparticle stability by measuring the electric potential energy of 
nanoparticles and their voltage at their surface and the parallel relation between 
their charge and the surrounded solution (Montes Ruiz-Cabello et al. 2014). The 
size of nanoparticles is controlled the value of zeta potential and its noticeable with 
smaller size that exerts remarkable electrostatic repulsion and highly stable zeta 
potential with range >30 mV. Zeta potential values lower than < 20 mV is revealed 
aggregated particles with poorly dispersed solution. The biological activity of 
nanoparticle size is directly related to acceptable zeta potential value and proper 
pharmaceutical designing (Patel & Agrawal 2011; Bhattacharjee 2016). 
2.1.3. Transmission electron microscopy 
 
The transmission electron microscopy (TEM) is a very helpful tool to detect the 
size, shape and the behaviour of nanomaterial at high resolution levels. A 
resolution ability of light microscope is restricted only by the visible light wave 
length while the electron microscopy is dependent in  fast moving electron with 
wave length less than 1A ( 1A= 10-10 m),by this technique highly improvement in 
image resolution can be done. A series of lenses are used to focus the electron 
onto the specimen and to magnify the image. The magnification ability of TEM is 
nearly to one million times, so the fundamental features of nano-size can be 
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visualised easily, recent types of TEM are provided images with more than 50 
million times, making the nanoscale imaging even easier (David J. Smith, 2015). 
The formation of TEM imaging is more complicated than the optical microscope by 
focusing the electron beam through the lens and the restricted performance with 
possible deviation of electron lenses (David J. Smith, 2015). The standard imaging 
method of TEM microscope is focused on amplitude or diffraction contrast, by 
passing a small part of electron through the specimen to magnify the final image. 
Greatest number of scattered electron are blocked to reach the image plane by 
placing small objective of aperture at the back face of the lens at focal plane which 
serves as helpful tool for the image contrast(David J. Smith, 2015). 
2.1.4. Inductively coupled plasma –optical emission spectroscopy 
 
Inductively coupled plasma –optical emission spectroscopy (ICP-OES) is one of 
the metal analytical techniques by detection and analysing of photon emission 
from the excited ions and metal atoms (Mermet 2005).Different sample state can 
be used to detection by (ICP-OES) by direct injection of the sample straight into 
the instrument with exceptional solid state which needs to be digested by acid first 
to ionise the sample (Mermet 2005). Argon gas is used to form plasma which is 
crucial to emit electromagnetic waves from the atom and excited electrons are 
detected by emission of specific wave length after return back to their ground 
state. The sample solution is injected first with a stream of argon to work as a 
nebulizer and passed through plasma at 7000°C to get excitation electron levels of 
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the samples. In our formulation, (ICP-OES) is used to detect iron and gold 
concentration in in hybrid nanoparticles formulation (Hou and Jones, 2000). 
2.1.5. UV/Visible spectroscopy 
 
UV/Visible spectroscopy is one of vital analytical instrument in chemistry which 
used to measure the absorbance of the material at ultraviolet-visible region. Once 
the material is adsorbed light, the outer surface electrons are excited to move 
them to different levels of energy and to promote the electromagnetic radiation to 
be detected at ultraviolet-visible region.  UV/Visible spectroscopy is performed by 
preparing the required detecting material in a solvent and measured with in a 
cuvette which exposed to the source of radiation with suitable wave length then 
getting to the monochromator to be passed toward the detector and measuring 
light intensity.  Each detected materials has different spectrum according to the 
possession of the electron according to the nucleus (Deeney and Sinclair, 1997).  
The calibration curve should be made for each sample by preparing standard 
serial dilution and the unknown measured samples are calculated by linear 
regression. This technique is used for detecting the proper coating processes in 
the hybrid nanoparticles formulation in each steps starting with iron oxide core, 
gold seeding till the final steps of polymer coating which determined different UV 
absorbance for each one.                                                                   
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2.1.6. Aims and objectives 
 
The main aims of work in this chapter are;  
-Synthesize iron oxide- gold hybrid nanoparticles and characterise each fabrication 
steps to ensure the proper synthesis processes.   
-Use ICP-OES, UV/Visible spectroscopy and photon correlation spectroscopy to 
describe the physical and chemical properties including metal concentration, size, 
shape and surface charge of the NPs to confirm the proper coating steps in each 
process . 
- Use AFM and TEM to help to determine the size and the shape of the particles.  
These types of nanoparticles are binding with cytochrome C by thiol –Au covalent 
bond which serves as active platform for further biological studies in the next 
chapter and targeting the apoptosis pathway of liver cancer cell lines.   
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2.2. Materials and methods 
2.2.1. Synthesis of iron oxide nanoparticles 
 
In this work the synthesis of the iron oxide particles follows the (Goon et al., 2009) 
method. Sodium hydroxide (Fisher Scientific Co, UK), Potassium nitrate (Sigma-
Aldrich Co, UK), Iron sulphate (ACROS Organics Co, USA), Sulphuric acid 
(Sigma-Aldrich Co, UK), Polyethyleneimine (Mw:750 000 D)(Sigma-Aldrich Co, 
UK) were used in the synthesis of the iron oxide core and polymer coating step. 
The magnetic core was prepared by wet chemical co-precipitation method. Firstly, 
1.03 g of sodium hydroxide and 1.82 g of potassium nitrate were dissolved in 
180ml deionized water. Nitrogen was bubbled over for 1 h at 90 °C. Next, (3.89 g) 
of iron sulphate is mixed with (20 m L) of 0.01 M sulphuric acid and adding to 
previous solution under nitrogen gas for 1 h and stirred at  90 °C for the rest 24 h 
under gas. Next day, the iron oxide NPs was separated by using highly permanent 
magnet from the outside of the mixing glass vial and the supernatant was 
removed, the magnetic particles then washed 5 times thoroughly and re-
suspended in 25 mL deionised water. The iron oxide concentration was 
characterised by ICP-OES and the hydrodynamic size and charge of the particles 
was measured by photon correlation spectroscopy (PCS). Transmission electron 
microscopy and atomic force microscopy are used in the size and shape 
discovering of magnetic particles. 
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2.2.2. Polymer coating of iron oxide nanoparticles 
 
The iron oxide NPs are coated electrostatically with poly(ethyleneimine) polymer 
between cationic polymer and the negatively charged of magnetic particles (Figure 
2.2.). These coating served as protecting layer against the aggregation of the 
particles and as active platform for gold seeds attaching to the iron oxide particles. 
In this step, the solution of 5 mL iron oxide and 50 mL of (5 mgmL-1) PEI (MW 750 
KDa) are sonicated together by a probe sonicator (Soniprep 150 plus, MSE Co, 
MSS150.CX4.5) for 2 h. 
The resulted particles are magnetically separated and washed 5 times with 
deionized water. The final nanoparticles were re-suspended in 5 mL of deionised 
water. 
 
 
 
  
 
Figure 2.2. Diagram of iron oxide NPS coated with PEI. 
 
In order to confirm the proper coating process, the particles charge was checked 
by zeta potential measurement which is in this case shift from the negative charge 
of iron oxide NPs to the positive value of PEI coating.   
 
Fe 
 
Iron core 
PEI 
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2.2.3. Gold seeding process 
 
Potassium carbonate (Fisher Scientific Co, UK), Chloroauric acid (Sigma-Aldrich 
Co, UK),Sodium borohydride (ACROS Organics Co, USA), Hydroxyl amine 
(Sigma-Aldrich Co, UK),.Polyethyleneimine; Mw:2000 D) (Sigma-Aldrich Co, 
UK),Sodium hydroxide (Fisher Scientific Co, UK) were used for gold seeding and 
polymer coating processes. 
 The mixture of 375 µL chloroauric acid (4% HAuCl4) and 500 µL of potassium 
carbonate (K2CO3, 0.2M) were stirred in 100 mL of icy cold water. After 10 min the 5 
mL solution of sodium borohydride (0.5 mgmL-1) was added slowly. At this point in 
time the solution colour change from yellow to deep red. 
The electrostatic interaction between the gold (negatively charged) and PEI 
(positively charged) achieved the Gold seeding formation as illustrated in (Figure 
2.3.) 
 
 
 
 
 
 
 
Figure 2.3.Diagram of gold seeding fabrication.   
 Fe   
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The (2 mL) of the magnetic NPs was mixed with (90 mL) of the previous gold-seed 
solution and stirrer for (2 h) at room temperature. The resulting particles are 
separated magnetically and washed 5 times with deionised water. To protect the 
gold seeds, the particles were stirred with 1 mgmL-1 of PEI (2 KD) polymer for 10 
min. 
The final particles are washed 5 times and re-suspended in 5 mL deionised water, 
these fabrication steps were characterised by zeta potential measurement by 
shifting the charge from the negative to positive according to the gold seeding and 
polymer coating, respectively. Hydrochloric acid (Sigma-Aldrich Co, UK), Nitric 
acid (Sigma-Aldrich Co, UK), Iron III standard (Sigma-Aldrich Co, UK), Iron oxide 
standard (Sigma-Aldrich Co, UK), Gold standard (Sigma-Aldrich Co, UK), 
Chloroform (Sigma-Aldrich Co, UK), Formvar (Agar Scientific Co, UK), Ethanol 
(Sigma-Aldrich Co, UK), Copper grid (Agar Scientific Co, UK) these materials were 
used in characterisation of HNPs. 
Another method in controlling the synthesis process is UV/Visible spectroscopy 
through gold SPR affecting the spectrum of magnetic NPs. 
2.2.4. Gold coating process 
 
The complete gold shell was achieved by gold reducing in the surface of the 
prepared particles and this was achieved by stirring with (110 mL, 0.01 M) NaOH 
at 60°C and (5 mL) of 1% of Chloroauric acid was added with (0.75 mL) of 0.2M  
hydroxyl amine. The iterative reduction of the two solutions was done by mixing 
1% of Chloroauric acid with (0.25 mL) of 0.2M hydroxyl amine for 10 min. After this 
72 
 
stage, the washing process was performed and particles re-suspended in 5 mL 
deionised water. To examine any surface charge changing of the final coating 
particles was checked by UV/Visible spectroscopy and zeta potential 
measurement. 
 
2.2.2.5 Hybrid nanoparticles characterisation  
 
2.2.2.5.1 ICP-OES (Inductively coupled plasma-optical emission                                                                
spectroscopy) 
 
To determine the metal content of the NPs, the ICP-OES (Inductively coupled 
plasma-optical emission spectroscopy, Optima 7000V DV, PerkinElmer, 
Wokingham, UK) was used. The sample preparation for metal detection was 
achieved by acid digestion (nitric acid: hydrochloric acid, 1:1) of (sample: acid, 1:5) 
with 100 °C heating. Prior to ICP-OES analysis diluted sample of (1:10) with 
deionised water was prepared. A calibration curve of Iron and gold standard (R2: 
0.999) was run with (10-0.05) ppm of the both metal respectively (Barnett et al. 
2013). The calculated ICP-OES iron concentration was determined in all the 
subsequent HNPs experiments.  
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2.2.2.5.2. UV/Visible spectroscopy 
 
Aqueous samples of iron oxide, gold seeds and iron oxide –gold NPs were 
prepared in quartz cuvette to be detected by UV/Visible spectroscopy (UV-2600, 
UV-Vis, ISR-2600 Plus Integrated sphere, Shimadzu, Germany). Triplicated 
experiments were run between 300-800 nm at room temperature (Hoskins et al. 
2012b). 
 
2.2.2.5.3. Photon correlation spectroscopy (PCS) 
 
The particle size and surface charge were measured by Photon correlation 
spectroscopy (Zetasizer Nano-ZS, Malvern Instruments, UK). Sonicated NPs in 
deionised water (1 mgmL-1 ) were prepared in screw-top glass vials and analysed 
at 25°C. Hydrodynamic diameter, zeta potential and polydispersity index (PdI) 
were measured at each synthesis steps of nanoparticles (Hoskins et al. 2012b).  
2.2.2.5.4. Transmission Electron Microscopy (TEM) 
 
The imagining of the NPs was performed by Transmission Electron Microscopy 
(TEM). The supportive film of polyvinyl formal ( Formvar ) was used in preparing 
the copper grids (200 mesh, Agar Scientific Co, UK) coated film. Firstly, the copper 
grids were washed in small beaker with chloroform and then dried by the filter 
paper. The lint –free cloth was used in polishing of a glass slide which immersed 
inside (3/4 of height) container of 0.5 mgmL-1 formvar. A glass slide removed 
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quickly and leaves it to dry. By using a sharp the edges of the glass slide were 
scratched to ensure the complete film removed from it, and then floating on top of 
fill water container. A film coated copper grids were prepared by laying the grids 
face down onto the film choosing the proper sit of thickness and wrinkles free. 
After that, the film was picked up and put it on the clean glass slide and leaves it to 
dry overnight. (2 µL) of each samples were pipetted onto the grid and dried for 3 h 
by heat lamp. The prepared sample was visualised under a JEOL JEM-12 
microscope (Barnett et al. 2013). 
2.2.2.5.5. Protein conjugation and quantification 
 
The conjugation processes was performed by stirring (25 mg) of cytochrome c 
(Sigma –Aldrich, Gillingham, UK) with (5 mL, 5 mgmL-1) of HNPs for 3 h at room 
temperature. At the same time (12.5 mg) of poly ethylene glycol (PEG) was added 
in parallel with pro-apoptotic protein (cytochrome c) into the previous solution of 
HNPs to cover the surfaces of hybrid particles. The final particles were 
magnetically separated and washed with distilled water five times. The resulted 
particles were resuspended with 5 mL of distilled water to get 5 mgmL-1 of iron 
which can be detected by ICP-OES instrument. The concentration of cytochrome c 
binding to HNPs was quantified by UV-VIS spectroscopy (UV-2600 UV-
VIS9NIR,Germany) at 410 nm and compared to standard calibration curve 
(R2=0.999). 
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2.3. RESULTS 
 
2.3.1. Photon correlation spectroscopy (PCS) 
 
The HNPs synthesis was checked in each step of formulation by measuring the 
zeta potential values. As illustrated in (Figure 2.4.) 
 
Figure 2.4. Zeta potential measurements of iron oxide-gold hybrid 
nanoparticles,(n=3,±SD).  
 
The surface negatively charge of iron oxide NPs (-10 mV) was contributed to 
sulphate surface presence in the synthesis process (Hoskins et al. 2012b). The 
shifting of the zeta potential to the positive charge (+28.5 mV) indicted the 
successful coating of magnetic NPs with poly(ethyleneimine) polymer. The 
presence of amine groups in the polymer gives the positively charge in this step of 
formulation. 
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The next steps of gold seeding and gold coating of Fe3O4-PEI were recorded with 
remarkable decrease in particles surface charges due to negative gold charge 
atoms and positive –OH group on polymer coating  (+10.9 mV and -5.65 mV) 
respectively. 
The hydrodynamic radius of each NPs synthesis steps were recorded as a large 
size for magnetic NPs (4160 nm) as a result of inherent magnetic iron particles. 
Consequently, the particles diameter were remarkably decrease with next 
formulation steps of polymer and gold coating related to aggregation reducing  
abilities of magnetic particles (Table 2-1). Polydispersity index (PdI) of HNPs 
referred to the homogeneity rate of the particles distribution in the formulation, 
which here showed values near 0.3 that detect a good dispersity index rate of this 
formulation (Table 2-1). 
Table 2-1.Hydrodynamic size and poly dispersity index of HNPs formulation 
measured by Photon correlation spectroscopy (n: 3, ave±SD) 
Formulation Hydrodynamic 
Size(nm) ±SD 
Poly dispersity 
index ±SD 
UV max 
Fe3O4 4160±47.95 0.27±0.33 _ 
Fe3O4-PEI 830.2±25.05 0.32±0.08 _ 
Fe3O4-PEI-Au seed 529±6.5 0.28±0.12 560 
Fe3O4-PEI-Au coating 392±15.4 0.21±0.11 650 
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2.3.2. Transmission Electron Microscopy (TEM) 
 
The actual size and shape of the hybrid iron oxide-gold nanoparticles can be 
recorded by projected area diameter of the grid used in TEM, as in this case it 
recorded around 40 nm for fully coated HNPs. 
First step of hybrid nanoparticle formulation started with TEM imaging of iron core  
at 150K magnification to verify the proper shape and size which was recorded 
about 40 nm as shown in (Figure 2.5., A), the PEI coating steps of iron core was 
imaged at 120K as shown in (Figure  2.5.,B) 
                                     
 
 Figure 2.5.TEM images of A) iron oxide core and B ) iron  core-PEI coating. 
The gold seeding processes was confirmed with 2 nm gold nanoparticles 
surrounding the iron core as shown in (Figure 2.6.) which appeared clearly on the 
surfaces of NPs  at 200K magnification. 
A B 
200 nm 200 nm 
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 Figure 2.6.  TEM image of gold seeded iron NPs. 
 
The final shape of HNPs was imaged at 100K magnification and showed 
approximately particle size around 40 nm. The image of final particles was showed 
external smooth shape with fully gold coated layer and no more appearance was 
observed for the gold seeds (Figure 2.7.)  
              
Figure 2.7.   TEM image of final HNPs. 
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100 nm 
79 
 
2.3.3. Inductively Coupled Plasma-Optical Emission   Spectroscopy (ICP-
OES) 
 
The metal concentration of the HNPs concerning with (iron and gold) particles 
content were detected by ICP. In this formulation the iron and gold concentration 
were 2.09±0.44 mgmL-1 (R2: 0.9997) and 1.16±0.21 mgmL-1 (R2: 0.999), 
respectively calculated from the standard iron and gold curves. The metal analysis 
using ICP was repeated for four different patches of iron oxide-gold NPs, 
presenting the reliable and reproducible synthesis process.  
2.3.4. Protein binding 
 
The amount of cytochrome c attached to HNPs was assessed by UV-VIS 
spectroscopy. The concentration of pro-apoptotic protein was (1.98 mgmL-1) 
attached to HNPs comparing to (1.78 mgmL-1) attached to PEG added HNPs 
(Table 2-2). The changed of CYT-c concentration was contributed to the 
attachment sites competition between the polymer and protein on the gold surface 
of the HNPs. The UV-VIS spectra (Figure 2.8.) revealed the absorbance of CYT c 
in HNPs at 410 nm, while no spectra was detected at previous wave length for 
HNPs with no protein conjugation. 
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Table 2-2.Iron, gold and cytochrome C concentration in HNP and HNP-CYT C 
formulation determined by ICP (Fe and Au) and UV visible (CYT-C). 
 
 
Samples 
 
 
Fe 
 
Au 
 
Cytochrome C 
mgmL-1 mgmL-1 mgmL-1 
HNP 2.0997 
 
0.7694 
 
_ 
HNP- C 1.4664 
 
0.2100 
 
1.989 
 HNP- C-PEG 1.4664 
 
0.2100 
 
1.7866 
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2.3.5. UV/Visible spectroscopy 
 
The absorption spectra of each formulated part in the HNPs was determined at the 
maximum absorption wave length in UV/Visible spectroscopy graph (Figure 2.8., 
A). The Fe3O4 alone did not show any absorbance within the wavelengths tested. 
The colloidal 2 nm gold seeds showed strong absorbance at around 480 nm. Once 
attached onto the Fe3O4-PEI a band shift was observed with a lambda max of 
approximately 540 nm. After subsequent coating the final HNPs showed a peak 
absorbance of 600 nm, this indicated that complete coating had formed. The 
significant signal was observed at 410 nm as successful indicator of pro-apoptotic 
protein (CYT-C) binding onto the HNPs surfaces (Figure 2.8.,B). 
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Figure 2.8. UV-Vis absorbance spectra of A) Fe3O4, Au seed, Fe3O4-PEI and 
HNPs and B) UV-Vis absorbance spectra detection of CYT-C attachment to the 
HNPs. 
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2.4. Discussion 
 
The successful HNPs synthesis were performed and detected by ICP-OES, 
UV/Visible spectroscopy, TEM and PCS. 
Metal content of the HNPs was detected by ICP-OES and calculated the 
concentration of the gold and iron which is consider as main critical step in the 
next  biological application of the new formulation.  
Generally, the gold coating processes of the magnetic nanoparticles was indicated 
in each step by UV/Visible spectroscopy and zeta potential measurements. Iron 
oxide core negative charge was shifted to the positive value with successful PEI 
coating as a functional binding layer to the next gold seeding (around 2 nm) 
followed by consecutive reduction of the gold onto the particles surfaces in the 
course of coating  process (recording negative charge due to the existence of 
gold) . The gold coating thickness was studied to determine the ideal physical 
properties for various applications (Huang et al., 2007; Zijlstra and Orrit, 2011). All 
the previous steps were indicated by the zeta potential measurements (Figure 
2.4.) and UV/Visible spectroscopy graph (Figure 2.8.).     
Zeta potential values are recorded with lower positive value of Fe3O4-PEI-Au seed 
comparing to second steps of PEI coating formulation. The complete particles 
coating with gold is showed negative zeta potential value that confirm the proper 
presence of gold negative charge and confirm the gold seeding and coating 
processes during the formulation steps. The absorbance measured by the 
UV/Visible spectroscopy was identified the gold occurrence in these construction. 
84 
 
After the gold seeding and coating processes the remarkable shift in the UV 
absorbance from 480 nm to 540 nm and 600 nm, respectively. The absorbance 
signal at 410 nm is confirmed the successful binding of pro-apoptotic protein 
(CYT-C) onto the HNPs surfaces as no signal was observed at this wave length 
prior to protein attachment.  
The magnetic iron oxide core was observed as aggregated particles when 
hydrodynamic diameter measured by PCS and this reflected the magnetic inherent 
properties of magnetic NPs in solution. For that reason, TEM images were 
recorded with smaller particles diameter comparing to PCS values and these 
studies were approved with previous researches that confirm the higher 
hydrodynamic diameter of magnetic NPs with aggregation formulation (Hoskins et 
al. 2012b). The next fabrication steps of iron oxide core coating with PEI polymer 
showed lower hydrodynamic diameter and recorded as (830 nm) comparing to 
high diameter measurement observed with iron core which analysed as (4160 
nm). These significant decreases in particles diameter were reflected the 
successful PEI coating that act as stabilising agents by decreasing the undesirable 
aggregation of magnetic iron core. The electron microscopy images were recorded 
slight increase in particles size ranging from 30 nm for naked iron core to 40 nm 
for fully coated NPs and these TEM measurements showed 10 nm thickness of 
the coated layer. The coating thickness is reflected the gold resonance abilities as 
well as the heating processes by working as a good heating and magnetic vehicle 
with thin coated layer formulation ( Prodan et al. 2003; Barnett et al. 2012). 
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Recently, the binding of nanoparticle with bio- therapeutic protein has been 
applied in cancer researches. The big challenges of binding of active protein 
without affecting the proper function of it was achieved by labelling cytochrome C 
site with negatively charged gold nanoparticles by thiol –Au covalent bind. The 
binding of gold nanoparticles at different cites of cytochrome C showed the type of 
electrostatic interaction between the amino acid side with nanoparticle ligand 
which control the proper behaviour of binding protein. Although, some binding 
sites of cytochrome C may lead to protein denaturation. In order to preserve the 
protein structure, the loosely folded motive is prefer in labelling processing as 
alternative to nucleation centre folding (Marie-Eve Aubin et al. 2008) 
The possibility of binding between the thiol residue of cytochrome C and the gold 
is basis on the covalent gold-thiol bonding. This technique used the organic linker 
between the gold nanoparticles and protein. Moreover, this strategy is offered a 
highly structurally defined type of bonding (Heaven et al. 2008; Jadzinsky et al. 
2007). More labelling strategies were used with peptide, oligonuclioside and 
bioactive molecules (Krpetic et al. 2009; Ackerson et al. 2010; Bowman et al. 
2008). 
Cytochrome C is categorised as vital targeting protein in many regimens of cancer 
therapies. However, apoptosis activation with 12.7 KDa CYT C molecular weight is 
experienced many challenges into cellular delivery mechanism without affecting 
the physical and chemical stability of bio-therapeutic proteins (Manning et al. 
2010). Countless efforts were reported to deliver CYT C properly and with 
sufficient levels inside cell cytoplasm, the electroporation way is one of applied 
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methods of CYT C intracellular delivery (Sharonov et al. 2005). Another technique 
is concerned with protein nanoparticles formation by nanoprecepitation coated 
with biocompatible types of polymer such as poly (lactic-co-glycolic) acid to 
enhance protein circulation time inside the body and to increase the cellular 
uptake of CYT C by Hela cells to initiate apoptosis (Morales-Cruz et al. 2014). 
Further researches showed the ability of direct binding of CYT C onto the 
functionalised nanoparticles surfaces such as metal type, gold (Aubin-Tam et al. 
2009), polymer (Morales-Cruz et al. 2014) and silica (Shang et al. 2009) . The 
testing of the apoptotic effects of these combination were reports with remarkable 
increases in the apoptotic markers and with death of targeting cells. In this study 
additional advantages are reported with CYT-C binding to the surfaces of HNP 
which serviced as vital carrier of therapeutic molecules and as imaging agents.  
 
2.5. Conclusion  
 
Hybrid iron oxide-gold NPs have been successfully formulated and characterised 
by several methods such as PCS, UV–vis absorption and TEM. All the checking 
steps confirmed the successful formation procedure of hybrid nanoparticles. The 
magnetic iron core with 30 nm diameter was manufactured and other formulated 
layers were diagnosed as a polyethylenimine intermediate layer and gold coating.  
The final size of HNPs was approximately diagnosed as 40 nm by TEM. 
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The synthesis steps of HNP and protein binding were successful as characterised 
by UV-Vis spectroscopy, which confirmed that 40% of loaded cytochrome C site 
are binding with negatively charged gold nanoparticles by thiol –Au covalent 
bonds. Further biological studies will be carried out on this formulation to detect 
the cellular uptake, cell viability, apoptotic effect and imaging studies against 
hepatocellular carcinoma cell lines.  
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Chapter Three 
Biological investigations & 
Cytotoxicity 
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3.1. Introduction 
 
Hepatocellular carcinoma (HCC) is the main type of primary liver cancer, which is 
diagnosed as highly vascular type of cancer and reportedly is the third biggest 
cause of cancer death in the world. The studies of molecular signaling pathways of 
this tumor type have been carried out extensively in previous studies, towards the 
direction of discovering new therapeutic targeting bio-molecules to decrease the 
high percentage of patient mortality within normal treatment pathways such as 
chemotherapy and surgery (Sharma et al. 2016; Ling Huang et al. 2017). The 
usual methods of cancer treatment often experience poor site specific targeting 
(Rasmussen et al. 2010). One of the new cancer treatment strategies is the use of 
nanomaterials to make nanomedicines, since 1970 the nanoscales have been 
used as drug carrier and imaging device in different pharmaceutical applications. 
The remarkable development in the synthesis of NPs was reported as active drug 
delivery system and controlled drugs release for trapping different types of the 
cancer cells (Felice et al. 2014; Fernandes et al. 2015; Ling Huang et al. 2017). 
Nanoparticle interaction with proteins has played vital role in the basis of bio-
activity of different types of nanoparticles. These give rise to the behavior of 
therapeutic molecules by affecting cellular uptake, accumulation behavior inside 
targeting cells and to generate bio-compatible nanoparticles with therapeutic goals 
in a biological environment.The successful binding of bio-active cytochrome C with 
hybrid iron –oxide NPs have been studied for HCC treatment (Malekigorji et al., 
2014; Figueroa CM, et al. 2017) and reported with significant synergism between 
doxorubicin and HNP-C as active cytotoxic device against HepG2 cell line, these 
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effects were recognized by different cell viability assays and imaging studies 
(Malekigorji et al., 2014). Cytochrome C as illustrated previously has a main role in 
proper activation of apoptosis pathways which is considered as crucial step in 
cancer treatment. Previous attempts to introduce cytochrome c have also been 
studied with lipid–apolipoprotein and mesoporus silica NPs (Kim et al., 2012; Park 
et al., 2010). 
The effectiveness of the most therapeutic devices should be proven first in 
different discovery steps of chemical and biological researches before to be 
proven as acceptable clinical therapies. Therefore, the preclinical screening of 
novel drug formulation is first done in biological environment by using different 
types of living cells and tissues to evaluate the pharmacological action of the novel 
therapeutic formulation (Pathania et al. 2014; Megha et al. 2015). The biological 
testing of novel drug formulation is crucial inside biological system which known as 
complicated chemical and biological system that can be directly or indirectly 
effects on the bio-therapeutic activities of introduce drug formulation. Most of these 
factors are related to pH, temperature, digestive enzyme, blood proteins and 
others factors related to the medium of targeted organs (Wijdeven et al. 2014; 
Lemke 2008). 
A variety of tests are used in vitro studies to predict the cytotoxicity of novel 
formulation. However, they cannot fully replace in vivo tests but can be considered 
as optimizing techniques for drugs activities and to avoid highly number of false 
positive results which start during in vivo studies and generate undesirable side 
effects for animals. By means of this technique we can save time and money for 
91 
 
further improvement in the medical researches and ethical consideration. In vitro 
tests are used to study the stability of the new therapeutic formulation and to 
evaluate specific criteria of drug mutagenic and cytotoxic effects by using living 
tissue with already known signaling pathways (Corvi and Madia, 2016). 
For novel biomedical and therapeutic applications, the conjugation of therapeutic 
proteins onto the surfaces of nanoparticles has been of main concern in recent 
years. Recently, hybrid iron oxide- gold nanoparticles were functionalised with 
hydrophilic polymer poly (ethylene glycol) to produce long circulating time by 
hiding HNP from the endoplasmic reticulum system. The presence of a functional 
gold shell on HNP surface (Au) allows the dative covalent bond to the thiol (-SH) 
group of cytochrome c (Malekigorji et al.,2014).  
3.1.1. Aims and Objectives 
 
The main aims of this chapter are: 
-To determine the cytotoxicity effect of cytochrome C hybrid formulation against 
the liver cancer and U937 cell lines and how to improve the potency of 
doxorubicin, paclitaxel, oxaliplatin, vinblastine and vincristine when co-administer 
with IC10 determine concentration of HNP-C by targeting the main apoptotic 
mechanism of each drug.  
-To investigate the activity of this formulation on liver cancer cell lines by cell 
viability assays (MTT assay, trypan blue). 
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- To analyse levels of apoptosis in treated cells by use of apoptosis detection kits 
and microscopy at different stages (caspase 3, western blot, TUNEL assay, 
fluorescence microscopy and AFM ). 
-To measure intracellular concentration quantification of cytochrome c after cellular 
exposure  
 
3.2. Materials and methods 
 
Doxorubicin, Paclitaxel, Oxaliplatin, Vinblastine and vincristine were purchased 
from LC Laboratories (Woburn, USA); cytochrome C and other materials were 
provided from Sigma-Aldrich (Gillingham, UK). Hepatocellular carcinoma cell line 
(HepG-2) was provided from ATCC [HEPG2] (ATCC® HB8065™), SK-HEP-1 was 
from ATCC (ATCC® HTB-52™); Huh-7D12 cell line was from ECACC (European 
Collection of Authenticated Cell Cultures) and U937 cell line was from LGC 
standard Co., UK. U937 cell line was supplied with phorbol-12-myristate 13-
acetate (PMA) (0.02%, 50 µgmL-1 in PBS (Phosphate Buffer Saline), Sigma- 
Aldrich) to prepare differentiated U937 to culture processes.  Hybrid iron-oxide 
gold nanoparticle were synthesised in the lab. The cell lines were grown as 
monolayer in ATCC- formulated Eagle`s Minimum Essential Medium for (SK-HEP-
1);DMEM culture media for (HepG-2 and Huh-7d) and PRMI culture media for 
(U937) and placed in a humidified incubator with 5% CO2 at 37 °C. To make 
efficient growth medium for this cell line were added 10% FBS (fetal bovine serum) 
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and 1% (penicillin/streptomycin) solution provided from Sigma. The IC 50 values 
and cell viability graphs were performed by using Graph Pad Prism 7 software. 
  
3.2.1. Cellular uptake of protein  
 
Liver cell lines and U937 were seeded in 6 well plates and incubated for 24 h at 37 
°C with 5% CO2.Next day the media was replaced by 100 µL (50 and 100 µgmL
-1) 
of cytochrome C and HNP-C per well and incubated for 1 and 4 h. After each 
incubation period the media was removed and the treated cells were washed with 
PBS preparing to detach by trypsin adding to each well. The suspension cells in 1 
mL fresh media were counted by automated cell counter (Invitrogen countess, UK) 
to transfer 100,000 cells of each cell line into Eppendorf tubes and centrifuged for 
5 min at (250 g). The resultant supernatant was removed and the precipitated 
pellets were resuspended with 1ml of sterilised water. The concentration of protein 
alone and in combination with HNP were measured at 410 nm and analysed per 
cell by using UV/Vis spectroscopy (UV-VIS with an ISR-2600 Shimadzu, 
Germany). 
 
3.2.2. Cell viability assays 
 
96 well plates were used to seed 15,000 cells with 100 μL of media per well for 
each cell lines and allowed to adhere overnight (24 h) in humidified incubator at 
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37% in 5%CO2 atmosphere. Serial dilutions of Doxorubicin (5-0.25 μM); 
Oxaliplatin (128-8 μM); Paclitaxel (100-1 nM); Vincristine and Vinblastine (100-1 
nM) alone and in combination with HNP-C (0.012 mgmL-1) were added to the 96-
wells of HepG2,SK-hep-1,Huh-7d and U937 cell lines and incubated for (24, 48 
and 72 h). At these three times vital dye (yellow MTT 3-(4,5-dimethyl-2-thiazolyl)-
2,5-diphenyl-2H-tetrazolium bromide) was used to detect the number of live cells 
which reflected the cytotoxicity effect for anticancer drug alone and with 
formulation. 
 
3.2.2.1. MTT Assay 
 
The reduction of the MTT by mitochondrial reductase enzyme which is related 
directly to the number of live cells leads to form insoluble purple formazan crystal; 
the crystals can be solubilized using DMSO. For each time points (24,48 and 72 h) 
removed the serial drugs solution from treated cells and add 100 μL of MTT 
sterilized solution, put in the incubator for 3-4 h to permit the reduction of 
Tetrazolium dye by oxidoreductase mitochondrial enzyme referring to the 
metabolic activity of the live cells forming insoluble formazan crystal then removed 
the MTT solution and replaced by 100 μL of DMSO to form colorimetric solution 
optical densities were measured in microplate reader(Techan Infinite, Austria) at 
570 nm.  
 
95 
 
 
 
3.2.2.2. Exclusion test of cell viability by Trypan blue  
 
The main principle of this technique is the determination of the percentage of 
viable cells in the suspension cultured media depending on the intact cell 
membrane that exclude trypan blue staining in the live cells in contrast to blue 
staining dead cells with  a destroyed outer membrane. 
HepG2,SK-hep-1,Huh-7d and U937 cell lines were introduced to undergo 
apoptosis by treating with previous detection serial dilution of (doxorubicin, 
paclitaxel, oxaliplatin, vincristine and vinblastine) alone and in combination with 
10% (0.012 mgmL-1) growth inhibition of HNP-cyt C  (50,000 cells/well) in 6 well 
plates for three time points 24 h, 48 h and 72 h and incubated at 37°C with 5% 
CO2. At the end of each required time of treatment, the supernatant was removed 
and put in suitable tube, and 0.5 ml of trypsin added to detach the cells from the 
bottom of the well and mixed with previous supernatant. The prepared cell 
suspension (50 µL) was mixed with 50 µL of trypan blue and pipette into automatic 
counter slide and then read it by (Invitrogen countess, UK) the percentage of 
viability was detected in relation to control cells. 
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3.2.3. Apoptosis assays 
 
3.2.3.1. Caspase-3 assay: 
 
Measuring the caspase-3 level as an indicator of apoptosis, this was performed by 
using caspase substrate (Ac-DEVD-pNA) as a colorimetric assay (Caspase 3 
Assay Colorimetric Kit ((ab39401) Abcam). The hydrolysis activity of caspase 3 
based on the cleavage pNA part of tetrapeptide chain of DEVD is based on the 
PARP (Poly (ADP-ribose) polymerase cleavage at (216 –Asp-Gly -217) as a main 
step in apoptosis execution. The results of this kit are quantified by measuring the 
light emission from p-NA cleavage part of this moiety and detected at 405 nm 
using microplate reader (Techan Infinite, Austria). The activity of caspase 3 
enzyme is calculated by the comparison between the absorbance of control cell 
(untreated cells) with the absorbance of treated cells and determined as fold 
increase from the control, triplicated experiments were performed for each 
samples.  
Liver cancer cells and U937 were induced to undergo apoptosis by treating with 5x 
IC50 of doxorubicin, paclitaxel, oxaliplatin, vincristine and vinblastine alone and in 
combination with 10% growth inhibition of HNP-cyt C in specific concentration 
(1×106/well) in 6 well plates. At the end of each required time of treatment, the 
supernatant were removed and put in suitable tube, and then added 0.5 mL of 
trypsin to detach the cells from the bottom of the well and mixed with previous 
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supernatant. The cell suspensions were centrifuged for 10 min at 250g. The 
supernatant was carefully removed and added 25 μL of cold lysis buffer to the cell 
pellet. This step allow to release cell protein to be determine by adding 25 μL 
assay buffer and 25 μL DDT (Dithiothreitol) stoke solution to each hydrolysis 
samples. To each well that undergo previous reaction were add 5 μL of caspase-3 
colorimetric substrate (Ac-DEVD-pNA) which reflect a series of  amino acid , then 
transfer the caspase -3 enzymatic reaction treated cells to 96 well flat bottom plate 
and incubated at 37°C for 1-2 hours. After incubation the plate was read at 405 nm 
by micro plate reader (Techan Infinite, Austria). Additional control were prepared 
by adding assay buffer, lysis buffer and DDT into one well without caspase 
substrate and assay buffer and DDT plus caspase substrate into other ones.  
 
 
3.2.3.2. Western blot  
 
Liver cancer cell lines (HepG2, Huh-7D12 and SK-hep-1) with U937 cells 
underwent apoptosis in the 6 wells plate (1×106/well). After 48 h of treatment 
period, the treated media were removed, and collected in suitable Eppendorf. After 
that 0.5 mL of trypsin were added to each well to detach the adherent cells and 
mixed with previous collected supernatant in corresponding pattern. The mixed 
suspension cells were centrifuged for 3 min at 250 rpm, 4°C.The produced cell 
pellets were washed with chilled PBS and centrifuged again to keep the final 
precipitated pellets at -80°C. 
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The chilled cell pellets were collected and lysed by adding 100 µL of RIPA buffer 
(“Radio-Immunoprecipitation Assay”) constituent from protease and protease 
inhibitor including, 150 mM sodium chloride (Sigma-Aldrich), 20 mM Hepes 
(CalbioChem), 2 mM ethylene-diamino-tetraacetic acid (EDTA, Sigma-Aldrich), 1% 
NP40 (Sigma Aldrich), 120 µM leupeptin (Sigma-Aldrich), 1 mM 
phenylmethanesulfonyl fluoride (PMSF, Sigma-Aldrich),  10 µM pepstatin (Sigma-
Aldrich) and 0.5% sodium deoxycholate (Sigma-Aldrich), for each pellet and 
centrifuge for 10 min at (14000 rpm, 4°C), the resultant supernatant were collected 
and kept at -80°C.  
(BCA) bicinchoninic assay (Sigma-Aldrich) was used as quantitative method in 96 
well plates to detect the protein concentration for each samples by mixing 10 µL of 
resulted lysate with 100 µL of BCA reagent (Sigma-Aldrich) and incubated for 30 
minutes at 37°C to be read it after at 570 nm using plate reader and then 
compared with BSA standard Bovine serum albumin (Sigma-Aldrich) with 
concentration range from 0.1-2 mgmL-1. 
The next step in western blot is the detecting of specific protein which is concern 
here with (PARP) cleavage as apoptosis indicator, each sample was mixed with 5 
µL of prepared buffer of (β-mercaptoethanol ,Sigma-Aldrich), and SDS-Nupage 
,1:20, Sigma-Aldrich) and boiled at 80°C then centrifuge gently and applied to gel 
electrophoresis process using 4-20% Bis Tris gels (Invitrogen) type in an XCell 
SureLock Mini Cell (Invitrogen) which loaded with hepes running buffer (100 mM 
hepes, 1% sodium dodecyl sulphate and 100 mM Tris ,SDS, Sigma-Aldrich), the 
standard protein ladder was used to detect the proper size of gel separated protein 
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PageRuler Plus Prestained Protein Ladder (Thermo Scientific). After that, the gel 
proteins were transferred electrically to the PVDF membrane (polyvinylidene 
difluoride membrane, GE Healthcare Life Sciences) soaked in transfer buffer (200 
mM glycine (Sigma-Aldrich), 0.075% SDS, 25 mM Tris and 10% methanol (Sigma-
Aldrich)) for 1.5 hours at 25 V. solution. The blocking process was performed to 
PVDF protein membrane by using milk solution (5 g of semi-skimmed dry 
milk+100 mL (TBST 1X) Tris buffer saline tween) Tris buffer prepared from 50 mM 
Tris hydrochloride (pH 7.4, Sigma-Aldrich), 150 mM NaCl, 0.1% Tween 20) and 
put on a Stuart Scientific Platform Shaker STR6 with gentle shaking for 1 hour and 
at room temperature to prevent random antibody binding on various banding of 
separated proteins. The primary detected antibody (PARP, Cell Signalling 
Technology) in ratio of 1:2000 was prepared to soak PVDF membrane overnight at 
4 °C and the membranes were washed after the incubation with TBST 1X , 
followed by another incubation period with secondary antibody which prepared by 
mixing anti-rabbit AB (Cell Signalling Technology)  with blocking milk solution in 
dilution ratio equal to 1:2500 (10µl:10ml)respectively. The UptiLight HRP 
chemiluminescent (Uptima) are used as a substrate to visualise the reactive 
protein bands on FluorChem M Imager.  
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3.2.3.3. Terminal deoxynucleotidyl transferase  (dUTP) nick end labelling 
(TUNEL) assay 
 
TUNEL colorimetric method was used to detect DNA damage marker for apoptosis 
detection in 96 well plate kits which are purchased from (R&D system). Liver 
cancer cell lines (Hep G2, Huh-7D, SK-hep-1) and U937 cell lines were cultured in 
96 well plates with concentration (1×105 cells /well) and then treated 
with(Doxorubicin, Paclitaxel, Oxaliplatin, Vinblastine, Vincristine) alone and in 
combination with 10% cell viability effect of HNP-C and leave it for 24 h in a 
humidified incubator with 5% CO2 at 37 °C. According to the manufacture’s kit 
protocol, the media was removed from each well and then the adherent cells were 
fixed with 3.7% buffered formaldehyde solution for 7 min, followed by washing with 
PBS (2 times) and centrifugation between each washing steps. The post-fix step 
was performed by filling the wells with 100% methanol for 20 min and wash with 
PBS preparing for the labelling procedure, 96 well plate centrifuge (Sigma 
Refrigerated centrifuge 4K15) was used for the following steps . Firstly, 50 μL of 
protein K solution (50 μL of distilled water with 1 μL of protein kinase) was added 
to each well for 15 min at room temperature and then centrifuged at 1000 X g for 3 
min and discard the buffer, Then wash twice with 200 μL of distilled water per well. 
Positive and negative controls were generated by adding 10 μL of TACS-
NucleaseTM ( Trevigen Apoptotic Cell System) to the control wells and incubate for 
1 h at 37°C to indicate the level of DNA breaks which serves as a substrate for 
further labelling reaction accompanied with unlabelled control to show the 
background of labelling processes. After incubation period, 50µl/well of quench 
endogenous peroxidase (0.5 mL of 30% hydrogen peroxide with 5.5 mL of 
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methanol (Sigma-Aldrich)) was added to avoid non-specific back ground staining, 
and then wash twice with distilled water. Labelling reaction is prepared by adding 
150 µl/well of 1X TdT (Terminal deoxynucleotidyl Transferase) buffer for 5 min and 
the 50 µl/well of labelling reaction mix (5ml 1X TdT, 35 µl TdT dNTP mix, 100 µl 
50X Mn2+ and 35 µl TdT enzyme) were used for more 1 h incubation time at 37°C 
to facilitate the addition of nucleotide to the 3 terminus of DNA and to detect the 
number of apoptotic cells. Next to labelling reaction 150µl/well of 1XTdT stop 
buffer were applied for 5 min to stop the labelling reaction and to prepare the 
sample to secondary labelling reaction with 50 µl/well Strep-HRP (Streptavidin- 
horseradish peroxidase) solution for 10min at room temperature to detect 
biotinylated antibody and to produce colorimetric reaction. At the final steps of the 
reaction 100 μL/well of 5% phosphoric acid were added to stop the reaction and 
measure the absorbance at 450 nm by plate reader (Techan Infinite, Austria). 
Experiments were carried out in triplicate. 
 
3.2.4. Apoptosis detection by imaging studies 
 
3.2.4.1. Fluorescent microscope 
 
Liver cancer cell lines with U937 were seeded on glass cover slip in 6 wells plate 
(1×106/well) and exposed to apoptosis by anticancer drugs alone and in 
combination with nanoparticle formulation in indicated concentration, after 24 h. 
treatment period the growth media was removed from each well and washing with 
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1 mL of (1X Annexin ,Life Technologies Co, UK) binding buffer follows the 
manufacture instruction  and repeated the washing steps to one more time. After 
that, 5 µL of Annexin V fluorescein probe (life technologies Co, UK) , 5 µL of 
Hoechst nuclei stain (life technologies Co, UK)  and 5 µL of propidium iodide (life 
technologies Co, UK) are mixed with 100 µL of (1X Annexin ) binding buffer was 
added to each well and incubated at room temperature for 15 min in dark place. 
Then, repeat the washing process with 1 mL of (1X Annexin) binding buffer. The 
fluorescence staining cells were fixed with 2% formaldehyde (Sigma-Aldrich) for 
10 min to prevent any disruption to cell membrane and then wash with PBS for 3-4 
times then put 2-3 drops of mounting media (Sigma-Aldrich) onto the face of each 
glass cover slip to prevent photo bleaching and to match the refractive index of the 
sample during the imaging process. The glass slips were fixed on the glass slides 
and visualise by fluorescence microscopy (InvitrogenTM EVOSTM FL, Thermo 
Fisher). 
 
3.2.4.2. Nanoparticles internalisation imaging by Transmission electron 
microscope 
 
Cross section imaging of liver cancer cell lines and U937 were captured by TEM 
microscope (JEOL, JEM-1230 microscope (Japan)) and all chemicals and 
materials used are purchased from (Agar Scientific).   
Cancer cells were incubated with 25 µgmL-1 of HNP-c after cells were seeded into 
Aclar slides in 6 wells plate for 24 h. next day the treated cells were washed with 
103 
 
PBS followed by fixation steps with 2.5% gluteraldehyde in Na cacodylate buffer: 2 
mM calcium chloride for 2 h. Then, cells were washed with previous buffer for 5 
min and repeated for 2 times. The post fixation step was performed by using 0.1% 
Osmium tetroxide in 0.1 M sodium cacodylate buffer: 2 mM Ca chloride for 1 h. 
Dehydration process with serial percentage (70%, 80%,90%,100% and 100 dry of 
ethanol for 15 min. to each steps ) were used as preparing to next polymerisation 
and infiltration steps with SPUR resin (13 g of NSA( Nonenyl Succinic Anhydride), 
5 g ERL (ERL 4221 RESIN), 3 g of DER( DER 736)  and 0.2 g of S-1 DMAE 
(Dimethyllaminoethanol)) with series of 1:3 dry alcohol/resin,2:3 dry alcohol/resin 
and 100% resin to get hard film and to be ready to cut and get thinner layer 
section. The ultra-sectioning process of resin was achieved by diamond knife 
using (Reichert-Jung Ultracut E Ultra Microtome) and placed the produce ultrathin 
sections into copper grids to stain by heavy metal (Lead citrate and Uranyl 
acetate) to increase contrast level of the final imaging of TEM microscope (JEOL, 
JEM-1230 microscope (Japan)) with specific software.  
 
3.2.4.3. Topographical imaging by atomic force microscopy 
 
Liver cancer cells and U937 were seeded into 6 wells plate containing sterilised 
glass coverslips and incubated for 24 h at 37% in 5% CO2. The media was 
replaced next day with 5x IC50 of (doxorubicin, paclitaxel, oxaliplatin, vincristine 
and vinblastine) alone and in combination with 10% growth inhibition of HNP-cyt 
C. After 24 h incubation the treated media was removed and the cells were 
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washed (3-4 times) with PBS and then fixed with 2.5% gluteraldehyde in PBS and 
incubated for 10 min. after the fixation process the cells were washed thoroughly 
with PBS for at least 5 times. The glass cover slips of the fixed cells are mounted 
on glass slides and leave it overnight to dry. Topographical studies of control and 
treated cells were imaged by atomic force microscopy (Bruker ,Germany) with 
Peak Force Tapping mode( ScanAsyst in air cantilever). 
3.3. Results 
 
3.3.1. Cell viability assays 
 
The effect of hybrid nanoparticle formulation with cytochrome C (CYT-C) 
conjugated onto their surface in combination with chemotherapeutic drugs on cell 
viability of HepG2, SK-hep-1 and Huh-7D was assessed using MTT and trypan 
blue assays. The cytotoxicity of the drugs alone and in combination was indicated 
by calculating the dose of the drugs required to decrease 50% of the cell viability 
which is called IC50. 
 
3.3.1.1. Cell viability assays of CYT-C, HNP and HNP-C 
The cytotoxicity of CYT-C, HNP and HNP-C were assessed by MTT and trypan 
blue assays on hepatocellular carcinoma cell lines HepG2 (epithelial origin), Huh-
7D(epithelial origin), SK-hep-1(endothelial origin) and differentiated U937 cell 
lines. The cell viability results of unloaded HNP and CYT-C did not show any 
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significant dose response effects against liver cancer cell lines and U937 at three 
times points of incubation times (P>0.001). The viability assays of HNP-C serial 
dilution (10-1 µM) were also tested against all liver cancer cell lines. significant 
decrease in cell viability  were noticed around (9.8±1.07µM) as IC50  concentration 
of HNP-C on HepG2 cell line after 72 h incubation time with both viability test 
(Figure 3.1.). 
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Figure 3.1. Dose response curve of NPs +cytochrome C +HEPG2 cell line of three 
independent experiments after 24 h,48 h and 72 h incubation time. 
 
 
In the Huh-7D cell line, a remarkable increase in cytotoxicity of HNP-C was 
observed after 48 h and 72 h incubation times and recorded as significant IC50 
(5.9±9.5 µM and 3.4±1.6µM ) for each time ,respectively.as showed in (Figure 
3.2.).   
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Figure 3.2. Dose response curve of NPs +cytochrome C +Huh-7D cell line of 
three independent experiments after 24 h,48 h and 72 h incubation time. 
The cell viability assays showed a significant reduction in IC50 around 
(4.8±2.18µM) with SK-hep1 after 72 h (figure 3.3. ) incubation with the HNP-C. 
1 0 0 1 0 2 1 0 4 1 0 6 1 0 8 1 0 1 0
0
1 0
2 0
3 0
4 0
5 0
6 0
7 0
8 0
9 0
1 0 0
1 1 0
H N P + C Y T -C  IN  S K -H E P -1
lo g c o n c (M  m o le )
c
e
ll
 v
ia
b
il
it
y
 %
H N P + C Y T C  2 4 h r
H N P + C Y T C  4 8 h r
H N P + C Y T C  7 2 h r
Figure 3.3. Dose response curve of NPs +cytochrome C +SK-hep-1 cell line of three 
independent experiments after 24 h,48 h and 72 h incubation time. 
 
 A dose response curve of HNP loaded with CYT-C are represented with noteable 
IC50 against U937 cell line at all incubated time points (Figure 3.4.) and showed as 
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9.56±6.01 µM at 24 h; 7.32±5.29 µM at 48 h and 3.87±1.8 µM at 72 h incubation 
time.  
The concentration of HNP-C that correspond to 10% inhibition concentration of cell 
viability was used in combination therapy and calculated to be approximately 
0.012 mgmL-1 of hybrid formulation. This percentage was used with serial dilution 
of chemotherapeutic drugs to evaluate the effect of delivered CYT-C on the 
cytotoxicity of chemotherapeutic drugs against liver cancer cell lines. 
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Figure 3.4. Dose response curve of NPs +cytochrome C +U937 cell line of three 
independent experiments after 24 h,48 h and 72 h incubation time.  
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3.3.1.2. Cell viability assays of DNA damage drug and anti-microtubule drugs 
with HNP-C 
 
DNA damaging drugs, doxorubicin and oxaliplatin, showed insignificant results 
after 24 h incubation in HepG2, Huh-7D and SK-hep-1 cell lines. One exception 
was observed in Huh-7D cells using MTT and trypan blue assays after doxorubicin 
exposure (3.79 µM and 4.744 µM, respectively). The combination of doxorubicin 
with HNP-C (0.012 mgmL-1) resulted in a decrease in the IC50 of Huh-7D cell line 
and recorded as 2.16 µM and 3.33 µM for MTT and trypan blue assay, after 24 h 
respectively. When liver cancer cells were incubated with the doxorubicin 
combined therapy for 48 h and 72 h a significant reduction in IC50 (p<0.05) was 
observed with in all cell lines compared with the drug alone.  
Remarkably, insignificant results were evident with either oxaliplatin alone or with 
HNP-C on SK-hep-1 treated cells at three time points of incubation.  
 
The cytotoxicity of anti-microtubule drugs: paclitaxel, vinblastine and vincristine 
were also evaluated on HepG2, Huh-7D and SK-hep-1 cell lines both alone and in 
co-administration with 0.012 mgmL-1of HNP-C. After 24 h incubation, no significant 
IC50 (p>0.05) was detected in both the MTT and trypan blue assays. Increasing 
incubation time of treatment to 48 h and 72 h resulted in a significant decrease in 
IC50 (p<0.05) in HepG2 and Huh-7D cells exposed to paclitaxel, vinblastine and 
vincristine. The co-administration of these anti-microtubule drugs with HNP-C 
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(0.012 mgmL-1) resulted in a more potent mix, with a significant increase in 
cytotoxic effect compared to the single drug treatment. Remarkably, no IC50 were 
noticeable in SK-hep-1(highly resistance cell line) with anti-microtubule drugs 
alone or when co-administer with HNP-C. 
 
3.3.1.3. Cell viability assays on HepG2 cell line  
 
The cytotoxicity of DNA damaging drugs was evaluated in HepG2 cells 
(Figure.3.5.) Here, no IC50 was observed in those cells treated with either drugs or 
with the CYT-C nano-formulation after 24 h. However, after 48 h and 72 h, an IC50 
was observed. After combination therapy, a 15-fold and 10-fold (respectively) 
decrease in IC50 was observed in those cells treated with doxorubicin combination 
therapy. While, oxaliplatin co-administration showed a 1-3-fold decrease in IC50 
after 48 h and 72 h incubation points. The anti-microtubule drugs showed no IC50 
value after 24 h incubation with HepG2 cells. After 72 h a 17.8-fold, 9-fold and 29-
fold decrease in IC50 was observed in those cells treated with combination 
therapies of paclitaxel, vinblastine and vincristine, respectively (Figure 3.6. ,3.7.)   
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Figure 3.5. Dose response curve of doxorubicin and oxaliplatin on HEPG2 cell line 
of three independent experiments after 24 h,48 h and 72 h incubation time, the x-
axis represent the serial dilutions of the drug and the y-axis represent the 
absorbance of MTT formazan crystalline which indicate the % of cell viability.   
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Figure 3.6.Dose response curve of Paclitaxel, vinblastine on HEPG2 cell line of three 
independent experiments after 24 h,48 h and 72 h incubation time, the x-axis represent 
the serial dilutions of the drug and the y-axis represent the absorbance of MTT formazan 
crystalline which indicate the % of cell viability.  
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Figure 3.7.Dose response curve of vincristine on HEPG2 cell line of three independent 
experiments after 24 h,48 h and 72 h incubation time, the x-axis represent the serial 
dilutions of the drug and the y-axis represent the absorbance of MTT formazan crystalline 
which indicate the % of cell viability.  
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Table 3-1. IC50 values of DNA damage drugs (Doxorubicin and Oxaliplation) and 
anti-microtubule drugs (Paclitaxel, vinblastine and vincristine) on HepG2 cell line 
achieved by MTT and trypan blue assays. Significant increase in the cytotoxicity 
was calculated by comparing with single drug treatment (n=3, aver ±SD).  
 
  
HEPG2 Cell line IC50(drug ) 
MTT 
IC50(drug+ HNP-
C)(MTT) 
IC50(drug ) 
Trypan blue 
IC50(drug+ HNP-C) 
Trypan blue 
Doxorubicin         
24 h NS NS NS NS 
Increase in cytotoxicity - -     
48 h 1.6±7.5µM 0. 1±2.34 µM 1.46±1.14µM 0.09±1.87µM 
Increase in cytotoxicity - 15-fold   15.2- fold 
72 h 0.1±4.69 µM 0.009±0.38 µM 0.27±3.54 µM 0.002±2.82 µM 
Increase in cytotoxicity   10.1-fold   12.5-fold 
Paclitaxel         
24 h NS NS NS NS 
48 h  NS 2.3±2.09nM NS 1.60±3.53nM 
Increase in cytotoxicity - Significant IC50   Significant IC50 
72 h 32±4.84 nM 1.7±1.97 nM 35.72±1.41nM 0.18±4.77nM 
Increase in cytotoxicity - 17.8-fold   193-fold 
Oxaliplatin         
24 h NS NS NS NS 
Increase in cytotoxicity - -     
48 h 17±1.56 µM 8±4.63 µM 25.21±2.82µM 6.510±1.41µM 
Increase in cytotoxicity - 1.1-fold - 2.8-fold 
72 h 7.54±3.06 µM 3±1.03 µM 6.51±2.79µM 3.33±3.72µM 
Increase in cytotoxicity - 1.5-fold - 1-fold 
Vinblastine         
24 h NS NS NS NS 
Increase in cytotoxicity - -     
48 h NS 0.01±4.09 nM NS 0.01±1.88nM 
Increase in cytotoxicity   Significant IC50   Significant IC50 
72 h 0.001±2.04 nM 0.0001±1.54 nM 0.02±4.02nM 0.001±2.42nM 
Increase in cytotoxicity - 9-fold   19-fold 
Vincristine         
24 h NS NS NS NS 
Increase in cytotoxicity - -     
48 h NS 0.009±3.56 nM NS 0.001±1.17nM 
Increase in cytotoxicity - Significant IC50   Significant IC50 
72 h 0.003±1.50 nM 0.0001±8.51 nM 0.05±3.39nM 0.0001±1.58nM 
Increase in cytotoxicity - 29-fold   499-fold 
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3.3.1.4. Cell viability assays on Huh-7D cell line  
 
The cytotoxicity of doxorubicin was tested in Huh-7D cells (Figure 3.8.), after 24 h 
a 0.75-fold and 0.42-fold decrease in IC50 was observed with the combination 
therapy (MTT and trypan blue respectively). Further increase in cytotoxic effect 
was observed after 48 h and 72 h incubation. Co-administration with oxaliplatin 
and HNP-C resulted in a 39-fold and 6.4-fold decrease in IC50 after 72 h (MTT and 
trypan blue, respectively). The anti-microtubule drugs (Figure 3.9., 3.10.) showed 
no IC50 in Huh-7D cells after 24 h. A significant increase in the cytotoxicity was 
observed in those cells treated with paclitaxel after 48 h and 72 h., Cells incubated 
with vincristine also showed a significant fold reduction in IC50 value with the 
combination therapies compared to single drug treatment after 48 h and 72 h. 
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Figure 3.8. Dose response curve of doxorubicin and oxaliplatin on Huh-7D cell 
line of three independent experiments after 24 h,48 h and 72 h incubation time, the 
x-axis represent the serial dilutions of the drug and the y-axis represent the 
absorbance of MTT formazan crystalline which indicate the % of cell viability. 
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Figure 3.9.Dose response curve of Paclitaxel, vinblastine on Huh-7D cell line of 
three independent experiments after 24 h,48 h and 72 h incubation time, the x-axis 
represent the serial dilutions of the drug and the y-axis represent the absorbance 
of MTT formazan crystalline which indicate the % of cell viability. 
  
117 
 
0 1 2 3 4 5
0
1 0
2 0
3 0
4 0
5 0
6 0
7 0
8 0
9 0
1 0 0
V IN C  2 4 h
H u h -7 D
lo g {V in c r is tin e  (n m o le )}
c
e
l
l
 
v
i
a
b
i
l
i
t
y
 
%
V IN C  2 4 h r
V IN C + H N P -C 2 4 h r
0 1 2 3 4 5
0
1 0
2 0
3 0
4 0
5 0
6 0
7 0
8 0
9 0
1 0 0
1 1 0
V IN C  4 8 h
H u h -7 D
lo g {V in c r is tin e  (n m o le )}
c
e
ll
 v
ia
b
il
it
y
 %
V IN C  4 8 h r
V IN C + H N P -C 4 8 h r
0 1 2 3 4 5
0
1 0
2 0
3 0
4 0
5 0
6 0
7 0
8 0
9 0
1 0 0
V IN C  7 2 h
H u h -7 D
lo g {V in c r is tin e  (n m o le )}
c
e
ll
 v
ia
b
il
it
y
 %
V IN C  7 2 h r
V IN C + H N P -C 7 2 h r
 
 
Figure 3.10.Dose response curve of vincristine on Huh-7D cell line of three 
independent experiments after 24 h,48 h and 72 h incubation time, the x-axis 
represent the serial dilutions of the drug and the y-axis represent the absorbance 
of MTT formazan crystalline which indicate the % of cell viability. 
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Table 3-2 .IC50 values of DNA damage drugs (Doxorubicin and Oxaliplation) and 
anti-microtubule drugs (Paclitaxel, vinblastine and vincristine) on Huh-7D cell line 
achieved by MTT and trypan blue assays. Significant increase in the cytotoxicity 
was calculated by comparing with single drug treatment (n=3, aver ±SD).  
 
 
 
 
 
HUH-7D Cell line IC50(drug ) 
MTT 
IC50(drug+ HNP-
C)(MTT) 
IC50(drug ) 
Trypan blue 
IC50(drug+ HNP-C) 
Trypan blue 
Doxorubicin         
24 h 3.79±7.5 µM 2.16±1.3 µM 4.744±4.16 µM 3.338±2.081 µM 
Increase in cytotoxicity - 0.75-fold - 0.42- fold 
48 h 2.11±1.46 µM 0.58±4.55 µM 2.949± 6.11 µM 1.903± 1.73 µM 
Increase in cytotoxicity - 2.6-fold - 0.5-fold 
72 h 1.7±2.1 µM 0.61±2.2 µM 1.631± 2.51 µM 0.6389± 2.64 µM 
Increase in cytotoxicity - 1.7-fold - 1.6-fold 
Paclitaxel         
24 h NS NS NS NS 
Increase in cytotoxicity - -     
48 h 37.04±1.63 
nM 
5.60±2.88 nM 41.08±1.52 nM 9.945±3.60 nM 
Increase in cytotoxicity - 5.6-fold - 3.13-fold 
72 h 31.48±7.48 
nM 
7.09±2.80 nM 32.57±3.21 nM 6.204±2.51 nM 
Increase in cytotoxicity - 3.4-fold - 4.2-fold 
Oxaliplatin         
24 h NS NS NS NS 
Increase in cytotoxicity - -     
48 h 17±1.57 µM 1.06±4.3 µM 23.58±4.93µM 8.49±1.154µM 
Increase in cytotoxicity - 15-fold - 1.7-fold 
72 h 15±7.48 µM 0.37±5.86 µM 16.83±2.08µM 2.135±1.52µM 
Increase in cytotoxicity - 39-fold - 6.9-fold 
Vinblastine         
24 h NS NS NS NS 
Increase in cytotoxicity - - - - 
48 h 0.029±3.16 
nM 
0.003±8.53 nM 0.049±2.51nM 0.004±7.63nM 
Increase in cytotoxicity - 8.6-fold - 9-fold 
72 h 0.003±6.30 
nM 
0.0003±5.39 nM 0.004±3.05nM 0.0003±1.73nM 
Increase in cytotoxicity - 9-fold - 12-fold 
Vincristine         
24 h NS NS NS NS 
Increase in cytotoxicity - - - - 
48 h 0.03±2.92 0.001±1.31 0.012±2.08 nM 0.006±1.53 nM 
Increase in cytotoxicity - 29-fold - 1-fold 
72 h 0.002±6.95 0.0001±9.53 0.003±3.60 nM 0.0002±4.16 nM 
Increase in cytotoxicity - 19-fold - 14-fold 
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3.3.1.5. Cell viability assays on SK-hep-1 cell line  
 
The SK-hep-1 cell line exhibited a much greater degree of drug resistance 
compared to the other cell lines tested (Figures 3.11. and 3.12.) . This may be 
because they did not possess any mRNA of hepatic-specific proteins (albumin and 
fibrinogen) or due to a difference in cellular uptake mechanism of drugs compared 
with the other cell lines (Eun JR. et al. 2014). Hence, the highly resistance nature 
of these cell lines against chemotherapeutics resulted in no IC50 values when 
incubated with all the drug molecules tested with exception of doxorubicin. 
Doxorubicin has been classified as an intracellular and extracellular affecting 
chemotherapeutic drug (non-specific cell cycle phase killing drugs) (El-Kareh, A. 
W., & Secomb, T. W. 2005). Hence, this may render it more effective in drug 
resistant cells. In this study, an IC50 was observed after 48 h in combination 
therapy of doxorubicin and HNP-C (2.38±2.86 µM and 2.55±3.88 µM) achieved by 
MTT and trypan blue, respectively. Further, with increasing incubation time to 72 
h, a further 0.25-fold and 0.88-fold increase in cytotoxicity was observed (MTT and 
trypan blue, respectively). 
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Figure 3.11. Dose response curve of doxorubicin and oxaliplatin on SK-hep-1 cell 
line of three independent experiments after 24 h,48 h and 72 h incubation time, the 
x-axis represent the serial dilutions of the drug and the y-axis represent the 
absorbance of MTT formazan crystalline which indicate the % of cell viability. 
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Figure 3.12. Dose response curve of Paclitaxel, vinblastine on SK-hep-1 cell line 
of three independent experiments after 24 h,48 h and 72 h incubation time, the x-
axis represent the serial dilutions of the drug and the y-axis represent the 
absorbance of MTT formazan crystalline which indicate the % of cell viability. 
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Figure 3.13. Dose response curve of vincristine on SK-hep-1 cell line of three 
independent experiments after 24 h,48 h and 72 h incubation time, the x-axis 
represent the serial dilutions of the drug and the y-axis represent the absorbance 
of MTT formazan crystalline which indicate the % of cell viability. 
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Table 3-3 .IC50 values of DNA damage drugs (Doxorubicin and Oxaliplation) and 
anti-microtubule drugs (Paclitaxel, vinblastine and vincristine) on SK-hep-1 cell line 
achieved by MTT and trypan blue assays. Significant increase in the cytotoxicity 
was calculated by comparing with single drug treatment (n=3, aver ±SD).  
 
 
 
 
 
 
 
 
 
 
 
 
 
  
SK-HEP-1 Cell line IC50(drug ) 
    MTT 
IC50(drug+ 
HNP-C)(MTT) 
IC50(drug ) 
Trypan blue 
IC50(drug+ HNP-C) 
Trypan blue 
Doxorubicin         
24 h NS NS NS NS 
  - -     
48 h NS 2.38±2.86µM NS 2.55±3.88 µM 
    Significant IC
50
   Significant IC
50
 
72 h 3±4.34 µM 2.4±1.21 µM 4.034 ± 5.12µM 2.14 ± 3.85µM 
  - 0.25-fold - 0.88-fold 
Paclitaxel         
24 h NS NS NS NS 
48 h NS NS NS NS 
72 h NS NS NS NS 
Oxaliplatin         
24 h NS NS NS NS 
48 h NS NS NS NS 
72 h NS NS NS NS 
Vinblastine         
24 h NS NS NS NS 
48 h NS NS NS NS 
72 h NS NS NS NS 
Vincristine         
24 h NS NS NS NS 
48 h NS NS NS NS 
72 h NS NS NS NS 
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3.3.1.5. Cell viability assays on U937cell line  
 
The cell viability tests in differentiated U937 cells showed that an IC50 was 
observed with all chemotherapeutic drugs used either alone or in combination with 
hybrid formulation in the 3 times points tested (Figures 3.14. , 3.15.) . This was 
with exception of doxorubicin, where no IC50 was observed with the single drug 
treatment, however, combination therapy resulted in IC50 values of  3.6 µM and 
3.55 µM, after 24 h (MTT and trypan blue assay, respectively). These significant 
cytotoxic effects may contribute to different cell membrane structures, cell size and 
the mechanisms of molecules uptake of this cell line, compared to other cultured 
hepatic cell lines. 
For oxaliplatin treated cells the higher toxicity effects were indicated with 
oxaliplatin combination therapy after 48 h where a 1.03-fold decrease in IC50 and 
1.73-fold decrease after 72 h was observed. The cytotoxicity of paclitaxel 
combination treated cells increased after 72 h. However, the most potent 
formulation observed was using vincristine treated cells after 24 h incubation 
period where a 52-fold increase in cytotoxicity was observed after combination 
therapy compared to the single drug treatment. 
 
 
 
 
 
125 
 
1 0 0 1 0 2 1 0 4 1 0 6
0
1 0
2 0
3 0
4 0
5 0
6 0
7 0
8 0
9 0
1 0 0
1 1 0
D O X  2 4 h
U 9 3 7
lo g {D o x o ru b ic in  (M  m o le )}
c
e
ll
 v
ia
b
il
it
y
 %
D O X  2 4 h r
D O X + H N P -C  2 4 h r
 
1 0 0 1 0 2 1 0 4
0
1 0
2 0
3 0
4 0
5 0
6 0
7 0
8 0
9 0
1 0 0
1 1 0
D O X  4 8 h
U 9 3 7
lo g {D o x o ru b ic in  (M  m o le )}
c
e
ll
 v
ia
b
il
it
y
 %
D O X  4 8 h r
D O X + H N P -C  4 8 h r
 
0 2 4
0
1 0
2 0
3 0
4 0
5 0
6 0
7 0
8 0
9 0
1 0 0
1 1 0
D O X  7 2 h
U 9 3 7
lo g {D o x o ru b ic in  (M  m o le )}
c
e
l
l
 
v
i
a
b
i
l
i
t
y
 
%
D O X  7 2 h r
D O X + H N P -C  7 2 h r
0 5 0 1 0 0 1 5 0
0
1 0
2 0
3 0
4 0
5 0
6 0
7 0
8 0
9 0
1 0 0
1 1 0
O X A  2 4 h
U 9 3 7
C O N C .{O X A L IP L A T IN  (M  m o le )}
c
e
l
l
 
v
i
a
b
i
l
i
t
y
 
%
O X A 24 H R
O X A + H N P -C  2 4 H R
 
0 5 0 1 0 0 1 5 0
0
1 0
2 0
3 0
4 0
5 0
6 0
7 0
8 0
9 0
1 0 0
1 1 0
O X A  4 8 h
U 9 3 7
C O N C .{O X A L IP L A T IN  (M  m o le )}
c
e
l
l
 
v
i
a
b
i
l
i
t
y
 
%
O X A 48 H R
O X A + H N P -C  4 8 H R
0 5 0 1 0 0 1 5 0
0
1 0
2 0
3 0
4 0
5 0
6 0
7 0
8 0
9 0
1 0 0
1 1 0
O X A  7 2 h
U 9 3 7
C O N C .{O X A L IP L A T IN  (M  m o le )}
c
e
l
l
 
v
i
a
b
i
l
i
t
y
 
%
O X A 72 H R
O X A + H N P -C 7 2 H R
 
 
Figure 3.14. Dose response curve of doxorubicin and oxaliplatin on U937 cell line 
of three independent experiments after 24 h,48 h and 72 h incubation time, the x-
axis represent the serial dilutions of the drug and the y-axis represent the 
absorbance of MTT formazan crystalline which indicate the % of cell viability.   
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Figure 125. Dose response curve of Paclitaxel, vinblastine on U937 cell line of 
three independent experiments after 24 h,48 h and 72 h incubation time, the x-axis 
represent the serial dilutions of the drug and the y-axis represent the absorbance 
of MTT formazan crystalline which indicate the % of cell viability. 
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Figure 136. Dose response curve of vincristine on U937 cell line of three 
independent experiments after 24 h,48 h and 72 h incubation time, the x-axis 
represent the serial dilutions of the drug and the y-axis represent the absorbance 
of MTT formazan crystalline which indicate the % of cell viability. 
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Table 3-4.IC50 values of DNA damage drugs (Doxorubicin and Oxaliplation) and 
anti-microtubule drugs (Paclitaxel, vinblastine and vincristine) on U937 cell line 
achieved by MTT and trypan blue assays. Significant increase in the cytotoxicity 
was calculated by comparing with single drug treatment (n=3, aver ±SD).  
  
U937 Cell line IC50(drug ) 
    MTT 
IC50(drug+ HNP-
C)(MTT) 
IC50(drug ) 
Trypan blue 
IC50(drug+ HNP-C) 
Trypan blue 
Doxorubicin         
24 h NS 3.6±1.07 µM NS 3.55±2.25µM 
Increase in cytotoxicity         
48 h 1.3±6.90 µM 0.9±3.02 µM 1.77±8.04µM 1.17±3.6µM 
Increase in cytotoxicity   0.4-fold   0.5-fold 
72 h 0.7±2.91 µM 0.3±6.07 µM 0.98±4.23µM 0.51±1.762µM 
Increase in cytotoxicity   1.3-fold   0.94-fold 
Paclitaxel         
24 h NS NS NS NS 
Increase in cytotoxicity         
48 h 67±1.02nM 65.2±4.22 nM 67.67±3.98nM 61.74±7.96nM 
Increase in cytotoxicity   0.03-fold   0.09-fold 
72 h 17±1.61 nM 8.77±2.62 nM 16.21±1.11nM 7.62±3.6nM 
Increase in cytotoxicity   0.93-fold   1.13-fold 
Oxaliplatin         
24 h 119.5±2.34 
µM 
84.30±1.30 µM 102.1±3.48µM 72.04±4.04µM 
Increase in cytotoxicity   0.41-fold   0.41-fold 
48 h 78.99±7.38 
µM 
38.76±1.34 µM 100.8±1.91µM 47.37±4.64µM 
Increase in cytotoxicity   1.03-fold   1.1-fold 
72 h 30.85±2.51 
µM 
18.09±5.06 µM 77.49±3.75µM 28.3±6.972µM 
Increase in cytotoxicity   0.6-fold   1.73-fold 
Vinblastine         
24 h 0.003±5.81 
nM 
0.0007±8.88 nM 0.016±3.51nM 0.006±7.11nM 
Increase in cytotoxicity   3.2-fold   1.6-fold 
48 h 0.001±2.46 
nM 
0.0001±5.08 nM 0.002±5.77nM 0.0003±4.219nM 
Increase in cytotoxicity   9-fold   5.66-fold 
72 h 0.0001±1.75 
nM 
0.00001±4.39 nM 0.0002±4.26nM 0.00017±3.87nM 
Increase in cytotoxicity   9-fold   0.17-fold 
Vincristine         
24 h 0.016±3.84 0.0003±2.78 nM 0.015±7.67 nM 0.003±4.97nM 
Increase in cytotoxicity   52-fold   4-fold 
48 h 0.0016±1.48 0.0001±3.49 nM 0.003±4.55 nM 0.0002±4.50nM 
Increase in cytotoxicity   15-fold   14-fold 
72 h 0.0003±9.70 0.00001±4.39 nM 0.0004±6.32 nM 0.0001±1.39nM 
Increase in cytotoxicity   29-fold   3-fold 
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3.3.2. Cellular uptake  
 
Most chemotherapies are hindered in their development or use due to major 
challenges in their ability to be administered or delivered to the correct site of 
action. Careful formulation into or onto nanoparticles has shown potential in this 
area for improvement in drug solubilisation, dissolution, circulation times or 
penetration ability.  
The effective targeting strategies of nanoparticles are controlled mainly by physical 
and chemical means. Physical targeting is achieved by applying specific 
fabrication technique of nanoparticles size, charge and stiffness process which 
affects the rate of tissue targeting and cellular uptake of these particles. The 
chemical site of formulation is the decorating of particle surfaces to receptive the 
specific environment criteria of delivered device.  
The tracking of the nanoparticles traveling way to the cell is the main point in 
therapeutic process in order to detect the vital site of targeting and also to improve 
the loading of therapeutic device inside the cells. One of these factors is nano-
shape like rod, spherical or disk shape of nanoparticles (Petros and Desimone, 
2010). So, the synthesis process and modifying shape of nanoparticles can be 
considered as a main point in targeting process. 
The rigidity of nanoparticles is also reflected the action of targeting processes. 
Few studies refer to the cellular uptake differences between hard and soft types of 
nanoparticles. Macrophages engulf the hard type of nanoparticles such as the 
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metallic ones while the Hela cells prefer the soft particles to be uptake (Jo and 
Auguste, 2009; Beningio and Wang.2002). 
The surface charge of nanoparticles can influence the circulation time of delivered 
particles and the rate of cellular retention or accumulation. Several studies have 
concerned with the effect of surface charge on the uptake process. Most 
researchers are agreed with ability of positively charged particles to be interacting 
electrostatically better than the negative one in most types of cell lines with some 
exceptional cases noticed with macrophage and stem cells characterised by 
different endocytosis or pinocytosis process of stem cells besides macrophage 
uptake ability rise with increasing surface charge of particles either negative or 
positive charge (Gratton et al., 2008; Chung et al., 2007) 
The internalisation of nanoparticles into the cells is also dependent on the 
formulation size that affects the mechanism of the uptake (Zhang, S.et al., 2008). 
The particles size range between 10-500 nm is believed to enter via 
macropinocytosis, while clathrin mediated endocytosis usually required 
nanoparticles around 100nm in size. The size range of 60-80 nm is more likely to 
be involved by caveolae pathways of endocytosis (Benmerah, A.,2007). Some 
reports proposed that the cellular uptake factors may be affected by other 
formulation design such as charge or surface coating more than the size effect. 
However, it is obvious that the smaller size of nanoparticle is more helpful to 
uptake into the cells (Huang et al., 2002).  
Cellular uptake of cytochrome C coupled to the HNP-C was measured in liver 
cancer cell lines and macrophage like differentiated U937 by measuring the 
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concentration per known number of cells and detected in microgram/picogram unit 
in 1 millilitre of cell suspension (Lison and Huaux, 2011) using UV/VIS 
spectrometry (Shimaduz,Germany) at 410 nm and calculated the protein 
concentration per each cell. A calibration curve was calculated by running the 
serial dilution of cytochrome C from 500-0.75 µgmL-1dissolved in water (R2= 
0.996). All the experiments were triplicated and average value was recorded. 
Liver cancer cell lines (HepG2, Huh-7D12 and SK-hep-1) and differentiated U937 
cells were incubated with 50 µgmL-1 or 100 µgmL-1 of Cyt-C alone or HNP-C for 1 
h and 4 h. The accumulated amount of Cyt-C was calculated by measuring the 
absorbance at 410 nm using UV/VIS spectrometry. The amount of free 
cytochrome C inside the HepG2 cell line (Figure 3.17.). was 5 pg and 6.1 pg after 
1 h and 4 h respectively at (50 µgmL-1 incubation concentration), compared to 12 
pg and 13 pg in the HNP-C sample at the same concentration and incubation time.  
At 100 µgmL-1 incubation concentration, the uptake of free protein did not change 
significantly from the 50 µgmL-1 which detected as (6 pg and 6.5 pg) after 1 and 4 
h respectively, this could be to the low stability or the difficulty large proteins often 
face in order for cellular internalisation to occur. At 100 µgmL-1 HNP-C enabled 
internalisation of 33 pg and 36 pg of Cyt-C per cell which was more than double 
the intake compared with the lower concentration. This data suggests that cellular 
uptake level of the Cyt-C conjugated onto the HNP was related to incubation 
concentration more than the incubation time. 
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Figure 3.17. Protein uptake study on HepG2 cell line after 1and 4h incubation time 
with 50 µgmL-1 and 100µ µgmL-1 concentration of cytochrome C and HNP-C 
formulation,* indicate the significant differences between hybrid formulation of 
protein uptake value with the free form of protein uptake at similar time and 
concentration(n=3 ,average±SD). The t-test analysis is performed by Microsoft 
Excel software. 
 
The uptake level of HNP-C in Huh-7D12 cells showed a high level of protein inside 
the cells after 1 h and 4 h with 14 pg and 19 pg being detected respectively at 50 
µgmL-1. This was 8-fold and 13-fold higher than for those cells incubated with the 
free protein (Figure 3.18.). In addition, a 25.5-fold and 28-fold increase in Cyt-C 
levels was observed in those cells incubated at 100 µgmL-1 HNP-C compared with 
free protein over 1 h and 4 h. 
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Figure 3.18. Protein uptake study on Huh-7D cell line after 1and 4h incubation 
time with 50 µgmL-1 and 100 µgmL-1 concentration of cytochrome C and HNP-C 
formulation,* indicate the significant differences between hybrid formulation of 
protein uptake value with the free form of protein uptake at similar time and 
concentration(n=3 ,average±SD). The t-test analysis is performed by Microsoft 
Excel software. 
 
For Cyt-C and HNP-C, around 2 pg of free protein was taken up by SK-hep-1 cell 
line after 1 h and 4 h incubation time at 50 µgmL-1 exposure concentration. While, 
significant uptake levels were recorded by HNP-C 7.5 pg and 9 pg at the same 
time and incubation concentration. At 100 µgmL-1 incubated concentrations, 13 pg 
and 19 pg of HNP-C were measured, while the uptake level of free protein stayed 
around 2 pg. These results revealed the higher internalisation ability of hybrid 
nanoparticles compared to the low free protein uptake (Figure 3.19.).  
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Figure 3.19.Protein uptake study on SK-hep-1 cell line after 1 h and 4h incubation 
time with 50 µgmL-1 and 100 µgmL-1concentration of cytochrome C and HNP-C 
formulation,* indicate the significant differences between hybrid formulation of 
protein uptake value with the free form of protein uptake at similar time and 
concentration(n=3 ,average±SD). The t-test analysis is performed by Microsoft 
Excel software. 
U937 cell line showed low levels of free protein uptake (around 4 pg) after 1 h and 
4 h at 50 µgmL-1 exposure concentration. However, approximately a 4-fold 
increase in protein uptake was noticed with HNP-C, which confirms the ability of 
our formulation for effective passage into the cells. At 100 µgmL-1 incubation 
concentration, the uptake results were recorded as 7-8 fold increase in protein 
concentration inside the cells comparing to the reduced levels of free protein level 
inside the cells (4.8 pg and 5 pg) after 1 h and 4 h incubation time (Figure 3.20.). 
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Figure 3.20. Protein uptake study on U937 cell line after 1 h and 4h incubation 
time with 50 µgmL-1 and 100 µgmL-1  concentration of cytochrome C and HNP-C 
formulation,* indicate the significant differences between hybrid formulation of 
protein uptake value with the free form of protein uptake at similar time and 
concentration(n=3 ,average±SD). The t-test analysis is performed by Microsoft 
Excel software. 
 
In all previous uptake experiments of hybrid formulation of protein into cancer cell 
lines show a concentration dependent pattern of uptake (p<0.05), rather than time 
dependent. The uptake values for HNP- C were maximum 20 pg per cells in U937 
and SK-hep-1 cell lines comparing to the higher internalise rate (more than 
30pg/cell) of hybrid formulation into HepG2 and Huh-7D cell lines This could be 
attributed to smaller size of U937 and SK-hep-1 cell lines (12 µm and 15 µm) 
respectively in parallel to (20 µm and 25 µm) size of HepG2 and Huh-7D cells. The 
main differences in the cells size may indicate the lower capacity of U937 and SK-
hep-1 in uptake value of the protein hybrid formulation (the size measurements 
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were performed by AFM imaging technique, which will be discussed later). Or 
perhaps the reduced intake into these two cell lines could be due to differences in 
proliferation rate between the cell lines. The real reason is unknown, and further 
investigation into this is required. 
3.3.3. Apoptosis Assays 
 
3.3.3.1. Caspase 3 results  
 
The human body has several mechanisms that work as safeguards against tumour 
progress. The process of apoptosis is considered as one of these vital 
mechanisms which regulates and recognises any faulty steps in cell proliferation. 
Caspase enzymes have a crucial role in apoptosis, therefore, any disturbance in 
there levels can be caused in cell mutation and cancer progression. In the resent 
years, caspase enzyme detection kits are used as one of the apoptosis markers in 
cancer research, especially targeting caspase 3 level as one of execution caspase 
members. In this research caspase 3 colorimetric methods (Abcam) was used as 
a convenient way in (DEVD) sequence recognition and following the manufacture 
instruction as mentioned before (materials and methods). The liver cancer cell 
lines (HepG2, Huh-7D and SK-hep-1) in addition to U937 cell lines are promoted 
to induce apoptosis by (doxorubicin, oxaliplatin, paclitaxel, vinblastine and 
vincristine) alone and in combination with hybrid nano-formulation of cytochrome 
C. The light emission of the P-NA part can be detected by microtiter plate reader 
at 405 nm. Quantified results can be calculated by comparison between induced 
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cells (apoptotic cells) absorbance and the absorbance of control (uninduced cells) 
as folding increase in caspase 3 expression values. In HepG2 cells, the 
experiments indicated that there was significant levels of Caspase-3 present in 
those cells treated with combination therapy (Figure 3.21.). Doxorubicin and 
Oxaliplatin presented a 2-fold and 2.6–fold increase in enzyme levels respectively, 
in combination form with HNP-C. In the cells treated with drugs alone, no 
significant increase in caspase-3 was observed compared to the control cells. The 
combination therapy with resulted in the greatest level of caspase-3 increase 
compared with the drugs alone in HepG2 cells were those treated with anti-
microtubule drugs (paclitaxel, vinblastine and vincristine) (Figure 3.21.).  Here we 
observed a 5.2-fold, 2.8-fold and 3-fold increase in enzyme level respectively..   
 
Figure 3.21. Represent the activity of caspase 3 in HEPG2 cells were treated with 
DNA damage drugs (doxorubicin and oxaliplatin); and antimicrotubule drugs 
(paclitaxel, vinblastine and vincristine), the results are represented as mean±SD. 
No. of experiments=3. The results are expressed as a significant difference 
between drug alone and combination therapy at *P value< 0.05.    
0
0.2
0.4
0.6
0.8
1
1.2
1.4
HepG2 cell line 
C
a
s
p
a
s
e
 3
 a
c
ti
v
it
y
 
* 
* 
* * * 
138 
 
In general, in Huh-7D cells, all combination treatments resulted in significant 
Caspes-3 production inside the cells when compared with the single drug dose 
and the control cells. The greatest level of caspase-3 enzyme was observed in the 
combination therapy of HNP-C with doxorubicin or oxaliplatin. These combinations 
resulted in a 1.8-fold and 2.2-fold increase in caspase 3 level compared to the 
single drug treatment, respectively. (Figure 3.22.).  
 
Figure 3.22. Represent the activity of caspase 3 in Huh-7D cells were treated with 
DNA damage drugs (doxorubicin and oxaliplatin); and antimicrotubule drugs 
(paclitaxel, vinblastine and vincristine), the results are represented as mean±SD. 
No. of experiments=3. The results are expressed as a significant difference 
between drug alone and combination therapy at *P value< 0.05.    
 
For SK-hep-1 cell line, no significant increase in caspase 3 levels was observed in 
cells treated with either drugs alone or in combination with HNP-C. The exception 
to this was with combination therapy of HNP-C and doxorubicin. Here, a 3.5-fold 
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increase in caspase-3 level compared with the single drug treatment occurred 
(Figure 3.23.). 
 
Figure 3.23. Represent the activity of caspase 3 in SK-hep-1 cell line which 
treated with DNA damage drugs (doxorubicin and oxaliplatin); and antimicrotubule 
drugs (paclitaxel, vinblastine and vincristine), the results are represented as 
mean±SD. No. of experiments=3. The results are expressed as a significant 
difference between drug alone and combination therapy at *P value< 0.05.    
 
Caspase 3 assay in U937 cell line represented as highest levels in both phases of 
treatment either with chemotherapeutic drugs alone or combined with HNP-C, with 
no significant differences between these methods of treatment (Figure 3.24.). 
These results coordinated with other detecting apoptosis methods of protein 
immunoblotting (western blot) and TUNEL assay results of apoptotic cells which 
showed the programed killing activities of single drugs alone and in combination 
therapies. The smallest size of these u937 comparing to other liver cancer cell line 
used may be considered as main cause of poor proliferative level of U937 cells 
treated with chemotherapeutic drugs that effect the action of HNP-c combination, 
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in addition to different mechanism of cellular uptake of these suspension cells 
comparing to liver cancer cells used in same treatment protocol.   
 
Figure 3.24. Represent the activity of caspase 3 in U937 cell line which treated with DNA damage 
drugs (doxorubicin and oxaliplatin); and antimicrotubule drugs (paclitaxel, vinblastine and 
vincristine), the results are represented as mean±SD. No. of experiments=3.  
 
3.3.3.2. Western Blot 
 
Apoptosis follows the regular physiological changes inside the body to control the 
proper balance between the live and dead cells, controls the morphology of the 
organ and modeling tissue and eradicates any mutated or injured cells (Galluzzi L. 
et al. 2008).Uncontrolled apoptosis affects the regulated pattern of cell growth and 
caused hyper-proliferative sickness, cancer and neuro diseases (Cotter TG. 2009). 
Cascade signalling pathways are involved in programmed cell death by activation 
of specialised caspase family. When inactive precursors of these enzymes are 
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activated by extrinsic and/or intrinsic apoptosis pathways the series of cleaving 
and stimulating steps are directed to the effector and executioners groups of 
caspase to initiate apoptosis (Li J and Yuan J., 2008). Apoptosis is mediated by 
caspase series family by the cleavage of many key proteins used in proper cell 
growth pathway (Fischer U. et al. 2003). 
 
One of the cellular caspase substrates is PARP-1. Cleavage fragments of this 
protein are considered as the main marker of apoptosis. PARP (Poly (ADP-ribose) 
polymerase) is a nuclear protein which is responsible to detect and repair any 
breaks in DNA strand. Once Caspase-3 enzyme cleaved the PARP protein as 
regular steps in apoptosis process, the repairing DNA step is impaired and 
cleavage PARP fragments are produced. For that reason, these detecting 
fragments can be considered as a main mark of apoptosis and can be imaged and 
analysed by western blot technique (Kaufmann SH. et al. 1993). 
Cleavage PARP bands in western blot are recognised as the main biomarkers of 
cells suicide by apoptosis which follows a unique pattern of protease enzymes 
activity. The detective PARP cleavage bands with combination therapy of 
anticancer drugs and nanoparticles formulation comparing to unnoticed bands with 
single drugs treatment are characterized the synergism effects of the combination 
therapy in contrast to inactivated signal with single drug treatment (Figures 3.25., 
3.26. and 3.27.).   
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Figure 3.25. illustrates the apoptotic activity of combination therapy in HepG2 which is 
represented by the detection of the dark PARP cleavage band patterns compared to the faint 
bands observed in single drug treatment. 
 
  
 
 
 
 
 
Figure 3.26. Illustrates the apoptotic activity of combination therapy in HUH-7D 
cell lines which is represented by the detection of the dark PARP cleavage band 
patterns compared to the faint bands observed in single drug treatment.   
PARP 
Cleaved PARP  
 
GAPDH 
PARP 
Cleaved PARP 
GAPDH 
143 
 
 
 
 
 
 
 
Figure 3.27. Illustrates the apoptotic activity of combination therapy in the SK-hep-1 cell line, dark 
signature of cleavage PARP is only noticed with doxorubicin with and without combination with 
HNP-C in these cell line, while unreactive bands being observed with all other combinations and 
treatments. 
 
 
 
 
 
 
 
 
Figure 3.28. Illustrates the apoptotic activity of combination therapy in U937 cell 
line which is represented by the detection of the dark PARP cleavage band 
patterns compared to the faint bands observed in single drug treatment.  
  
PARP 
Cleaved PARP  
GAPDH 
Cleaved PARP 
 
GAPDH 
144 
 
The PARP bands were present in those cells treated with single drugs in U937 
cells, showing a different behaviour compared to the liver cell lines. Strong 
synergism effects were detected with combination therapies and visualised as 
robust signalling bands as illustrated in (Figure 3.28.). GAPDH served as loading 
control. 
 
3.3.3.3. Tunel Assay 
 
The detection of DNA fragmentation as a one of most important features of 
apoptosis is applied now in many fields of the cancer researches. One of these 
methods is the labelling nick end of damaged DNA with TDT-mediated dUTP-
biotin nick end labelling (Gavrieli et al., 1992). 
TUNEL assay (HT Titer TACS colorimetric assay, TREVIGEN) was originally used 
in the quantitative detection of death apoptotic cell at the late stage by dUTP 
labelling of the free 3-hydroxy termini of DNA breaks and catalyse by the presence 
of TDT enzyme. The end labelling dUTP was labelled by secondary blue marker 
(TACS-Sapphire) in the presence of HRP-conjugated streptavidin to be detected 
at 450nm using plate reader (Lozano, G.M., et al., 2009). 
In these experiments, the percentage of the DNA fragmentation are illustrated the 
significant results with the combination therapy comparing to minor level of these 
fragmentations were observed in single anticancer drug treatment. By means of 
this labelling process, the results confirm the killing activities of our combination 
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therapy by apoptosis against the liver cancer cell line except in the case of the Sk-
hep-1 cell line only which showed positive results with combination of 
nanoparticles formulation and DNA damage drugs (Doxorubicin). The experiments 
are triplicated for each sample and calculated the percentage of apoptotic cells in 
relative to untreated control cells. 
Under conditions of anticancer drugs treatments (doxorubicin, paclitaxel, 
oxaliplatin, vincristine and vinblastine), negligible apoptosis levels were observed 
with liver cells treated with each drug, while the highest level of apoptosis signals 
were noticed with the combined therapies. 
 In Hep-G2 cells, TUNEL results showed significant levels of apoptosis within cells 
treated with combination therapy (Figure 3.29.). The DNA damage drugs 
(doxorubicin and oxaliplatin) presented significant absorbance levels (4-folds and 
8 –fold) in DNA damage levels respectively, when combined with hybrid 
nanoparticle-formulation of cytochrome C. In parallel to non-significant levels of 
apoptosis was noticed with cells treated with each drugs alone in relative to control 
(untreated cells). TUNEL assay colorimetric reactions also showed the highest 
significant level of apoptosis in Hep-G2 cells treated with anti-microtubule drugs 
(paclitaxel, vinblastine and vincristine) combined with HNP-C (Figure 3.29.) as( 3,9 
and 6 fold) increase, respectively for each combination in relative to the low 
absorbance levels on the cells treated with chemicals alone.   
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Figure 3.29. Apoptosis percentage from TUNEL assay on Hep-G2 cell line treated 
with (Doxorubicin, Paclitaxel, Oxaliplatin, Vinblastine and vincristine) alone and in 
combination with HNP-C for 24 h incubation time.*belong to significant value of 
combination therapy in relative to free drug (p<0.05). All statistical analyses were 
calculated by t.test using Microsoft Excel software,(n=3,±SD). 
 
TUNEL assay analysis of Huh-7D cell line possessed the higher significant DNA 
damage levels with chemotherapeutic drugs treatment in combination with HNP-C, 
the apoptosis absorbance detected levels of cells treated with DNA damage drugs 
(doxorubicin and oxaliplatin) with hybrid nano-formulation of cytochrome C were 
showed (4 and 3 fold ) increase in apoptosis in comparing to single drugs 
treatment, respectively. The apoptosis activity also increased in cells treated with 
combination therapies of HNP-C and anti-microtubule drugs and represent around 
4-fold increase in DNA damage levels in parallel with no significant levels were 
observed with single drugs treatment in relative to control (Figure 3.30.).  
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Figure 3.30. Apoptosis percentage from TUNEL assay on Huh-7D cell line treated 
with (Doxorubicin, Paclitaxel, Oxaliplatin, Vinblastine and vincristine) alone and in 
combination with HNP-C for 24 h incubation time.*belong to significant value of 
combination therapy in relative to free drug (p<0.05). All statistical analyses were 
calculated by t.test using Microsoft Excel software,(n=3,±SD). 
. 
 
For SK-hep-1 cell line, no significant results were obtained in TUNEL assay with 
cells treated with drugs alone or with hybrid formulation of cytochrome C, with one 
exceptional significant level of DNA damage was observed with combination 
therapy of HNP-C and doxorubicin comparing to negligible value with cells treated 
with this drug alone and showed 5-fold increase in TUNEL assay response in 
relative to single drug treatment. The results are calculated as percentage in 
relative to control as illustrated in (Figure 3.31.). 
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These results are also confirmed with other apoptotic assays used such as 
(western blot and fluorescent microscopy) which showed only significant results 
with combination therapy of doxorubicin and HNP-c comparing to minor responses 
with other combination drugs formulations.  
 
 
Figure 3.31. Apoptosis percentage from TUNEL assay on SK-hep-1 cell line 
treated with (Doxorubicin, Paclitaxel, Oxaliplatin, Vinblastine and vincristine) alone 
and in combination with HNP-C for 24 h incubation time.*belong to significant 
value of combination therapy in relative to free drug (p<0.05). All statistical 
analyses were calculated by t.test using Microsoft Excel software,(n=3,±SD). 
 
 
U937 cell line showed the highest DNA damage levels in both phases of treatment 
either with chemotherapeutic drugs alone or combined with HNP-C, with no 
significant differences between these methods of treatment (Figure 3.32.). These 
results matched the other apoptosis methods of protein immunoblotting (western 
blot) and with fluorescent labelling results of apoptotic cells which showed the 
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programed killing activities of single drugs alone and in combination therapies. The 
smallest size of these u937 (as detected by AFM images) comparing to other liver 
cancer cell line used may be considered as main cause of poor proliferative level 
of U937 cells treated with chemotherapeutic drugs that effect the action of HNP-c 
combination, in addition to different mechanism of cellular uptake of these 
suspension cells comparing to liver cancer cells used in same treatment protocol.   
 
 
Figure 3.32. Apoptosis percentage from TUNEL assay on U937 cell line treated 
with (Doxorubicin, Paclitaxel, Oxaliplatin, Vinblastine and vincristine) alone and in 
combination with HNP-C for 24 h incubation time. All statistical analyses were 
calculated by t.test using Microsoft Excel software,(n=3,±SD). 
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3.3.4. Imaging studies 
 
3.3.4.1. Fluorescent microscopy imaging 
 
Apoptosis (programmed cell death) is characterised by several cellular 
components changes such as condensed nucleus, DNA fragmentation and 
morphological changes of cell surfaces. During the recent years, detecting of 
different stages of apoptosis is developed by using different methods concerning 
with early and late apoptosis level. In the early stage of apoptosis, the 
phosphotidylserine (PS) is translocated from the inner to outer face of cell 
membrane which facilitates the early recognition of apoptosis by binding the 
overlapped  PS with  fluorescein isothiocyanat labelled- annexin V (annexin V-
FITC) that has a strong and natural attraction to PS. The binding fluorescein label 
is detected by the fluorescence microscopy and considered the most vital indicator 
of early stage of programmed cell death that caused by a variety of death signals 
stimuli.   
The liver cancer cells were exposed to apoptosis stimuli by anticancer drugs 
(Doxorubicin, Paclitaxel, Oxaliplatin, Vinblastine and Vincristine) alone and in 
combination with HNP-C. The early stage of cell death was recognised by binding 
the annexin- V fluorescence probe to the PS outer membrane of the apoptotic 
cells. The apoptotic cells were visualised as a green staining of outer membrane 
under a fluorescence microscope. To recognize cells at the late stage of apoptosis 
from the earlier one, propidium iodide (PI) was used in fluorescence binding assay 
that had the ability to penetrate only destructive cell membrane and detecting as a 
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red colour under the microscope. The condensed nucleus can be further detected 
as blue staining nuclei with Hoechst fluorescence dye. 
Randomly five fields of vision were chosen under the fluorescence microscope 
(InvitrogenTM EVOSTM FL, Thermo Fisher) for counting the apoptotic cells as a 
green staining signal by Annexin-V prob.   
 
In HepG2 cell line, the Annexin V assay detected the significant percentage of 
apoptosis within cells treated with combination therapy in parallel to single 
treatment models (Figure 3.34.). Doxorubicin and Oxalipltin combined with HNP-C 
formulation were used to induce apoptosis in HepG2 cell lines which showed an 
increase in the percentage of early apoptotic cells from single to combination 
treated cells (28% to 70% Annexin V, respectively) for doxorubicin and (26% to 
67% Annexin V, respectively) for oxaliplatin treated cells. Anti-microtubule drugs 
(Paclitaxel, Vinblastine and Vincristine) also induced highest level of apoptosis 
stained cells when combined with HNP-C and calculated as (73%, 79% and 78%, 
respectively). In contrast to slight increase in apoptosis percentage with cells 
treated with each drugs alone and recorded as (19%, 23% and 18%, respectively). 
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Figure 3.33. Fluorescent microscopy imaging of Doxorubicin (A), Paclitaxel (B), 
Oxaliplatin (C), Vinblastine (D) and Vincristine(E) and in combination with HNP-
C(A+,B+,C+,D+ and E+) for 24 h incubation period in (HepG2). 
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Figure 3.34. Apoptosis detection cells with Annexin V staining probe. HepG2 Cell 
lines were treated with single drugs Doxorubicin (A), Paclitaxel (B), Oxaliplatin (C), 
Vinblastine (D) and Vincristine(E) and in combination with HNP-C(A+,B+,C+,D+ 
and E+) for 24 h incubation period. Data represent as (mean±SD, n=3).*significant 
difference (p<0.05) between combination drugs with HNP-C and single drug 
treatment by paired t-test. 
 
 
Huh-7D incubated cells with single chemotherapeutic drugs (Doxorubicin, 
Paclitaxel, Oxaliplatin, Vinblastine and Vincristine) were analysed under 
fluorescence microscopy to detect the Annexin V binding probe which showed no 
noteable increase in apoptotic cells at the early stage (33%, 32%, 35%, 22% and 
20%, respectively) comparing to highly significant level of apoptosis cells with 
combination form of HNP-C with each single drugs (78%, 78%, 66%, 70% and 
60%,respectively) (Figure 3.36.) . 
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Figure 3.35. Fluorescent microscopy imaging of Doxorubicin (A), Paclitaxel (B), 
Oxaliplatin (C), Vinblastine (D) and Vincristine(E) and in combination with HNP-
C(A+,B+,C+,D+ and E+) for 24 h incubation period in (Huh-7D). 
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Figure 3.36. Apoptosis detection cells with Annexin V staining probe. Huh-7D Cell 
lines were treated with single drugs Doxorubicin (A), Paclitaxel (B), Oxaliplatin (C), 
Vinblastine (D) and Vincristine(E) and in combination with HNP-C(A+,B+,C+,D+ 
and E+) for 24 h incubation period. Data represent as (mean±SD, n=3).* 
significant difference (p<0.05) between combination drugs with HNP-C and single 
drug treatment by paired t-test.  
 
Representative (Figure 3.38.) of SK-hep-1cells treated with combination therapies 
of HNP-C and each following single chemotherapeutic drugs (Paclitaxel, 
Oxaliplatin, Vinblastine and Vincristine) for 24 h and then stained with annexin V 
fluorescent probe as early apoptosis marker shows no major increase in the 
number of green membrane staining cells of SK-hep-1 with all single and 
combination therapies with previously mentioned treated drugs. In contrast, to 
significant apoptotic green signal was observed with doxorubicin and HNP-C 
combination therapies of SK-hep-1 treated cells comparing to cells treated with 
doxorubicin alone and calculated as (12% to 49%, single to combination therapy) 
percentage of apoptosis.  
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Figure 3.37. Fluorescent microscopy imaging of Doxorubicin (A), Paclitaxel (B), 
Oxaliplatin (C), Vinblastine (D) and Vincristine(E) and in combination with HNP-
C(A+,B+,C+,D+ and E+) for 24 h incubation period in (SK-hep-1). 
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Figure 3.38.Apoptosis detection cells with Annexin V staining probe. SK-hep-1Cell 
lines were treated with single drugs Doxorubicin (A), Paclitaxel (B), Oxaliplatin (C), 
Vinblastine (D) and Vincristine(E) and in combination with HNP-C(A+,B+,C+,D+ 
and E+) for 24 h incubation period. Data represent as (mean±SD, n=3).* 
significant difference (p<0.05) between combination drugs with HNP-C and single 
drug treatment by paired t-test.  
For U937 cells, (Figure 3.40.)  significant positive results were observed with both 
faces of treatment methods (single and combination therapy), which recorded for 
(Doxorubicin, Paclitaxel, Oxaliplatin, Vinblastine and Vincristine) as 
(43%,40%,40%,45% and 44%, respectively) for single drugs treatment, in parallel 
to combination therapies of each previously mentioned drugs with HNP-C that 
shows (70%,82%,76%,70% and78%, respectively) for combination therapy. 
However, this method simplified the weak synergism pattern of combination 
therapies in U937 in early apoptosis stage comparing to other methods that 
concern with the detection of more progressive stages of apoptosis process such 
as DNA damage (TUNEL assay) and cleavage protein (Western blot) which shows 
more killing pattern but with non-significant qualitative effect between combination 
of hybrid formulation of cytochrome C and chemotherapeutic drugs paralleling to 
single treatment. 
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Figure 3.39. Fluorescent microscopy imaging of Doxorubicin (A), Paclitaxel (B), 
Oxaliplatin (C), Vinblastine (D) and Vincristine(E) and in combination with HNP-
C(A+,B+,C+,D+ and E+) for 24 h incubation period in (U937). 
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Figure 3.40. Apoptosis detection cells with Annexin V staining probe. U937 Cell 
lines were treated with single drugs Doxorubicin (A), Paclitaxel (B), Oxaliplatin (C), 
Vinblastine (D) and Vincristine(E) and in combination with HNP-C(A+,B+,C+,D+ 
and E+) for 24 h incubation period. Data represent as (mean±SD, n=3).* 
significant difference (p<0.05) between combination drugs with HNP-C and single 
drug treatment by paired t-test.   
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3.3.4.2. Nanoparticles internalization inside the cells 
 
Transmission electron microscopy (TEM) was used to verify the internalization of 
HNP-C formulation inside culture cells. The main pathway of NPs internalisation 
inside the cells is endocytosis way through several basic mechanisms: caveolae –
mediated endocytosis, clathrin-mediated endocytosis and macropinocytosis. 
Clathrin-mediated endocytosis is the selective uptake mechanism in internalisation 
of most types of nutrients, NPs and recycles particles through specific receptors. 
The HNPs can be visualised in the holes inside the cells (Figure 3.41. A), or be 
internalised deeper inside the cells by macropinocytosis (Figure 3.41. B and E). 
Clathrin-mediated endocytosis of HNPs are also observed near the cell nucleus 
(Figure 3.41. C, D, G and F) as HNPs visualised at cell membrane and near 
nucleus and mitochondria in Huh-7D cell line (Figure 3.41. F and H) .Higher 
internalisation levels of HNPs with different mechanisms were observed on HepG2 
cell line as illustrated in (Figure 3.41. E).The bioactivity of NPs has been confirmed 
with successful internalisation of nano-formulation with the living cells. It is 
important to know their ability to cross the cell membrane and their intracellular 
concentration to exert the targeting therapeutic goal. TEM can offer unique 
imaging information of NPs cellular uptake by endocytosis. It is important to 
discover the ability of the NPs to reach the targeted biological cells and to predict 
the specific traffic pathways of these therapeutic formulations to select the suitable 
therapeutic protocol of administration. Moreover TEM images are played additional 
role in detection of any structural changes of treated cells (Manuela. 2016).   
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Figure 3.41.In vitro cellular uptake studies of HNP-C in(A,E) HepG2 cell line, 
(B,F,H) Huh-7D cell line, (C,G) SK-hep-1 cell line and (D) U937 cell line after 24 h 
incubation with 25 µgmL-1of HNP-C using TEM microscope (N) is referred to cell 
nucleus.   
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. 3.3.4.3. AFM topography imaging 
 
Atomic force microscopy (AFM) imaging was used in order to visualize the surface 
morphological of the liver cancer cells treated with combination therapies in 
parallel to cell treated with single chemotherapeutic drugs. The tapping model of 
AFM microscope was used to obtain images and in order to visualize the 
roughness and blebbing of the apoptotic cell surfaces in order to truly evaluate the 
differences in cellular state between the drug and combination treatment. The 
treated cells are compared to control (no treatment) cells and cells treated with 
IC10 of HNP-C used as percentage of combination therapy.  
AFM images of HepG2, Huh-7D, Sk-hep-1 and U937 cell lines (Figures 3.42., 
3.43., 3.44. and 3.45.), show that there was no obvious morphological changes 
between the control cells and the cells incubated with HNP-C. This confirms the 
previous tests of the safety usage of HNP-C against liver cancer cell lines. The 
AFM images of single drugs treated cells (Figures 3.42., 3.43. and 3.44., A1-F1) 
showed only slight surface modification of treated cells compared to the control. 
These results are confirmed the previous cytotoxicity assays of not detected any 
significant IC50 values after 24 h of single drugs treated cells. In contrast, obvious 
morphological changes were observed in the cells treated with combination 
therapies of CYT-C nanoformulation and chemotherapeutic drugs in all cell lines 
as illustrated in (Figures 3.42., 3.43. and 3.44.,B2-F2). Here, it can be observed 
that cellular rearrangement is occurring with surface bobbling and roughness 
obvious. This can only be due to the synergy between the drugs and HNP-C in 
combination and their enhanced cytotoxic effect. The only exception to this trend 
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were observed in the SK-hep-1 cell lines that pictured with non-obvious 
morphological changes on the surfaces of combination therapies treated cells with 
all chemotherapeutic treated cells with  unique changes was observed (Figure 
3.40.,B2) by remarkable changes with blebbing cells surfaces with doxorubicin and 
CYT-C treated cells and again these are confirmed previously with different cell 
cytotoxicity assays and apoptosis detecting kits of the negative detecting results 
with highly resistance SK-hep-1 cell lines in parallel to other cultured liver cancer 
cell lines.    
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Figure 3.42. AFM image of Hep G2 cells: A1) Control cells, A2) Cells with HNP-
C, B)Cells with DOX,C)Cells with OXA,D)Cells with PAC,E)Cells with VINB,F)Cells 
with VINC. Cells incubated with drug alone (1) and with drug combination (2) for 
24 h.  
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Figure 3.43. AFM image of Huh-7D cells: A1) Control cells, A2) Cells with HNP-
C, B)Cells with DOX,C)Cells with OXA,D)Cells with PAC,E)Cells with VINB,F)Cells 
with VINC. Cells incubated with drug alone (1) and with drug combination (2) for 
24 h. 
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Figure 3.44. AFM image of SK-HEP-1 cells: A1) Control cells, A2) Cells with HNP-
C, B)Cells with DOX,C)Cells with OXA,D)Cells with PAC,E)Cells with VINB,F)Cells 
with VINC. Cells incubated with drug alone (1) and with drug combination (2) for 
24 h.  
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Figure 3.45. AFM image of U937 cells: A1) Control cells, A2) Cells with HNP-C, 
B)Cells with DOX,C)Cells with OXA,D)Cells with PAC,E)Cells with VINB,F)Cells 
with VINC. Cells incubated with drug alone (1) and with drug combination (2) for 
24 h.   
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3.4. Discussion 
 
The production of novel drug is crucial to develop with the remarkable increase in 
mortality rate among liver cancer suffering patients. One of these methods is 
concerned with targeting of pro-apoptotic protein (Cytochrome-C) towards affected 
cells and stimulating apoptosis. This could offer a significant increase in the 
efficacy of chemotherapeutic drugs by working in synergism pattern with main 
killing pathway of chemo drug. This successful combination can be done by 
understanding the mechanism of action of each component (Yamada Y. and 
Harashima H., 2008; Delgado et al. 2014). 
Actually, many cancers are associated with a mutant P53 tumour suppressor 
pathway that is responsible for a short and inadequate chemotherapeutic drug 
response against cancer. Consequently, many efforts have motivated to use (Cyt-
C) a vital mediator of death program with direct stimulating of intrinsic apoptosis 
pathway and avoiding mutant extrinsic pathway that is responsible to release Cyt-
C from the mitochondrial intermembrane space (Lanni J. S. et al., 1997; Ryan 
K.M. et al., 2001; Santra S.et al., 2010). 
The most usable method in the cancer treatment is the systemic administration of 
chemotherapeutic agent; with unspecific directing goal inside the body this type of 
treatment will experience undesirable side effects towards healthy cells. Liver 
cancer is usual treatment with few reported drugs such as doxorubicin, paclitaxel 
and sorafenibe, with effective results in only 20-25% of treated patients which 
unmet medical requirements. This however needs to be formulated with effective  
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drug delivery vehicle to overcome unspecific targeting problem of the cancer 
therapy (Gish RG, et al, 2007). 
Targeting apoptosis is the main goal of most anticancer therapy that is participated 
in proper cell growth, so any disturbance in apoptosis pathways has been 
considered a main cause of cancer. Cancer cells are recognized to be ATP-
consuming cells -which fuel by mitochondria - to nourish the highly proliferation 
rate of tumour cells (Dias N. and Bailly C., 2005). Therefore, this part of the cell is 
considered as a main goal of cancer research to understand the molecular 
targeting pathways of apoptosis mechanisms inside the cells. Most 
chemotherapeutic agents commonly activate apoptosis by releasing pro-apoptotic 
protein (cytochrome C) from inter mitochondrial membrane space and initiate cell 
death. Therefore, many efforts were made to develop mitochondrial targeting 
therapy to initiate the killing process (Hail N. Jr., 2005; Sharma et al. 2016; Ling 
Huang et al. 2017).   
The delayed response to chemotherapy regime or to any inducer of cytochrome c 
release alone comparing to rapid response of the combination therapy has been 
approved to be the main activating way of apoptosis inside the mitochondria 
(Rajendran L. et al., 2010; D'Souza G.G. and Weissig V., 2009). So, the 
successful delivering of cytochrome C with anticancer drug to increase the 
potency of the active drug part in starting apoptosis is the main goal of this 
research.  
Numerous chemotherapeutic agents have been participated in activation of 
apoptotic pathways upstream of the mitochondria and then joined by the intrinsic  
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apoptotic route. However, the mutation of many key death proteins such as P53 
creates resistance to the action of the most anti-cancer drugs. So, the delivery of 
the effective modulator that acts directly on the downstream of apoptosis and 
stimulate effector caspase to produce irreversible cell death even in the presence 
of improper upstream function is the main reason to evade any resistance of 
extrinsic pathway (Amaral JD., et al., 2010). Activation of the caspase cascade is 
considered as a key step to initiate apoptosis. In this study, it proved that 
apoptosis stimulated through mitochondrial pathway (intrinsic apoptosis pathway) 
downstream of effector caspase 3 by successful targeting of cytochrome-c with 
iron oxide-gold hybrid nanoparticles (Malekigorji et al. 2014). 
Pro-apoptotic protein (cyt c) is faced restricted factors to be effectively transported 
across cell membrane. Generally, proteins are experienced a lot of difficulties 
inside the body such as degradation and unstable physical and chemical features 
making it challenging to be used alone without developing proper delivery system 
to support a required dose of the drug into the cell cytoplasm and to utilize a 
desired healing effect (Torchilin, V., 2008). 
The delivery of the cytochrome c binding to the iron oxide-gold hybrid 
nanoparticles are offered many features of applied the gold as the shell of the 
nanoparticles which can simply be decorated with different types of ligand such as 
cyt c. In addition, the magnetic properties of the iron oxide nanoparticles core 
which could be directed to the specific site in the body by applying external source 
of magnetic field, by this application we can get highly aggregation of the bio-
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activated magnetic nanoparticles inside tumour cells (Yallapu MM  et al. 2011; 
Pissuwan D. et al. 2006). 
The biological tests of the new formulation were investigated by applying different 
assays such as MTT and trypan blue. These two methods are applied to detect 
the cytotoxicity effect of either the nano-formulation or chemotherapeutic drugs 
and supported with apoptotic examined methods to evaluate the effectiveness of 
the new formulation and to prepare the formulation to future in vivo studies.   
The effect of HNP, CYT C and HNP-C on the viability of the hepatoma cell lines 
and differentiated U937 were tested by MTT and trypan blue methods with serial 
dilution ranged from (10 -1 μM) for both formulation respectively. A dose response 
curves were recorded with no noteable cytotoxicity effect of HNP and CYT-C on 
the cultured cell line at all incubation time points (24 h, 48 h and 72 h), which 
detected the biocompatibility of the applied formulation to be safely used for further 
in vitro studies. Moreover, no cytotoxic effects of HNP against pancreatic cancer 
(Bxpc3 cell line) (Hoskins et al. 2012a) and cytochrome C on liver cancer 
(HepG2cell line) (Malekigorji et al. 2014; Ling Huang et al. 2017) were also verified 
in previous studies.  
The dose response studies of CYT-C hybrid formulation were constructed to 
investigate the apoptotic activity of this protein against liver cancer and 
differentiated U937 cell lines. Generally, significant IC50 were noticed after 72 h 
incubation time with cultured cancer cell lines as illustrated in the results section. 
In order to prove the effect of co-administration of CYT-C with experimental 
chemotherapeutic used in this study, the effective IC10  concentration of CYT-C 
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hybrid formulation were used with detectable serial dilutions of anti-cancer drugs 
which noticed to be 0.012 mgmL-1 of loaded CYT-C and dosed the cultured cancer 
cells with these combination. This chosen amount of CYT-C is corresponding to 
10% inhibition effect on the cell viability that represented the perfect percent to be 
used together with varying concentration of chemotherapeutic drugs. Previous 
studies were recorded the effective concentration of internalised CYCT-C and to 
investigate the required dose – which itself does not trigger apoptosis- which can 
improve the apoptotic action of a conventional chemotherapeutic drugs. In this 
study, the recorded IC10 value of loaded CYT-C was considered to be 10-100% 
lower than that previous reported studies (Malekigorji et al. 2014). By means of 
this combination, significant IC50 were verified with the most combination therapies 
in comparing to single drug treatment against the cultured hepatoma and U937 
cell lines (as mentioned previously in results section). By this way, the efficacies of 
the used anti-cancer drugs are remarkably increased and the required treated 
dose will be decreased lower than the usual experience one with single drug 
treatment, confirming the synergism effect between the pro-apoptotic protein and 
anti-cancer drugs by targeting the main mechanism pathway of each drug and 
enhance its apoptotic activity.  
These results were considered as a smart way for hepatocellular carcinoma 
treatment, since no effective chemotherapy regime was recorded with exceptional 
concern with surgical inoperable liver cancer types. 
The apoptotic effects of delivered CYT-C were checked by several studies that 
concerned with enzymatic and morphological changes related to different 
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apoptotic stages. The relative caspase 3 activity was measured as a result of 
CYT-C binding to Apaf-1 and pro-caspase 9 to form apoptosome and 
consequently start the apoptotic signal of caspase cascade pathway (McIlwain et 
al. 2013). As illustrated previously, the combination of chemotherapeutic and 
hybrid formulation of CYT-C were activated 3-4 fold levels of caspase 3 in relative 
to single drug treatment in liver cancer cell lines. This activation is confirmed the 
affordable apoptotic effect of CYT-C hybrid formulation towards liver cancer cell 
lines. Moreover, the activation of initiator caspase ( Caspase 9) and execution 
caspase 3 were also confirmed by targeting the CYT-C binding to hyaluronic acid 
against human lung adenocarcinoma (A549) cell line which results in the induction 
of downstream apoptosis pathway (Figueroa  et al. 2017). 
The apoptosis induction is also confirmed by protein binding visualization protocol 
which is known as western blot (immunoblotting technique), with concern that the 
most detectable cleavage nuclear protein poly (ADP-ribose) polymerase-1 (PARP) 
is used as a main apoptotic marker of bio-therapeutic treatment. In previous study, 
they examined the covalently binding of cytochrome C to antennapedia (Antp) 
peptide and used Hela cervical cell line as in vitro cultural model. Significant 
apoptosis marker results of immunoblotting assay were listed with cells exposed to 
CYT-C binding ANTP and recorded with remarkable cleavage of 116 KDa PARP-1 
precursor into 89 KDa PARP-1 fragments in parallel to unaffected response 
against PARP-1 protein in cancer cell treated with either CYT-C or Antp alone 
(Imesch et al. 2013; Delgado et al. 2014; Weon Sup Shin et al. 2016). In this 
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study, remarkable bands were clearly imaged under the combination therapies 
channels comparing to fairly detected protein bands with single drugs treatments.  
Subsequently, this confirms the previous apoptotic effect of CYT-C hybrid 
formulation combined with anti-cancer drugs against caspase 3 levels. 
Further laboratory investigations were performed to detect the apoptotic effects of 
CYT-C nano-formulation and they concerned with DNA 3-OH labeling kits (TUNEL 
assay) which considered as one of apoptosis indicating methods. As illustrated in 
results section, the quantification methods of TUNEL assay were expressed as 
significant fold increase in the absorbance levels of combination therapy against 
liver cancer and U937 cell lines in parallel to the reduced spectro-absorbance of 
anti-cancer treated cells. Moreover, the fluorescent binding (Annexin) probes were 
used to detect the early stages of apoptosis by labeling the external cell 
membrane folding protein in apoptotic cells phosphotidylserine (PS) and to be 
differentiated from late apoptosis and necrotic cells that permit to fluorescent 
propidium iodide (PI) probes to penetrate the cell membrane. The apoptosis 
induction were confirmed previously in (A549) cell line when incubated with CYT-C 
loaded nano-formulation comparing to native loading cytochrome C and imaged 
under confocal microscope to visualise green fluorescent Annexin-V signal in cells 
underwent apoptosis and red fluorescent signal for late apoptotic cells (Figueroa  
et al. 2017). Another fluorescent study is also reported with HepG2 incubated with 
doxorubicin alone and binding to hollow mesoporous silica nanoparticles (HMSNs) 
as active drug delivery system, the last formulation is grafted with CYT-C and 
studied the apoptotic effect of each formulation against HepG2 cell line. The 
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HMSNs nanoparticles grafted with doxorubicin and CYT-C were showed 
significant apoptosis levels of this formulation comparing to negligible apoptotic 
effects with nanoparticle alone or with doxorubicin. These results are confirmed 
our investigation in potentiate the apoptotic killing activity of DOX- nano-
formulation when binding to CYT-C in dose dependent manner (Ling Huang et al. 
2017).  
 
3.5. Conclusion 
 
The results of this chapter were reflected the increasing killing abilities of 
chemotherapeutic therapies when co-administered with cytochrome C hybrid 
formulation by targeting the natural killing mechanism inside the cells and 
activated its pathways. Subsequent to this work further lab work were done in 
chapter 4 to formulate one platform therapeutic device and to check its chemical 
and biological effects against hepatic cancer cells. 
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4.1. Introduction  
 
Polymeric amphiphiles have been used as an excellent vehicle to improve the 
drug solubilisation in aqueous environment (Bromberg L. 2008; Branco MC. et al. 
2009). These types of polymers have the spontaneous ability to form micelle like 
aggregates through hydrophobic-hydrophobic interaction once they interact with 
aqueous environment (Qui L. et al. 2007). The agricultural nature of polymeric 
nano-aggregate may be formed as different shaped such as copolymer (Letchford 
K and Burt H. 2007), star polymer (Lapienis G. 2009), dendrimers (Duncan R. and 
Izzo L. 2005) and graft polymer (Thompson C. et al. 2008). The grafting polymer is 
performed by water soluble backbone and then grafted with hydrophobic groups to 
form a comb like structure. Generally, the most usage types of hydrophilic polymer 
as a backbone are polyethylenimine (Cheng et al. 2006) and polyallylamine 
(Hoskins et al. 2011). Previous research has concerned with promising drug 
solubilizer agents by grafting poly (allylamine) polymer with cholesterol and dansyl 
moiety (Hoskins et al. 2012d). The hydrophobic model drugs used with this 
macromolecule are prednisolone, propofol and griseofulvin (Hoskins et al. 2012d). 
The formation of single platform of polymeric amphiphiles and HNPs is served as 
dual function vehicle for imaging and active delivery of pharmaceutical products. 
Previous study is concerned with grafting of hydrophilic poly (allylamine) polymer 
(PAA) with 5-(4-chlorophenyl)-1,3,4-oxadiazole-2-thiol(oxadiazole, Ox)  in ratio of 
5% (PAA-OX) (Barnett et al. 2013a). The polymer grafting with oxadiazole is 
presented as the hydrophobic site of the micelles via its aromatic nature. 
Moreover, it offers an active binding site to HNP by possessing thiol group (SH) in 
178 
 
its structure and forming dative covalent bond between (SH) functional group and 
gold surface of HNP (Barnett et al. 2013b).  
Paclitaxel (PTX) will be used in this chapter as hydrophobic drug model to check 
its water solubility behaviour after loading into PAA-HNP-C platform. This chemical 
compound is poor water soluble (less than 1 µgmL-1) with lacking ionisable 
functional groups (Singla et al. 2002; Beijnen et al. 1994). The bioavailability of this 
compound is indicated as (< 2%) and low penetration abilities through cell 
membrane (increase level of P-glycoprotein) that makes the most common 
administration route of this drug by intravenous. The higher metabolism level of 
this drug is also recorded inside the body by P450 enzymes.  The current trade 
formulation of PTX is named Taxol® and dissolved in mixture of 50 % 
Cremophor® EL with 50 % dehydrated ethanol (v/v), this solvent mixture is 
responsible to produce serious  side effects  affecting nervous  and cardiac system 
which limits its use (Fu-Heng Yang et al. 2015). Moreover, Cremophor® EL is 
responsible to produce serious systemic haematological toxicity via stress based 
oxidative damage mechanism. For that reason, it is urgent to improve a new way 
to administer PTX without affecting its efficacy and to direct its action towards 
specific cancerous site with lower undesirable side effects (Fu-Heng Yang et al. 
2015). In this study, PTX is encapsulated into PAA-OX5 alone and into PAA-OX5-
HNP platform to check the loading percentage of hydrophobic drugs and to check 
its solubility improvement comparing to drug alone. In vitro studies in 
hepatocellular carcinoma (HepG2, Huh-7D and SK-hep-1) cell lines were 
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performed to check the cytotoxicity effect and cellular uptake of PTX alone and 
incorporated with PAA amphiphiles. 
 4.1.1 Aims and objectives 
 
The aims of this chapter are: 
- To perform synthesis and grafting of hydrophilic poly (allylamine) polymer (PAA) 
with 5-(4-chlorophenyl)-1,3,4-oxadiazole-2-thiol(oxadiazole, Ox). 
-To increase efficacy of paclitaxel against HepG2, SK-hep-1 and Huh-7d cell lines 
by combining the HNP-CYT-C and paclitaxel into polymer formulation as a single 
platform for treatment. 
-To detect the cytotoxicity effect of these new formulations using the MTT assay 
and to determine the cellular uptake level of paclitaxel alone and after the polymer 
loading formulation by HPLC. 
4.2. Materials and Methods 
 
4.2.1. Polymer preparation 
 
PAA (2 g)( Sigma-Aldrich, UK) was dissolved in (1:1) methanol: chloroform with 
stirring at 37C° accompanied by the addition of (2 mL) of triethylamine drop by 
drop and left the reaction for 30 min. 5-(4-chlorophenyl)-1,3,4-oxadiazole-2-thiol 
(Oxadiazole, Ox) (0.375 g) was dissolved in 20 mL (1:1) methanol: chloroform and 
added drop by drop over 30 min to the previous polymer solution and left for 18 h 
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at 37 ° C. Next day, the solution was evaporated by reduced pressure rotary 
evaporating; the resultant polymer residue was washed with diethyl ether for 3 
times and dried thoroughly. Then, the residue was dissolved in deionised water 
and dialysed by 12-14 KDa visking membrane (Medical international Ltd, UK) for 
24h against deionised water. The dialysed solution was freeze-dried and further 
polymer structure characterisation was performed by using proton nuclear 
magnetic spectroscopy (1H NMR, 400 MHz) at 25 °C in deuterated water 
(D2O)(Bruker, UK) and functional groups spectra on a diamond tipped was 
obtained by attenuated total reflectance- fourier transform infrared spectroscopy 
(ATR-FTIR) (Nicolette IS50, Thermo-Fisher, UK).All the rest chemicals used in 
preparation were purchased from (Sigma-Aldrich, UK). HNP synthesis was 
performed as illustrated in chapter 2. 
4.2.2. PAA-Ox5-HNP Conjugation and characterisation 
 
PAA (10 mL, 5 mgmL-1) was prepared in deionised water with probe sonication for 
10min. HNPs-C (500 µl) (previously prepared in chapter 2) were added into 
polymer solution and sonicated for further 10 min. Nano-aggregates were formed 
in aqueous solution via probe sonication. The resultant solution was filtered using 
0.22 µm syringe filters preparing to additional analysis. The critical aggregation 
concentration (CAC) was calculated by using a hydrophobic methyl orange UV 
probe following adaptation of Uchegbu’s method. The stock solution of methyl 
orange was prepared with sodium tetraborate buffer as (25 μM, 0.02 M, pH 9.4, 
respectively) in deionised water. Polymer serial solutions of (0.0195 - 5 mgmL-1) 
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were prepared with methyl orange solution as the diluent. After that, each 
prepared sample was sonicated for 5min and left to cool for another 5 min to reach 
room temperature. The prepared polymer solutions were measured in a UV-2600 
UV-VIS(NIR) spectrometer (Shimadzu, Germany) and recorded the maximum 
absorbance at (350-600 nm) and the control was the stoke solution of methyl 
orange. The hypsochromic shift upon aggregate formation of the polymer solution 
wavelength maxima was determined comparing with the λmax of methyl orange 
stock solution (463 nm).  
The other method was used to detect the CAC by measuring the surface tension 
of the polymers which made up in aqueous solution (nine solutions, 0.0195 - 5 
mgmL-1) were prepared and sonicated for 5 min before cooling to room 
temperature. The surface tension of polymer solutions was measured at 25 °C 
using a torsion balance (OS, White Electrical Instrument Co, London). The 
platinum ring and platform were cleaned with ethanol and doubly distilled water 
prior to analysis of each sample. The measurement was conducted in triplicate for 
each polymer solution to obtain an average value. The surface tension of 
deionised water was determined between each concentration to ensure no cross 
contamination of samples had occurred.  
TEM imaging, Photon correlation spectroscopy and Zeta potential were carried out 
as previously illustrated in (Chapter 2). 
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4.2.3. Drug Loading of Nano-aggregates 
 
The PTX was loaded into aqueous polymer solution alone and into nano-
aggregate using prob sonication with (25 mg) drug: polymer feed ratio (1:1) for 10 
min. the resultant solution was filtered to remove unsolubilised PTX molecules 
using 0.22 μm syringe filter for further study of optimal loading concentration of 
PTX with both formulations. PTX concentrations standard curve were determined 
by preparing (10mg) serial dilution of PTX with mobile phase consisting of 55:45 
(v:v) water: acetonitrile and measuring with HPLC (Perkin Elmer Flexar LC Auto 
sampler) the mobile phase was run at 1 mL/min and sample analysis performed at 
227 nm absorbance measurements. All measurements are performed at room 
temperature and PTX encapsulation concentration calculated in respect to PTX 
standard curve. The PTX optimal formulation was analysed using Photon 
correlation spectroscopy, Zeta potential and TEM imaging. The formulation was 
also freeze-dried for NMR and ATR-FTIR spectra measurements. 
4.2.4. Biological characterisation of nano-aggregates and formulation 
 
4.2.4.1. Cell viability assay (MTT) 
 
96 well plates were used to seed 15,000 cells with 100μL of media per well for 
each cell lines and allowed to adhere overnight (24 h) in humidified incubator at 
37% in 5% CO2 atmosphere. Serial dilutions of Paclitaxel (100-1nanomole) alone 
and in combination with active IC10 value of CYT-C combination in PAA-Ox5-HNP-
C formulation (0.012 mgmL-1) (as illustrated in Chapter 3) was added to the 96-
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wells of HepG2,SK-hep-1 and Huh-7d cell lines and incubated for (24 h, 48 h and 
72 h). At these three times vital dye (yellow MTT 3-(4,5-dimethyl-2-thiazolyl)-2,5-
diphenyl-2H-tetrazolium bromide) was used to detect the number of live cells 
which reflecting the cytotoxicity effect for anticancer drug alone and with 
formulation. 
For each time points (24 h,48 h and 72 h) removed the serial drugs solution from 
treated cells and add 100 μL of MTT sterilized solution, put in the incubator for 3-4 
h to permit the reduction of Tetrazolium dye by oxido-reductase mitochondrial 
enzyme referring to the metabolic activity of the live cells forming insoluble 
formazan crystal then removed the MTT solution and replaced by 100 μL of DMSO 
to form colorimetric solution optical densities were measured in microplate 
reader(Tecan Infinite, Austria) at 570 nm. The percentage of cell viability was 
calculated relative to the absorbance of untreated cells and PBS as (positive and 
negative control, respectively).  
 
4.2.4.2. Cellular uptake of PTX 
 
Liver cell lines were seeded in 6 well plates (50,000 cells /well) and incubated for 
24 h at 37 °C with 5% CO2.Next day the media was replaced by100 µL (50 µgmL
-
1) of PTX concentration (in PAA-Ox5-HNP-C formulation comparing to free drug) 
per well and incubated for 4 h. After incubation period the media was removed and 
the treated cells were washed with PBS preparing to detach by trypsin adding to 
each well. The suspension cells in 1 mL fresh media were counted by automated 
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cell counter (Invitrogen countess, UK) to transfer 100,000 cells of each cell line 
into Eppendorf tubes and centrifuged for 5 min at (250 g). The resultant 
supernatant was removed and the precipitated pellets were resuspended with 1 
mL of sterilised water and vortex for 30 seconds. The concentration of PTX alone 
and in combination PAA-Ox5-HNP-C were measured at 227 nm using HPLC 
(Perkin Elmer Flexar LC Autosampler) and analysed per cell by T-Test analysis 
within the Microsoft Excel ® software package. 
4.3. Results 
 
4.3.1. Synthesis and Characterisation of PAA-Ox5 
 
The fabrication of PAA-Ox5 polymers were performed by simple substitution of the 
primary amines in the parent PAA structure and the chloride functional group of 
the oxadiazole compound. The spectra of 1H NMR spectroscopy was detected the 
successful steps of polymer synthesis (Figure 4.1.). The showed peaks at δ0.75, δ 
2.50, δ 3.00, δ1.40 and δ 1.50 can be attributed to the CH2 and CH groups in the 
homopolymer backbone, respectively.  
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Figure 4.1. The spectra of 1H NMR spectroscopy of PAA polymer structure carried 
out on 400MHz NMR at 25 °C. 
 
More peaks were observed at δ7.25-7.75 when fabricated PAA-Ox5 polymers 
were analysed and it detected the aromatic CH groups present in the oxadiazole 
pendant group (Figure 4.2.). The proton on the –SH group of the oxadiazole 
pendant was not detected on this spectra; this is likely to be due to rapid exchange 
between the thiol and D2O solvent.  
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Figure 4.2.The spectra of 1H NMR spectroscopy of fabricated PAA-Ox5 polymer structure carried 
out on 400MHz NMR at 25 °C. 
 
4.3.1.1. FTIR 
 
FTIR analysis of the PAA-Ox5 amphiphile was run between 4000 – 650 cm
-1 to 
detect the specific functional groups existing (Figure 4.3.). Here, characteristic 
peaks were observed at 3273 cm-1 and 2846 cm-1 which result from the N-H 
stretching and C-H stretching in the PAA backbone, respectively. An additional 
peak at 1597 cm-1 was observed and indicated that hydrophobic pendant group 
attachment had been successful as a result of this peak the bending and 
stretching vibrations of the aromatic ring C=C present in the oxadiazole structure. 
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Figure 4.3.FTIR spectra of PAA-Ox5 using diamond tripped ATR-FTIR (64scan). 
 
4.3.1.2. Methyl orange 
 
The CAC was determined for the amphiphiles using a hydrophobic methyl orange 
UV probe. Here, a hypsochromic shift was not observed in the λmax values for 
absorbance in the UV spectra (Figure 4.4.). At higher concentrations an increase 
in λmax was observed but this is likely to be due to the translucent nature of the 
concentrated sample interfering with absorbance measurement. As such the CAC 
was determined using a different measurement via surface tension. 
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 Figure 4.4. Methyl orange CMC measurement  
 
4.3.1.3. Surface tension (N/M) 
 
The surface tension for the PAA amphiphiles both with and without incorporation 
of HNPs was determined. The surface tension of water is 0.072 N/m. As the nano-
aggregates form, they cause a change in surface tension of the aqueous media 
due to the surface layer becoming saturated forcing the amphiphiles into the bulk 
and hence aggregation occurs. The CAC is a measure of how stable the 
aggregates are in solution and give an indication of whether they will undergo 
breakdown after dilution. The data from this test (Figure 4.5.) shows that the CAC 
for the PAA-Ox5 was 0.313 mgmL-1 whereas; the HNP containing amphiphile was 
0.039 mgmL-1. This suggested that the aggregates formed at lower concentration 
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when the magnetic HNPs were incorporated in the structure. The reason for this is 
not known, however, it may be possible that the magnetic attractive forces being 
stronger than the intermolecular forces and hence drive forward aggregation. 
 
Figure 4.5. Surface tension (N/M) of PAA-Ox5 and PAA-Ox5-HNP. 
 
4.3.2. Characterisation of PAA-Ox5 and PAA-Ox5-HNP Nano-aggregates 
 
The formations of nano-aggregates were achieved by probe sonication of the PAA 
in deionised water. Variable techniques were used to characterise the formulation 
synthesis steps which concern with size and zeta potential measuring by PCS and 
TEM. TEM imaging were showed the PAA-Ox5 micelles structure with 
approximately (50 nm) diameter which smaller value comparing to PCS value that 
showed (88 nm). These differences are due to the different measurement 
techniques between the TEM and PCS as illustrated before in HNPs synthesis 
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chapter (Chapter 2). The poly dispersity index of the PAA-Ox5 was (0.55) 
indicating that the mono-dispersity of nano-aggregates were not exist for long 
time. PAA-Ox5 zeta potential was also measured and showed (+ 38 mV), this high 
value is due to the presence of function amine groups to PAA backbone. 
HNP was conjugated with PAA-Ox5 through dative covalent linkage between the 
gold surfaces of HNP and the thiol functional group of oxadiazole pendant group in 
PAA-Ox5. It is supposed that only one thiol group was attached to one HNP 
contributing to low concentration of HNP used in conjugation and to the steric 
hindrance effect. HNP attachment to PAA-Ox5 was confirmed by TEM images 
which observed as dark condense parts within nano-aggregate (Figure 4.6.B) 
owing to randomly attachment of HNP onto oxadiazole pendant to form PAA-Ox5-
HNP. 
The zeta potential value of PAA-Ox5-HNP (17 mV) was showed a sharp decrease 
value comparing to nano-aggregate surface charge. This change is possibly 
contributing to HNPs incorporation detecting to the PCS during aggregate 
formation and to dynamic equilibrium effect. 
Remarkable increases in PAA-Ox5-HNP particles size were recorded as PCS 
measurements (186nm) and with TEM instrument as (100 nm). These big 
variations are contributing to HNPs conjugation that inhibits the compact 
aggregate due to steric hindrance. Moreover, significant decrease in PDI values 
from 0.55 to 0.137 for PAA-Ox5 and PAA-Ox5-HNP, respectively were also 
observed during measurements and may contribute to the steric hindrance effect 
of conjugated HNPs that increase the intramolecular aggregate formation in 
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parallel to low levels of larger intermolecular aggregate which results in less 
compact PAA-Ox 5-HNP aggregates formation. 
TEM images showed clear structure of PAA-Ox5 (Figure 4.6.A) comparing to 
condensed unclear ones with PAA-Ox5-HNP TEM (Figure 4.6.B). Probably due to 
the cluster formation of the PAA-Ox5-HNP by inherent magnetic effects of HNP 
during the TEM grid drying time before the complete water droplet drying, this 
phenomenon is familiar with variety of magnetic nano-material organising to be 
imaged by TEM. 
         
Figure 4.6.TEM images A) PAA-Ox5 and B) PAA-Ox5-HNP nano-aggregates.   
A B 
100 nm 100 nm 
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4.3.3. PTX loading into nano-aggregates 
 
The PTX was incorporated into PAA nano-aggregate via hydrophobic-hydrophobic 
interaction. Polymer concentration to drug ratio was used is (1:1) by loaded 25 mg 
of PTX into 5 mg (5 mgmL-1) of aqueous PAA nano-aggregate solution. 
Interestingly, the PAA-Ox5-HNP nanoparticles presented with higher 
encapsulation ability of PTX (0.684 mgmL-1) into their hydrophobic core comparing 
to (0.598 mgmL-1) of PTX into PAA-OX5 nano-aggregate; this may possibly 
happen due to the nature of PAA-Ox5-HNP which characterised as less compact 
aggregate that accommodate a larger amount of PTX molecules The aqueous 
solubility of PTX was increased 700-fold and 600-fold with the PAA-Ox5 and PAA-
Ox5-HNP aggregates, respectively. 
 
4.3.4. Biological characterisation of drug nano-aggregates  
 
The cytotoxicity of the PTX-PAA amphiphiles on liver cancer cell lines was 
detected via MTT assay (Figure 4.7.). Serial dilutions of Paclitaxel (100-1 nM) 
alone and in combination with active IC10  value of CYT-C combination in PAA-
Ox5-HNP-C formulation (0.012 mgmL-1) (as illustrated in Chapter 3) was added to 
the 96-wells of HepG2,SK-hep-1,Huh-7d and U937 cell lines and incubated for (24 
h, 48 h and 72 h). At these three times vital dye (yellow MTT 3-(4,5-dimethyl-2-
thiazolyl)-2,5-diphenyl-2H-tetrazolium bromide) was used to detect the number of 
live cells which reflecting the cytotoxicity effect (IC50) for anticancer drug alone and 
with formulation. After 24 h incubation time with PTX-PAA amphiphiles significant 
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IC50 was determined on HepG2 at (50 nM and 40 nM) of PAA-Ox5 and PAA-Ox5-
HNP-C formulation comparing to the IC50 of PTX alone, respectively.  
Through increasing incubation time to 48 h also significant IC50 of PAA-Ox5 and 
PAA-Ox5-HNP-C formulation was detected as 1.99 nM and 0.8 nM in parallel to 
the cytotoxic concentration of PTX alone, respectively. Moreover, 72 h incubation 
period was showed 31-fold and 43-fold decreased in IC50 of PAA-Ox5 and PAA-
Ox5-HNP-C formulation compared to free drug cytotoxicity. 
The cytotoxicity results of PTX against Huh-7D cell line (Figure 4.7.) were showed 
significant IC50 (53nM and 11nM) of PAA-Ox5 and PAA-Ox5-HNP-C formulation 
after 24 h comparing to the IC50 with PTX alone. Both 48 h and 72 h incubation 
times were determined with 8-fold and 10-fold increase in cytotoxicity with PAA-
Ox5 formulation comparing to PTX alone at each time, respectively. Besides to 
remarkable increase in PAA-Ox5-HNP-C formulation cytotoxicity which determined 
as 15.7-fold and 33-fold decrease in IC50 after 48 h and 72 h comparing to PTX 
alone at each time, respectively. 
SK-hep-1 cell line was showed no significant response to PTX alone and to PAA-
Ox5-HNP-C formulation after 24 h and 48 h incubation time with one significant 
exception result was recorded with PAA-Ox5-HNP-C formulation after 48 h 
incubation time and determined as (84.27 nM). However, significant IC50 of both 
PAA-Ox5 and PAA-Ox5 polymer formulation was determine after 72 h incubation 
time and recorded as (73.32 nM and 57.39 nM ) corresponding to undetected IC50 
value with PTX alone, respectively.   
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Table 4-1.IC50 values of ( Paclitaxel ,PTX+ PAA-Ox5 and PTX+ PAA-Ox5 –HNP-
C) on HepG2 ,Huh-7D and SK-hep-1 cell lines achieved by MTT assay. Significant 
increase in the cytotoxicity was calculated by comparing with single drug treatment 
(n=3, aver ±SD). 
HepG2 cell line Drug alone   PTX+PAA-Ox5 PTX+PAA-Ox5-HNP-C  
Paclitaxel       
24 h NS 50±3.05  nM 40±1.5nM   
Increase in cytotoxicity  Significant IC50 Significant IC50 
48 h NS 1.99±0.7   nM 0.98±1.3 nM 
Increase in cytotoxicity - Significant IC50 Significant IC50  
72 h 32±4.84 nM 1 nM 0.7 nM 
Increase in cytotoxicity - 31-fold 43-fold 
Huh-7D cell line       
24 h NS 53 ±1.52 nM 11±2.5 nM 
Increase in cytotoxicity - Significant IC50   Significant IC50 
48 h 37±1.05 µM 4±2.61  nM 2.21±1.82 nM 
Increase in cytotoxicity - 8-fold 15.7-fold 
72 h 31±1.12 µM 3±2.5  nM 0.9±2.1 nM 
Increase in cytotoxicity - 10-fold 33-fold 
SK-hep-1 cell line       
24 h NS NS NS 
Increase in cytotoxicity - -   
48 h NS NS 84.27±3.1nM 
Increase in cytotoxicity   - Significant IC50  
72 h NS 73.32±1.54 nM 57.39±4.02nM 
Increase in cytotoxicity  Significant IC50  Significant IC50   
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Figure 4.7. Dose response curve of ( Paclitaxel ,PTX+ PAA-Ox5 and PTX+ PAA-
Ox5 –HNP-C )on HepG2 ,Huh-7D and SK-hep-1 cell lines of three independent 
experiments after 24 h,48 h and 72 h incubation time, the x-axis represent the 
serial dilutions of the drug and the y-axis represent the absorbance of MTT 
formazan crystalline which indicate the % of cell viability.   
196 
 
PTX uptake studies were carried out with liver cancer cell lines (Fig.8) and the 
drug concentration was quantified per cell. After 4 h incubation time with 50 µgmL-
1of PTX alone and with PAA-Ox5 formulation, 145-fold more drug uptake by the 
HepG2 cell comparing to free drug. Moreover, 174-fold more PTX concentration 
was founded inside the cancerous cell incubated with PAA-Ox5-HNP-C 
formulation. Huh-7D uptake studies are also showed significant PTX uptake level 
inside the cell with both formulation and determined as (134-fold and 156-fold) with 
PAA-Ox5 and PAA-Ox5-HNP-C formulations, respectively. Interestingly, 
remarkable increase in PTX level were also observed when incubated with SK-
hep-1 cells and resulted in significant (99-fold and 124-fold) increase in cellular 
uptake level comparing to free drug with both PAA-Ox5 and PAA-Ox5-HNP-C 
formulations  
 
Figure 4.8.PTX uptake study on A)HepG2 ,B)Huh-7D and C)SK-hep-1 cell lines 
after  4h incubation time with 50 µgmL-1 concentration of PTX and PAA-OX5 and 
PAA-OX5-HNP-C formulations,* indicate the significant increase in drug uptake 
between free drug and formulation (n=3 ,average±SD). The t-test analysis is 
performed by Microsoft Excel software.   
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4.4. Discussion  
 
Over the past decade the study of emerging bi-functional platform as active drug 
delivery vehicles has been extensively studied (Barnett et al. 2013a). One of the 
interesting emerging designs is Incorporation of HNPs with PAA-OX5 amphiphilic 
polymer that serves as active way in therapeutic imaging and drug delivery(Barnett 
et al. 2013a). In this chapter the potential of metallic amphiphilic polymer function 
was used as drug carrier with ability of incorporation of specific bio-particle to the 
surfaces of HNP. As studied previously with the binding of CYT-C as dative 
covalent bond to gold surfaces ( Malekigorji et al., 2014). 
The HNPs were incorporated into PAA-OX5 polymer via dative covalent bonding 
between the gold surfaces and thiol function group of the oxadiazole pendant 
group. Several techniques were used to characterise the synthesis steps of 
polymer and HNP binding by 1H NMR, FTIR, TEM and Zeta potential 
measurements as illustrated in results section. PTX incorporation mechanism with 
PAA-OX5-HNP-C was carried out by exploiting hydrophobic drug encapsulated 
into hydrophobic core of amphiphilic polymer. Here, PTX molecule was used to 
investigate the optimal improvement of hydrophobic drug hydro-solubilisation by 
preparing drug: polymer feed ratio (1:1). The encapsulation concentration results 
were showed (0.684 mgmL-1) of  PTX into PAA-Ox5-HNP-C hydrophobic core 
comparing to (0.598 mgmL-1) of PTX into PAA-OX5 nano-aggregate; this may be 
due to the nature of PAA-Ox5-HNP which characterised as less compact 
aggregate that accommodate a larger amount of PTX molecules (Table 4-1). The 
aqueous solubility of PTX was increased 700-fold and 600-fold with the PAA-Ox5 
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and PAA-Ox5-HNP aggregates, respectively. These results are agreements with 
previous studies of the propofol and griseofulvin loading drugs into PAA-Ox5 alone 
and with nano-aggregate, these loading procedure were improved the aqueous 
solubility of  propofol and griseofulvin by 137-fold and 53-fold increase for both 
drugs, respectively. Moreover, the loading capacities of nano-aggregates were 
presented with higher solubility levels of propofol and griseofulvin by 250-fold and 
56-fold increase, respectively (Barnett et al. 2013a)   
The cytotoxicity of paclitaxel was evaluated on HepG2, Huh-7D and SK-hep-1 cell 
lines alone and in co-corporation with PAA-Ox5 and nano-aggregates. After 24 h 
and 48 h incubation on HepG2, no significant IC50 (p>0.05) was detected in the 
MTT assay with PTX alone, while significant IC50 (p<0.05) were detected as 
(50±3.05 nM ; 40±1.5nM ,at 24 h) and (1.99±0.7 nM; 0.98±1.3 nM, at 48 h) with 
both PTX- PAA-Ox5 and nano-aggregates, respectively. Increasing incubation 
time of treatment to 72 h resulted in a 31-fold and 43-fold decrease in IC50 was 
observed in those cells treated with PTX-PAA-Ox5 and nano-aggregates 
respectively (Figure 4.7.) comparing to PTX treated cells. These significant 
increases in PTX amphiphilic polymer and nano-aggregate cytotoxicity are 
approved with increasing the potency of this hydrophobic drug by increasing the 
uptake levels through the cell membrane and enhancing the aqueous solubility of 
PTX. These results are in agreement with previous results of improving the 
cytotoxicity of propofol and griseofulvin on BXPC-3 pancreatic cell line after their 
incorporation with PAA-Ox5 and nano-aggregates (Barnett et al. 2013a). 
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The cytotoxicity of PTX was tested in Huh-7D cells, after 24 h a significant 
decrease in IC50 was observed with (PTX+ PAA-Ox5 and PTX+ PAA-Ox5 –HNP-
C). Further increase in cytotoxic effect was observed after 48 h and 72 h 
incubation. PTX encapsulation resulted in a 8-fold and 15.7-fold decrease in IC50 
after 48 h (PAA-Ox5 and PAA-Ox5 –HNP-C, respectively). A significant increase 
in the cytotoxicity was observed in those cells treated with PTX after 72 h., and 
showed a significant (10-fold and 33-fold) reduction in IC50 value with ( PTX-PAA-
Ox5 and PTX-PAA-Ox5 –HNP-C, respectively) compared to single drug treatment 
after 48 h and 72 h. 
As illustrated in (Chapter 3) The SK-hep-1 cell line showed a different behaviour 
against chemotherapeutic drugs compared to the other cell lines tested. Hence, 
the highly resistance nature of these cell lines against PTX resulted in no IC50 
values when incubated at all-time points incubation tested. However, remarkable 
changes were observed with PTX+ PAA-Ox5 and PTX+ PAA-Ox5 –HNP-C 
formulation which showed significant increase in cytotoxicity of these formulation 
after 48 h and 72 h  incubation period. These results are confirmed the activity of a 
PTX-PAA amphiphiles polymer in increasing the aqueous solubility of PTX and 
increasing the uptake level by the highly resistance SK-hep-1 cell line. The 
cytotoxicity results are showed highly increasing levels of the nano-aggregate 
cytotoxicity comparing to PTX-PAA amphiphiles polymer as shown in all incubated 
liver cancer cell line which confirmed the potential activity of CYT-C protein in 
PTX+ PAA-Ox5 –HNP-C formulation to increase the potency of PTX and 
increasing its cytotoxicity against liver cancer cell line.  
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PTX uptake studies were also showed significant increase in drug uptake level 
when encapsulated with 50 µgmL-1 of PTX-PAA amphiphiles polymer and nano-
aggregate after 4 h incubation comparing to cell incubated with free drug. This 
investigation is in agreement with previous studies of 6-TG conjugate to the 
surfaces of HNP (Barnett et al. 2013b) which showed 10-fold decrease in IC50 
when compared with free drug cytotoxicity. Moreover, the increasing uptake level 
of CYT-C protein levels inside liver cancer cell lines (Chapter 2) when conjugated 
to gold surfaces of HNP in parallel to negligible level of free protein inside the 
cancer cells.  
 
4.5 Conclusion 
 
The work in this chapter highlights the potential benefit from formulating the HNP-
CYT-C and PTX into one single platform for co-administration. These exciting 
findings require further investigation but hold great potential as a future therapy for 
liver cancer patients. 
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5.1. General Conclusions 
 
 
This research focused on testing five different chemotherapeutic agents in 
combination with HNP-c for liver cancer treatment. The data consistently showed 
that on HepG2, Huh-7D and U937 cells, there was a synergistic effect with 
combined therapy resulting in greater apoptosis and increase in cytotoxicity 
compared to the drug alone. The cytotoxicity assays showed that the lower IC50 
values were obtained using the anti-microtubule drugs (paclitaxel, vinblastine and 
vincristine) compared to the DNA damaging drugs (doxorubicin and oxaliplatin). 
The third cell line tested (SK-hep-1 cells) demonstrated resistant behavior against 
treatment with exceptionally significant results observed with DNA damage drugs, 
doxorubicin in both treatment regimes. The data offered the hypothesis that, by 
introducing the cytochrome C into the liver cancer cells and co-administering with 
anticancer agents, a synergistic effect will occur, resulting in increased apoptotic 
levels and cellular death. These findings indicate that clinical use of cytochrome C 
in parallel with clinically used anticancer agents may result in more positive patient 
outcome and novel low cost therapy. 
In order to push this formulation forward, it is important to combine HNP-C and 
chemotherapeutic agents in single supramolecular device to be used clinically as 
single therapeutic agent with multifunctional components. Unfortunately, most 
anticancer drugs are hydrophobic with impossible binding ability to HNP-C. 
Therefore, a new formulation has been designed to improve the cytochrome –c 
nano-formulation.  
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A single device treatment was designed by combining HNP-C and PTX together 
with PAA polymer. Here I fabricated an amphiphilic poly(allylamine) derivative 
grafted with oxadiazole groups (PAA-Ox5). The thiol functionality in the oxadiazole 
groups allowed for irreversible conjugation of the HNP-CYT-C constructs into the 
integral polymer structure, whilst the PTX was encapsulated into core-shell 
polymeric aggregate formed via hybrophobic-hydrophobic interactions. The PAA-
Ox5-HNP nanoparticles offered higher encapsulation ability of PTX (0.684 mgmL-
1) comparing to (0.598 mgmL-1) of PTX into PAA-OX5 nano-aggregate; this may 
contribute to the less compact aggregate nature of PAA-Ox5-HNP that capsulate 
larger amount of PTX molecules. In addition to remarkable aqueous solubility of 
PTX was increasing to 700-fold and 600-fold with the PAA-Ox5 and PAA-Ox5-
HNP aggregates, respectively.  
Cell viability studies were performed in order to check whether this supramolecular 
formulation was useful in the fight against liver cancer. Here, measuring PTX 
cellular uptake levels and cytotoxicity effect of PTX against (HepG2, Huh-7D and 
SK-hep-1) and differentiated U937 cell lines. After 24 h and 48 h incubation in 
HepG2, no significant IC50 (p>0.05) was detected in the MTT assay with PTX 
alone, while significant IC50 (p<0.05) were detected as (50±3.05 nM ; 40±1.5nM 
,at 24 h) and (1.99±0.7 nM; 0.98±1.3 nM, at 48 h) with both PTX- PAA-Ox5 and 
nano-aggregates, respectively. Increasing incubation time to 72 h resulted in a 31-
fold and 43-fold decrease in IC50 was observed in those cells treated with PTX-
PAA-Ox5 and nano-aggregates, respectively. These results showed the 
remarkable cytotoxicity effect of PTX  increasing against HepG2 cell line at 24 h  
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incubation time compared to non-significant IC50  recorded when co-administered 
with HNP-C. Moreover, Huh-7D12 cell line responded significantly to PTX-PAA-
Ox5 and nano-aggregates with decreasing IC 50 values (increasing cytotoxicity) of 
PTX treated cells starting from 24hr treated time and recorded as (53 nM ,11nM) 
for PTX-PAA-Ox5 and nano-aggregates, respectively. The PTX combination 
therapy with HNP-C that was used in Chapter 3 showed no IC50 values after 24 h 
treatment; these results confirmed the increasing potency of PTX after its 
encapsulation with PAA-Ox5 and nano-aggregates with increasing the uptake and 
solubility levels of PTX.  
Other reported studies also confirmed the activities of other types of nano- 
formulation in targeting and killing the hepatocellular carcinoma  such as 
PEGylated liposomes composed of distearoylphosphatidylcholine( WU et al. 2018) 
against SK-hep-1 cell line and hollow mesoporous silica nanoparticles (HMSNs) 
hosted with CYT-C against Hep-G2cell line (Ling Huang et al. 2017)  
 
5.2. Future work 
Regardless of all the advantages of nanoparticles, there is always a chance for 
additional improvements in this field. For example, polymer formulation was only 
tested with selected cytotoxicity assays and it would be useful to investigate this 
novel formulation further using flow cytometry, western blot and apoptotic assays 
to track the different stages of apoptosis. Furthermore, this formulation needs to 
be applied to primary cell lines with highly differentiated types of cells in 
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preparation for this formulation to be used in vivo studies, and to check its 
cytotoxic effect against animal models such as mice. The work in this thesis has 
shown that a nano-formulation using a combined strategy for treatment of liver 
cancer has resulted in optimal therapeutic effects. Following on from these 
studies, in vivo trials are required. These will be carried out in xenograft mouse 
models in order to determine whether the in vitro effect being observed translates 
into in vivo success. Other reported in vivo studies also confirmed the activities of 
other types of nanoparticles such as Silica nanoparticles (SiNPs) (Wai-Tao et al. 
2017), Silicon dioxide (silica) nanoparticles (SDNPs) against hepatic cancer 
(Almansour et al. 2018) and Hybrid iron oxide–gold against pancreatic cancer 
(Oluwasamni et al. 2016).Nanoparticles (HNPs) are tested via intravenous and 
subcutaneous administration in mice and tracked the pharmacokinetic and 
pharmacodynamics behaviour of these nanoparticles. The rate of accumulation 
and clearance of the particles are also tested and the size of each treated cancer 
checked before and after nano-therapy. 
It is postulated that in fact, greater tumour retardation will be experienced in vivo 
compared with only drug treatment, however, the ability to either eradicate tumour 
regrowth or indeed totally eliminate liver cancer requires full investigation. 
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